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Statins are the most widely used drugs for the management of hyperlipidemia.
Clinical trials have demonstrated the beneficial effects of statins in treatment of
hyperlipidemia and in prevention of cardiovascular diseases. Statins as a class of drugs
are generally well tolerated; however, statin-associated myopathy is a major clinical
concern. The risk of myopathy further increases with concurrent use of statins with
potentially interacting medications (PIMs). There is limited information on the risk of
myopathy associated with the use of statins and PIMs.
The purpose of this study was to evaluate the risk and risk factors of myopathy in
patients using statins with PIMs compared to those patients using statins without PIMs.
The study was a retrospective cohort analysis using the Texas Medicaid database. The
study population included patients who were new statin users between the ages of 21 and
64 years and were eligible for Texas Medicaid benefits between September 1, 1998 and
vii
August 31, 2003. The main outcome measures were the incidence rates of myopathy per
100 person-months of treatment and the odds of developing myopathy.
In 8,822 eligible patients, 113 cases of myopathy occurred during an average
follow-up of 3.9 months. The overall incidence of myopathy in the study population was
0.32 per 100 person-months. Patients using statins with PIMs had 2.7-fold (95% CI:
1.83–4.03) greater risk of developing myopathy than patients using statins without PIMs.
In addition, increasing number of comorbidities was associated with 1.3 times (95%CI:
1.159-1.637) greater risk of myopathy. Also, the risk of myopathy decreased (OR: 0.997;
95% CI: 0.995-0.999) with increasing statin use.
The risk of myopathy was higher for patients using statins and PIMs as compared
to patients using statins without PIMs. Health care professionals need to monitor patients
closely when they use statins and PIMs concurrently, especially in patients with multiple
comorbidities.
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INTRODUCTION AND LITERATURE REVIEW 
 
INTRODUCTION 
 According to the American Heart Association, 106.9 million Americans aged 20 
years and older (50.7% of the United States population) had total cholesterol levels above 
200 mg/DL, in 2002, mainly due to increase in low density lipoprotein cholesterol.1
Statins or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors are the most 
widely used drugs to treat elevated cholesterol.  According to Med Ad News, the two top 
selling drugs are cholesterol lowering drugs (Lipitor® and Zocor®).2 Cholesterol 
lowering drugs represent the second best therapeutics category by sales among the 
world’s top 200 prescription drugs.3
Statins are shown to be highly effective in treating dyslipidemia and reducing the 
risk of cardiovascular events in primary and secondary prevention trials.  Statins are 
considered as first-line of drug therapy.  As a class of drugs, statins are generally well-
tolerated; however, the major clinical concern related to statin therapy is myopathy.  This 
was evident from the recent withdrawal of cerivastatin, which was withdrawn from the 
market in 2001 because of 31 deaths associated with drug-induced rhabdomyolysis. 
 
1 Heart Disease and Stroke Statistics 2006 Update. Dallas: American Heart Association, 2006. 




The clinical presentation of myopathy ranges in severity from simple myalgia to 
the most severe manifestation, rhabdomyolysis.  The incidence of myopathy varies 
between 0.1 percent and 5.0 percent depending on dose and type of statin, and severity of 
the condition.4 However, this risk increases with concurrent use of potentially interacting 
medications with statins. 
 Most statins are metabolized by the cytochrome P450 system, except pravastatin.  
This enzyme system is responsible for metabolism of many other pharmacologic agents.  
The combination of statins with other agents that inhibit the cytochrome P450 system 
increases the risk of myopathy.  One study estimated the risk of myopathy to be 6-fold 
higher in patients who used potentially interacting medications with statins as compared 
with statin-only users.5 There is very limited information on the magnitude of risk when 
statins are taken with potentially interacting medications. 
 The potential for statin-induced myopathy is becoming more of a concern as 
guidelines recommend more aggressive treatment of elevated cholesterol levels.6 This 
means that the number of people who will be treated with higher statin doses and 
combination therapies will increase to meet the current guidelines.  At the same time, 
patients with multiple medications due to comorbidities are also at an increased risk of 
myopathy.  Given this scenario, it is important to identify patients who are at a higher risk 
of myopathy. 
 
4 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and 
safety of statins. J Am Coll Cardiol 2002;40:567-72. 
5 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims 
database. Am J Cardiol 2006;97:S61-8,  Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized 
rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90. 
6 Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National 
Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. 
3
The general purpose of this study was to estimate the risk of myopathy in Texas 
Medicaid patients and determine the risk factors for myopathy.  By identifying the risk 
factors of myopathy, health care professionals will be better able to manage their patients 
with high cholesterol who are on multiple medications, and who have certain risk factors 
that predispose them to the risk of myopathy. 
This chapter is divided into the following sections: 
 General background on hyperlipidemia; 
 Overview of statins; 
 Background of myopathy; 
 Statins and potentially interacting medications; 
 Rationale of the study; 




GENERAL BACKGROUND ON HYPERIPIDEMIA 
 
EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE 
According to the American Heart Association, the prevalence of cardiovascular 
diseases (CVD) is 34.2% and the cost of CVD is $393.5 billion.7 CVD is the leading 
cause of death in the United States.8 Coronary heart diseases (CHD), which are also 
commonly referred to as coronary artery diseases (CAD), account for about half of all 
cardiovascular deaths in the U.S.9 About 13.0 million people in the U.S. suffer from 
CHD.  A majority of these patients suffer from myocardial infarction (MI) or angina 
pectoris.  It is estimated that the incidence of new MI is 565,000 and that of angina 
pectoris is 400,000 annually.10 This poses a significant burden on the society in terms of 
the use of health care resources and cost.  About 90% of the CHD patients have at least 
one of the following major risk factors: hypertension, high cholesterol, current smoker or 
diabetes.11 According to a study conducted in 52 countries, nine risk factors including 
cigarette smoking, abnormal lipid levels, hypertension, diabetes, abdominal obesity, a 
lack of physical activity, low daily fruit and vegetable consumption, alcohol 
overconsumption, and psychosocial factors (e.g. depression, perceived stress) account for 
 




11 Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary 
heart disease events. JAMA 2003;290:891-7. 
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over 90% of the risk of an initial MI.12 Controlling these risk factors or modifying them 
altogether can decrease the risk of CHD.  One of the most important risk factors to 
control is abnormal level of lipids or hyperlipidemia.  The next section presents 
information on hyperlipidemia, its prevalence and association with CHD. 
 
BACKGROUND ON HYPERLIPIDEMIA AND ITS ASSOCIATION WITH CHD 
Hyperlipidemia (which is also commonly referred to as dyslipidemia or 
hypercholesterolemia), is defined as an elevation of lipid levels in the blood plasma.  
Lipoproteins are responsible for the transport of lipids, mainly triglycerides (TG) and 
cholesterol, through the plasma.  The four main classes of lipoproteins are high-density 
lipoproteins (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) 
and chylomicrons.  Another class, intermediate density lipoprotein (IDL) resides between 
VLDL and LDL. The amount of TG and cholesterol carried by each lipoprotein is 
variable.  For example, VLDL and chylomicrons are rich in TG and LDL is a carrier for 
cholesterol.13 Apolipoproteins (Apo) are the protein constituents of these lipoproteins.  
Their main function is to regulate enzymes and bind to receptors thereby controlling lipid 
metabolism.   
 
12 Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with 
myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-
52. 
13 Gaw A. Hyperlipidemia as a risk factor for vascular disease. In: Gaw A, Packard C J, Shepherd. J, eds. 
Statins : the HMG-CoA reductase inhibitors in perspective. London, New York: Martin Dunitz ; 
Independence, KY, 2004:1-18. 
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LDL cholesterol makes up 60 to 70% of total serum cholesterol.  The National 
Cholesterol Education Panel (NCEP) recognizes it as the primary target for lipid lowering 
therapies.14 Other targets include triglycerides and HDL cholesterol levels.   
Studies such as the Framingham Heart Study,15 the Multiple Risk Factor 
Intervention Trial (MRFIT),16 and the Lipid Research Clinics Primary Prevention Trial 
(LRCPPT)17 have shown a positive strong correlation between LDL cholesterol levels 
and the risk of CHD among men and women initially free of CHD.  These studies have 
provided evidence that LDL is an important risk factor for CHD.  Similarly, recent 
published meta-analyses found that elevated triglycerides were associated with an 
increase in cardiovascular risk.18,19 Results of Framingham study have also shown a 
negative association between HDL cholesterol levels and the occurrence of CHD.20  A
review of trials by Boden et al. has shown a similar inverse relationship between HDL 
cholesterol and the risk of CHD.21 In summary, all of these trials provide evidence that 
 
14 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
15 Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham 
Study. Ann Epidemiol 1992;2:23-28. 
16 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature 
death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the 
Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8. 
17 Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary Prevention Trial 
results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. 
JAMA 1984;251:365-74. 
18 Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J 
Cardiol 1998;81:7B-12B. 
19 Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk 
factor in coronary artery disease. Eur Heart J 1998;19:M8-14. 
20 Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham 
Study. Ann Epidemiol 1992;2:23-28. 
21 Boden WE.  High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: 
Assessing the data from the Framingham to the Veterans Affairs High-density Lipoprotein Intervention 
Trials.  American Journal of Cardiology 2000; 86 (Suppl 12A): 19L-22L.  
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there is an increased risk of CHD with an increase in LDL and TG levels, and a decrease 
in HDL levels. 
 
PRIMARY AND SECONDARY CAUSES OF HYPERLIPIDEMIA 
The primary cause of hyperlipidemia is the underlying metabolic defects, which 
have a genetic basis.  Primary hyperlipidemias include familial or polygenic 
hypercholesterolemia, familial combined hyperlipidemia, familial hypertriglyceridemia 
and rare dyslipidemia’s such as dysbetalipoproteinemia.22 The Fredickson/World Health 
Organization classification of lipoprotein phenotype (i.e. lipoprotein I, IIa, IIb, III, IV and 
V) is used to distinguish the many different types of hyperlipoproteinemia.23 Types I and 
V are rare while types IIa, IIb, III and IV are more common.  This classification is widely 
used and gives guidance for cholesterol management.  
Secondary causes of hyperlipidemia are related to disease risk factors and drugs 
associated with hyperlipidemia.  Disease risk factors include diabetes, obesity, 
hypothyroidism, and post-renal transplantation. Drug risk factors include steroids, 
diuretics, beta-blockers and immunosuppressants. In addition, diet is also a significant 
risk factor contributing to hyperlipidemia.24 Given so many causes of hyperlipidemia, the 
prevalence of hyperlipidemia is large in the population. 
 
22 Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 
1998;82:3J-10J. 
23 Ibid. 
24 Gaw A. Hyperlipidemia as a risk factor for vascular disease. In: Gaw A, Packard C J, Shepherd. J, eds. 
Statins : the HMG-CoA reductase inhibitors in perspective. London, New York: Martin Dunitz ; 
Independence, KY, 2004:1-18. 
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PREVALENCE OF HYPERLIPIDEMIA 
According to the NCEP guidelines for cholesterol management, a total cholesterol 
level of 200 to 239 mg/dl is considered borderline high and above 240 mg/dl is 
considered high.  Similarly, LDL above 130 mg/dl is considered high and HDL below 
40mg/dl is considered low.25 Based on this classification, in 2002, there were about 
106.9 million adults who had total cholesterol of 200 mg/dl or higher, 95 million who had 
LDL greater than 130 mg/dl and 54.7 million who had HDL lower than 40 mg/dl.26 
A comparison of data from the National Health and Nutrition Examination 
Surveys (NHANES) 1999-2000 to NHANES 1988-1994 showed no statistically or 
clinically significant change in mean cholesterol levels over the ten-year period.27 This 
lack of change in cholesterol levels occurred despite a modest increase in use of lipid 
lowering drugs.  Although, there has been a decreasing trend in elevated cholesterol 
levels since 1980, this decrease has become smaller over the years.  This may be due to 
the large number of eligible people who may not be receiving dietary or pharmacological 
interventions.  NCEP has developed guidelines for cholesterol testing and management.   
 
NATIONAL CHOLESTEROL EDUCATION PANEL GUIDELINES 
The NCEP expert panel on detection, evaluation, and treatment of high blood 
cholesterol in adults examines the available evidence on CHD and high cholesterol, 
 
25 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
26 Heart Disease and Stroke Statistics 2006 Update. Dallas: American Heart Association, 2006. 
27 Ford ES, Mokdad AH, Giles WH, et al. Serum total cholesterol concentrations and awareness, treatment, 
and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition 
Examination Survey, 1999 to 2000. Circulation 2003;107:2185-9. 
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identifies relevant issues, and develops guidelines for physicians and other heath care 
providers.  Since 1987, three sets of guidelines have been issued for management of 
cholesterol.   
The Adult Treatment Panel I (ATP I) provided a strategy for primary prevention 
of CHD in persons with LDL levels between 130 and 159 mg/dl, in persons with LDL 
levels greater than 160 mg/dl and those with multiple (>2) risk factors. ATP II 
reemphasized the importance of primary prevention and also added the need for intensive 
management of LDL cholesterol in persons with established CHD.  The core of ATP III 
is based on ATP I and ATP II; however, the focus of these guidelines is on primary 
prevention in persons with multiple risk factors.28 
The following are some of the new features of ATP III guidelines:29 
 LDL cholesterol levels less than 100 mg/dl are optimal; 
 HDL cholesterol levels should be greater than 40 mg/dl (compared to greater than 
35 mg/dl in earlier reports) because this cut off is a better measure of depressed 
HDL; 
 The triglyceride cutpoints were lowered to give more attention to moderate 
elevations; 
 Persons with diabetes without CHD, most of whom have multiple risk factors, 
have the same risk as patients who are CHD risk equivalent.  (CHD risk 
equivalents are persons that have clinical forms of atherosclerotic disease other 
 
28 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
29 Ibid. 
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than CHD, or have diabetes or multiple risk factors with 10-year risk for CHD 
greater than 20%); 
 Patients with multiple risk factors are identified for more intensive treatment 
using Framingham projections of 10-year absolute risk reduction; 
 Patients with metabolic syndrome are identified as candidates for intensified 
therapeutic lifestyle changes (TLC); 
 A complete lipoprotein profile is the preferred initial test rather than screening for 
total cholesterol and HDL alone; 
 The use of plant stanols/sterols and viscous fiber is encouraged as dietary therapy 
to enhance lowering of LDL cholesterol; 
 Strategies are provided to promote adherence to therapeutic lifestyle changes and 
drug therapies; and 
 Persons with triglycerides greater than 200 mg/dl should be treated beyond 
lowering LDL levels. 
Recently, Ford et al.30 established the distribution of the 10-year risk for CHD among 
U.S. adults using the NCEP ATP III algorithm.  Based on this data, there were about 23 
million (15. 5%) adults at moderate risk, and about 4 million (2.9%) adults at high risk as 
defined by ATP III guidelines.  This risk varied with age and sex.  The percent of people 
with high risk increased with age and was higher for men compared to women.  A large 
number of this population would then be eligible for some kind of intervention to reduce 
 
30 Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US 
adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 
2004;43:1791-6. 
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LDL levels.  Table 1.1 defines LDL cholesterol levels and cutpoints for initiation of TLC 
and drug therapies. 
 
Table 1.1:  LDL cholesterol goals and cutpoints for therapeutic lifestyle changes 
and drug therapy in different risk categories based on ATP III 
 
Risk Category LDL Goal 
(mg/dL) 





LDL level at which 
to consider drug 
therapy (mg/dL) 
CHD or CHD 
equivalents (10 year risk 
>20 %) 
 
<100 >100 >130 
>2 risk factors (10 year 
risk < 20 %) 
<130 >130 10-year risk 10 to 
20 %: > 130, 10-
year risk<10 %: 
>160 
 
0 to 1 risk factors < 160 >160 >190  
(160 to 189: drug 
optional 
Source: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
Based on these NCEP guidelines, an estimated 36 million Americans are eligible 
for drug therapy, of which 32% will be under the age of 45 and 27% will be above 65 
years of age.31,32 This represents a 140% increase in the overall eligibility as compared to 
 
31 Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein 
cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5. 
32 Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for 
primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of 
the treatment-eligible population. Circulation 2002;105:152-6. 
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ATP II guidelines.  In summary, a significant number of people require some kind of 
management of hyperlipidemia. 
 
MANAGEMENT OF HYPERLIPIDEMIA 
The two main approaches to the management of hyperlipidemia, as stated in the 
NCEP guidelines are therapeutic lifestyle changes and drug therapy. 
 
Therapeutic lifestyle changes for management of hyperlipidemia 
The first step in TLC for management of hyperlipidemia includes dietary 
management.  ATP III guidelines recommend a reduced intake of saturated fats and 
cholesterol to reduce LDL levels.  In addition, a higher intake of total fat (mostly 
unsaturated fat) can help to reduce triglycerides and raise HDL levels.  Also, moderate 
physical activity and weight reduction (in case of obese patients) is recommended along 
with dietary changes.  ATP III recommends changes in lifestyle to lower lipid levels 
before initiating drug therapy.33 
Drug therapy for management of hyperlipidemia 
A large portion of the population who have high short-term and long-term risk for 
CHD will need drug therapy along with TLC.  This is based on the NCEP cutpoints for 
drug therapy (Table 1.1).  The most important drugs for lowering blood cholesterol 
 
33 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
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include bile acid sequestrants, niacin, cholesterol absorption inhibitors, hormone 
replacement therapy (HRT), fibrates, and statins.  These drugs are described in detail, 
especially statins which is the focus of this dissertation. 
 
BILE ACID RESINS 
The agents in this class include cholestyramine, colestipol and colesevelam.  
These drugs act by interrupting the enterohepatic circulation of bile acids by binding 
them in the intestine to form an insoluble complex that is excreted in the feces.34 Due to 
depletion in bile acids, their hepatic synthesis is increased, which results in the increased 
transport of cholesterol to liver and decreased levels of serum cholesterol.35 In some 
persons, bile acid resins increase the VLDL levels, thereby raising serum triglyceride 
levels.36,37 
The major action of bile acid sequestrants is to lower LDL cholesterol.  These 
drugs reduce the LDL cholesterol by 15 to 30%, increase HDL cholesterol by 3 to 5% 
and they have no effect or slight increase on triglyceride levels.38 In the Lipid Research 
Clinics Primary Prevention Trial, treatment with cholestyramine reduced the risk of 
 
34 Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile 
acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 
1999;159:1893-900. 
35 Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 
1989;76 Suppl 1:65-71; discussion 71-4. 
36 Beil U, Crouse JR, Einarsson K, et al. Effects of interruption of the enterohepatic circulation of bile 
acids on the transport of very low density-lipoprotein triglycerides. Metabolism 1982;31:438-44. 
37 Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511. 
38 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
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CHD.39 In addition, bile acid resins in combination with other lipid lowering drugs 
enhances the lipid lowering effects of these drugs.40,41,42 
The main disadvantage of bile acid sequestrants is gastrointestinal side effects.  
These include bloating, abdominal discomfort, nausea, constipation and dyspepsia.43 
Colesevelam has fewer side effects than the other drugs.44 In addition, concurrent 
administration of bile acid resins with digitalis, thiazide diuretics, beta-blockers, warfarin 
and exogenous thyroid hormones increases the absorption of the latter drugs.45 
NIACIN 
Niacin is a cholesterol-lowering drug that reduces LDL and triglyceride levels and 
increases HDL levels.46 It modifies lipid levels by inhibiting lipoprotein synthesis and 
reducing the production of VLDL particles by the liver through reduced transport of free 
fatty acids to the liver.47 
39 Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary Prevention Trial 
results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64. 
40 Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin 
therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40. 
41 The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for 
severe primary hypercholesterolemia. JAMA 1988;260:359-66. 
42 Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and 
cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 
1993;153:1321-9. 
43 Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol 
Metab 2003;88:2445-61. 
44 Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile 
acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 
1999;159:1893-900. 
45 Cziraky M. Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. 
Pharmacoeconomics 1998;14:29-38. 
46 Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol 
Metab 2003;88:2445-61. 
47 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation 2002;106:3143-421. 
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Niacin decreases LDL levels by 5 to 15%, triglyceride levels by 20 to 50% and 
increases HDL levels by 15 to 35%.48 In a meta-analysis conducted to evaluate the safety 
and efficacy of niacin, it was shown that niacin was associated with a 20% decrease in 
triglycerides, a 12% decrease in LDL levels and a 16% increase in HDL levels.49 Niacin 
was shown to decrease the risk of recurrent myocardial infarction in the Coronary Drug 
Project, 50and the total mortality in patients who had received niacin was reduced in a 15-
year follow-up.51 
The major disadvantages of niacin therapy relate to its side effects.  These include 
flushing, itching, headache, fatigue and gastrointestinal symptoms such as nausea, 
dyspepsia, flatulence, vomiting, diarrhea and activation of peptic ulcer may occur.  Other 
major side effects include hepatotoxicity, hyperuricemia and gout, and hyperglycemia.  
These risks are increased at higher doses and the risk of hepatotoxicity is increased with 
sustained released preparations (except Niaspan).52 The use of niacin with statin therapy 
has been cautioned due to case reports of myopathy (discussed later).53 Although 
efficacious, the long-term use of these drugs has been limited due to side effects. 
 
48 Ibid. 
49 Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein 
cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 
2005;45:185-97. 
50 Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 
1975;231:360-81. 
51 Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: 
long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. 
52 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation 2002;106:3143-421. 
53 Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-8. 
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CHOLESTEROL ABSORPTION INHIBITORS 
Ezetimibe is the first cholesterol absorption inhibitor approved by FDA in 
November 2002.  It blocks reabsorption of cholesterol secreted into bile, and the 
enterohepatic circulation of endogenously produced cholesterol.  The reduction in LDL is 
due to increased endogenous catabolism of LDL.54 
Ezetimibe has been shown to reduce LDL levels by 15 to 20% with trivial effects 
on triglycerides and HDL levels.55 Ezetimibe in combination with statins are highly 
effective in controlling lipid levels.56,57 It can be used as an adjunct in persons whose 
LDL levels are not well controlled with statins.  However, its effects on cardiovascular 
endpoints are not known.  There has been one case-report in the literature in which 
patients developed myopathy after ezitimibe was added to the statin therapy.58 This drug 
will have to be continuously monitored for long-term effects. 
 
HORMONE REPLACEMENT THERAPY 
In a study conducted on Framingham cohort of women, it was shown that 
postmenopausal women had two to six times greater incidence of CVD as compared to 
pre-menopausal women.59 This may be because of the artherogenic changes in plasma 
 
54 Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol 
Metab 2003;88:2445-61. 
55 Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol 
absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 
2002;90:1092-7. 
56 Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with 
primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34. 
57 Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for 
treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91. 
58 Fux R, Morike K, UF G. Ezitimibe and statin-associated myopathy. Ann Intern Med 2004;140:671. 
59 Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the 
Framingham study. Ann Intern Med 1976;85:447-52. 
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lipid levels associated with estrogen deficiency.60 These changes can be avoided with the 
use of hormone replacement therapy (HRT).  However, there is considerable controversy 
and confusion over the use of HRT to reduce CHD risk in postmenopausal women.  
There has been discrepancy in the results of observational studies and controlled trials.  
 The Nurses Health Study,61 an observational study, suggested that there was a 
beneficial effect of estrogen replacement on CAD as well as a significant reduction in the 
probability of CAD events for women who were on estrogen replacement therapy.  In 
contrast, the Heart and Estrogen/Progesterone Replacement Study (HERS),62 a secondary 
prevention trial, indicated that estrogen plus progestin therapy did not reduce the overall 
risk of MI or death from CHD.  Further analysis showed that the combination therapy 
increased the risk of CHD events in the first year, which reduced significantly in the 
following years.  More recently, the Women’s Health Initiative (WHI) study,63 a 
randomized controlled trial, showed a small but significant increase in the risk of CHD in 
women using HRT.  As can be seen from the above evidence, there is a lot of uncertainty 
in the use of HRT for prevention of CHD.  The ATP III does not recommend the use of 
HRT in prevention of CHD in postmenopausal women.64 
60 Warren MP, Halpert S. Hormone replacement therapy: controversies, pros and cons. Best Pract Res Clin 
Endocrinol Metab 2004;18:317-32. 
61 Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of 
cardiovascular disease. N Engl J Med 1996;335:453-61. 
62 Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention 
of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study 
(HERS) Research Group. JAMA 1998;280:605-13. 
63 Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy 
postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. 
JAMA 2002;288:321-33. 
64 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult 
Treatment Panel III). JAMA 2001;285:2486-97. 
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FIBRATES 
Three fibrates are currently available in the U.S.: gemfibrozil, fenofibrate, and 
clofibrate.  In addition, bezafibrate and ciprofibrate are available outside the U.S.  
Fibrates are mainly used in the reduction of triglycerides, although they have a mild 
effect on LDL levels.65 
Mechanism of Action 
The mechanism of action of fibrates is complex and there may be some variation 
in this class.   They have an effect on lipoprotein lipase, which increases the catabolism 
of triglyceride rich lipoprotein thereby decreasing triglyceride levels.  Triglyceride levels 
are also decreased due to increased fatty acid oxidation that reduces the formation of 
VLDL triglycerides.  Fibrates also increase the production of apolipoprotein A (apoA) I 
and apoA II, which contribute to an increase in HDL levels.66 Recent research has shown 
that all these activities are due to stimulation of peroxisome proliferator activator receptor 
alpha. Through this mechanism, the activity of apoA I, fatty acid transport protein, fatty 
acid oxidation, and possibly lipoprotein lipase are upregulated by fibrates.67,68 In 
 
65 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation 2002;106:3143-421. 
66 Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein 
metabolism. Circulation 1998;98:2088-93. 
67 Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in 
mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25. 
68 Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. J Clin Endocrinol 
Metab 2003;88:2445-61. 
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addition, triglyceride lowering transforms small dense LDL into normal sized LDL, 
thereby increasing resistance of LDL to oxidation.69 
As mentioned earlier the primary indication for fibrates is lowering of 
triglycerides levels.  Many trials have been conducted to evaluate the efficacy of fibrates 
on lipid levels.   
 
Efficacy of fibrates 
Recently, Birjmohun et al.70 published a meta-analysis evaluating the effects of 
fibrates.  This study evaluated 53 trials that compared fibrates with placebo.  According 
to the study, the use of fibrates caused a decrease of 36% in TG levels, a decrease of 8% 
in LDL levels, and an increase of 10% in HDL levels.  The effects varied between 
fibrates with gemfibrozil having the greatest effect on reduction of TG (48%).  Most 
trials showed a reduction in LDL; however, some trials did show an increase or 
unchanged levels of LDL.  Most trials showed an increase in HDL levels except 
clofibrate trials, which showed a decrease in HDL levels.  The increase in HDL levels 
was more profound in patients having combined hyperlipidemia and/or 
hypercholesterolemia.71 These results are consistent with the NCEP guidelines.72 
69 Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein 
metabolism. Circulation 1998;98:2088-93. 
70 Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein 
cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 
2005;45:185-97. 
71 Ibid. 
72 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation 2002;106:3143-421. 
20
The studies evaluating the effect of fibrates on CV outcomes are limited.  Therapy 
with gemfibrozil reduced the risk of MI in both primary and secondary prevention trials, 
and reduced the risk of CHD events and stroke in secondary prevention trial.73,74 
Clofibrate also has been shown to reduce the risk of MI in primary prevention trial;75 
however, these beneficial effects have not been shown in all clinical trials.76,77 With the 
exception of Veterans Administration HDL Intervention Trial (VA-HIT),78 no other trials 
have shown a reduction in risk of CHD death.  In fact, in the WHO Clofibrate Study,79 
total mortality was significantly greater in the clofibrate group due to increased number 
of non-CHD deaths.  Based on the above evidence, the effect of fibrates on CV outcomes 
and mortality are inconsistent. 
 
Safety of fibrates 
Fibrates are generally well tolerated; the most common side effects are skin 
reactions and gastrointestinal side-effects.  In a meta-analysis conducted by Birjmohun et 
 
73 Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in 
middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary 
heart disease. N Engl J Med 1987;317:1237-45. 
74 Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart 
disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density 
Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8. 
75 Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of 
ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118. 
76 Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 
1975;231:360-81. 
77 The Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol 
and reducing triglycerides in patients with coronary artery disease. Circulation 2000;102:21-7. 
78 Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart 
disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density 
Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8. 
79 Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of 
ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118. 
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al.,80 the incidence of adverse effects was 33% in the fibrate group versus 30% if the 
placebo group.  Besides the above-mentioned side effects, the other adverse reactions that 
occurred less frequently included hepatoxicity and musculoskeletal symptoms.  There 
was no statistically significant difference in the number of musculoskeletal symptoms 
experienced by the treatment group versus the placebo group (relative risk (RR): 1.23; 
95% confidence interval (CI): 0.65-2.32, p=0.52).81 The risk of musle-related events is 
increased in persons suffering from renal failure.  In spite of low reporting of myopathy 
in clinical trials, there have been case-reports of myopathy published in the literature 
related to use of fibrates. 
 
Case-reports and incidence of muscle-related events 
Acute rhabdomyolysis had been reported during treatment with ciprofibrate,82 
gemfibrozil,83,84 fenofibrate,85,86 clofibrate,87 and bezafibrate.88 Alseikh-Ali et al.89 
reviewed the adverse events reported to the FDA in which gemfibrozil or fenofibrate was 
 
80 Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein 
cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 
2005;45:185-97. 
81 Ibid. 
82 Giraud O, Chanu B, Farge D, et al. Acute rhabdomyolysis associated with digestive disorders during an 
overdoes of ciprofibrate. Gastroenterol Clin Biol 1995;19:231-232. 
83 Magarian GJ, Lucas LM, C C. Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873-1874. 
84 Gorriz JL, Sancho A, JM L-M. Rhabdomyolysis and acute renal failure associated with gemfibrozil. 
Nephron 1996;74:437-438. 
85 Clouatre Y, Leblanc L, D O. Fenofibrate-induced rhabodmyolysis in two dialysis patients with 
hyopthyroidism. Nephrol Dial Transplant 1999;14:1047-48. 
86 Barker BJ, Goodenough BB, JM F. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 
2003;26:2482-83. 
87 Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: Are adverse effects predictable and reversible? 
Cardiology 2002;97:115-121. 
88 Ibid. 
89 Alsheikh-Ali Alawi A., Kuvin J T., H. KR. Risk of adverse events with fibrates. Am J Cardiol 
2004;94:935-38. 
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the suspected cause of the adverse event.  Rates of muscle-related events without 
rhabdomyolysis were 15.7 per million prescriptions of gemfibrozil versus 8.8 per million 
prescriptions of fenofibrate.  Rates of rhabdomyolysis were even higher (59.6 per million 
prescriptions of gemfibrozil versus 5.5 million prescriptions or fenofibrate).  In an 
epidemiologic study, the relative risk of myopathy for fibrate users was 42.2 as compared 
to non-users and 5.5 as compared to statin users.90 In another study, the average 
incidence of myopathy was estimated to be 2.82 per 10,000 person years.91 
In summary, there is inconsistency in reported rates of myopathy related to use of 
fibrates.  However, it appears that the risk of myopathy is greater with fibrates than with 
statins.  Therefore, the use of statins and fibrates together may further increase the risk of 
myopathy, which can lead to rhabdomyolysis.  A discussion on studies evaluating safety 
of combination statin-fibrate therapy will be presented later.  Caution is needed when 
using these two drugs together.  
 
The next section describes statins in the management of hyperlipidemia, which is the 
primary focus of this dissertation.  This section is divided into the following sections: 
 History and chemistry of statins;  
 Pharmacokinetics and mechanism of action; 
 Primary and secondary prevention trials; and  
 Safety and tolerability of statins. 
 
90 Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based 
follow-up study. Epidemiology 2001;12:565-9. 
91 Graham D. J., Staffa J. A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated 
with lipid-lowering drugs. JAMA 2004;292:2585-90. 
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SECTION II 
OVERVIEW OF STATINS 
 
ORIGINS AND CHEMISTRY 
 Statins, also known as 3-hydroxy-3methyl-glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, are the most commonly prescribed medications for hyperlipidemia.  
The lipid lowering benefit of statin drugs was discovered in 1976, and these agents were 
subsequently introduced in the 1980’s.92 The earlier statins were fungal metabolites but 
are now produced synthetically.  Currently six statins are available in the U.S.  Of these, 
lovastatin (Mevacor® by Merck) and pravastatin (Pravachol® by Bristol-Myers Squibb) 
are natural products derived from fungal metabolites.  Simvastatin (Zocor® by Merck) is 
a semi-synthetic derivative.  Fluvastatin (Lescol® by Novartis) was the first entirely 
synthetic compound, followed by a generation of other synthetic statins such as 
atorvastatin (Lipitor® by Pfizer) and most recently rosuvastatin (Crestor® by 
AstraZeneca).  Cerivastatin (Baycol® by Bayer) is also a synthetic statin, but was 
withdrawn from the market in 2001 due to occurrence of fatal rhabdomyolysis. 
 
MECHANISM OF ACTION 
 Statins work by suppressing the biosynthesis of cholesterol.  Figure 1.1 illustrates 
the biosynthetic pathway of cholesterol.   
 
92 Gaw A. The discovery and development of the statins. In: Gaw A, Packard C J, Shepherd. J, eds. Statins 
: the HMG-CoA reductase inhibitors in perspective. London, New York: Martin Dunitz ; Independence, 
KY, 2004:24-28. 
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Figure 1.1:  The cholesterol biosynthetic pathway, showing the rate limiting step 
catalyzed by HMG-CoA reductase 
 
Source: Evans M, Rees A.  Effects of HMG-CoA reductase on skeletal muscle: are all statins the same? 
Drug Saf  2002;25:649-663. 
 
The rate limiting enzyme in this pathway is 3-hydroxy-3-methylglutaryl 
coenzyme reductase A (HMG-CoA), which catalyzes the conversion of HMG-CoA to 
mevalonate.93 Statin competitively inhibit the enzyme HMG-CoA reductase, which 
decreases the cholesterol synthesis by some 10 to 60%, depending on the dose and 
individual statin.94 This decrease in cholesterol biosynthesis results in an increase in the 
number of LDL receptors in the liver and consequently, increased clearance of LDL from 
 
93 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol 2005;19:117-25. 
94 Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase 
inhibitors. Clin Pharmacokinet 2002;41:343-70. 
X
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plasma.  LDL levels are also decreased due to decreased hepatic production of VLDL and 
increased breakdown of VLDL.95 Along with cholesterol, the synthesis of ubiquinone 
and dolichol is also affected, which may lead to toxicity of statins.   
 
PHARMACOKINETICS OF STATINS  
 Lovastatin and simvastatin are administered as lactone pro-drugs, and are 
enzymatically hydrolyzed in vivo to their active, hydroxyl-acid form.  All the other 
statins are administered as the active hydroxyl acid.96 Table 1.2 summarizes some of the 
key pharmacokinetic properties of the individual statins. 
 
95 Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase 
inhibitors. A new therapeutic alternative. Drugs 1988;36 Suppl 3:72-82. 
96 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol 2005;19:117-25. 
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Table 1.2: Comparison of statin drugs on pharmacokinetic parameters including bioavailability, solubility, protein
binding, elimination half-life, presence of active metabolites, and isoenzymes used for metabolism
Pharmacokinetic
Parameter
Lovastatin Pravastatin Simvastatin Fluvastatin Atorvastatin Cerivastatina Rosuvastatin
Bioavailability (%) 5 18 5 24 12 60 20
Solubility Lipophilic Hydrophilic Lipophilic Lipophilic Lipophilic Lipophilic Hydrophilic
Protein binding >95 ~50 95-98 >98 98 >99 90
Active metabolites Yes No Yes No Yes Yes Minor
Elimination half-
life (h)
3 1.8 2 1.2 14 2.5 19
Isoenzymeb 3A4 None 3A4 2C9 3A4 3A4, 2C8 2C9/2C19
Source: Schachter M. Chemical, pharmacokinetic, and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-125
a Voluntarily withdrawn from clinical use
b Isoenzyme refers to the specific isoenzyme in the cytochrome P450 system that is responsible for the metabolism of each drug.
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As seen in Table 1.2, statins generally possess a low systemic bioavailability 
(except cerivastatin) indicating extensive first-pass extraction.  Also, all statins are 
extensively bound to plasma proteins, with the exception of pravastatin, resulting in low 
systemic exposure to the active drug.97 
The two important pharmacokinetic properties that differ across statins are the 
solubility of statins and the metabolism of statins by isoenzymes.  These properties affect 
drug-drug interactions, and toxicity of statins.98 Lipophilic statins can enter the 
hepatocyte cell membrane through passive diffusion and inhibit cholesterol synthesis.  
However, these statins will also pass through other cell membranes and can lead to statin 
toxicity.  In contrast, hydrophilic statins have carrier-mediated uptake in the liver, making 
them hepatoselective and less toxic.99 
Statins that are lipophilic must be metabolized to a water soluble form for renal 
excretion.  This process depends on cytochrome P450 (CYP450) isoenzymes.100 The 
CYP450 isoenzyme metabolizes a large number of drug products in humans. As a result, 
a lipophilic statin is subject to metabolic inhibition by concomitantly administered drugs 
with stronger affinity for the same isoenzyme.101 It has now been recognized that statins 
metabolized by CYP450 system are more likely to produce muscle toxicity because of 
drug interactions with other drugs that are metabolized by the same isoenzyme system; 
 
97 Ibid. 
98 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 
99 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol 2005;19:117-25. 
100 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 
101 Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase 
inhibitors. Clin Pharmacokinet 2002;41:343-70. 
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drug interactions increase levels of statins in the blood with an increased risk of 
toxicity.102 In contrast, a water soluble statin depends very little, if at all, on the CYP450 
system, making it less susceptible to drug interactions. 
 In summary, the pharmacokinetic properties differ across statins, especially in 
terms of their dependence of CYP450 system.  It is important to understand these subtle 
differences between statins, as they may have clinical consequences. 
 
EFFICACY OF STATINS 
 Statins are the most commonly prescribed drugs for the treatment of 
hyperlipidemia because of their efficacy in reducing LDL levels.  In a recent general 
review of statin drugs, Maron et al.103 compared the efficacy of different doses of the 
statins available in patients without hypertriglyceridemia.  Their findings are shown 
below in Table 1.3. 
 
102 Muscari A, Puddu GM, Puddu P. Lipid-lowering drugs: are adverse effects predictable and reversible? 
Cardiology 2002;97:115-21. 
103 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. 
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Table 1.3: Comparison of different doses of statin drugs on the efficacy of decreasing total cholesterol, LDL,
triglycerides, and increasing HDL levelsa
Statin Drug and Dose (mg) Percent Change in Lipid and Lipoprotein
Levels









- 10 20 20 40 0.2 -22% -27% 4-8% -10-15%
10 20 40 40 80 0.4 -27% -34% 4-8% -10-20%
20 40 80 - - - -32% -41% 4-8% -15-25%
40 80 - - - - -37% -48% 4-8% -20-30%
80 - - - - - -42% -55% 4-8% -25-35%
Source: Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213.
a Rosuvastatin was not available in the market at the time of this review
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As seen from Table 1.3, the dose required to lower LDL levels by a specific 
amount varies substantially among the statins.  For example, to lower LDL levels by 41% 
requires 40 mg of simavstatin but 80 mg of lovastatin.  In addition, the dose-response 
relationship for all statins is curvilinear; doubling the dose above the minimal effective 
dose only decreases the LDL levels by an additional six percent.  The maximum 
reduction in LDL levels ranges from 24% to 60%.104 In summary, statins are effective in 
reducing lipid levels, though their effectiveness varies by type and dose of statin.  Many 
clinical trials have been conducted to evaluate the efficacy of statins. 
 
Clinical trials of statins 
 The clinical benefits of statins have been demonstrated in data from seven major 
randomized controlled trials (RCT’s), including nearly 57,000 patients.  Of these seven 
trials, three trials (the Scandinavian Simvastatin Survival Study [4S],105 the Cholesterol 
and Recurrent Events Trials [CARE],106 and the Long-Term Intervention with Pravastatin 
in Ischemic Disease [LIPID] trial107) were secondary prevention trials, and two trials (the 
West of Scotland Coronary Prevention Study [WOSCOPS]108 and the Air Force/ Texas 
 
104 Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511. 
105 The Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 
4444 patients with coronary heart disease. Lancet 1994;344:1383-9. 
106 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial 
infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. 
N Engl J Med 1996;335:1001-9. 
107 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention 
of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad 
range of initial cholesterol levels. N Engl J Med 1998;339:1349-57. 
108 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-
7. 
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Coronary Atherosclerosis Prevention Study [AFCAPS/TexCAPS]109) were primary 
prevention trials.  A summary of trials for the secondary and primary prevention was 
published by Maron and colleagues.110 The results of this summary can be found in 
Table 1.4. 
 
109 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in 
men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary 
Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. 
110 Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. 
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Table 1.4: Summary of secondary and primary prevention trials of the effect of statins on reduction of LDL,




































Source: Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213
a. The Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
Lancet 1994;344:1383-9.
b. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol
levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
c. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with
pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
d. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland
Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
e. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol
levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
f. p value not significant
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Among the secondary prevention trials, the 4S trial demonstrated a reduction in 
coronary events in both men and women, in individuals younger and older than 60 years 
of age, and in subjects with risk factors such as smoking, hypertension, and diabetes.111 
The CARE study extended the results of 4S to individuals with average cholesterol 
levels.  In this study, patients with LDL levels below 125 mg/dL showed no reduction in 
coronary events, suggesting that statin treatment of CHD patients with low LDL levels 
may not be warranted.112 The LIPID study extended the findings of CARE by including 
subjects with unstable angina and by using CHD death as primary end point.  There was a 
24% reduction in CHD deaths in the pravastatin group.113 
In the area of primary prevention, the WOSCOPS trial showed significant risk 
reductions in nonfatal myocardial infarction and coronary deaths after five years. 114 In 
AFCAPS/TexCAPS study, lovastatin reduced the risk for a first acute major coronary 
event, in men and women with average LDL levels and low HDL levels.115 
111 Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of 
diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin 
Survival Study (4S). Diabetes Care 1997;20:614-20. 
112 Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial 
infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. 
N Engl J Med 1996;335:1001-9. 
113 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention 
of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad 
range of initial cholesterol levels. N Engl J Med 1998;339:1349-57. 
114 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-
7. 
115 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in 
men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary 
Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. 
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Apart from these five trials, data from two additional RCT's (the Heart Protection 
Study [HPS]116 and the Lescol Intervention Prevention Study [LIPS]117) have been 
reported.  The HPS trial, which is the largest study to date, showed the benefits of statin 
therapy (simvastatin) in both primary and secondary prevention patients who are at high 
risk of cardiovascular events.  Results showed a reduction in cholesterol levels, CHD 
events and total mortality, and benefits were seen in sub-populations including women, 
people older than 70 years, and individuals with LDL levels less than 116 mg/dL.118 
The LIPS trial assessed the effects of fluvastatin in patients who successfully 
completed their first percutaneous coronary intervention.  Results showed a 22% 
reduction in major adverse coronary events.  These benefits were more pronounced in 
patients with diabetes and those with multivessel disease.119 
All of these trials, demonstrate the beneficial effect of statins in the reduction of 
LDL levels, and CHD associated mortality and morbidity.  These benefits have been 
observed irrespective of the age group, cholesterol levels, various CHD risk factors, and 
in the presence or absence of prior CHD. 
 
116 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering 
with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-
22. 
117 Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following 
successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-
22. 
118 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering 
with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-
22. 
119 Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following 
successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-
22. 
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SAFETY OF STATINS 
 Statins are generally well-tolerated.  The most common side effects are headaches 
and gastrointestinal upset (e.g., constipation, flatulence, dyspepsia, and abdominal pain).  
Rare cases of peripheral neuropathy and polyneuropathy have been reported, but a clear 
association with statin use has not been demonstrated.120,121 Discontinuations due to 
statin-related side-effects are generally in the range of one to five percent, and are not 
different compared to patients taking placebo.122 The most serious adverse effects 
related to statin use include an elevation of liver enzymes and myopathy.  Severe 
rhabdomyolysis resulting in deaths was the reason of withdrawal of cerviastatin from the 
market.  A discussion of both the serious side-effects follows. 
 
Statins and hepatotoxicity 
 Statins are highly hepatospecific and therefore appear to inhibit cholesterol 
synthesis in the liver greater than any other tissue.123 Elevated hepatic transaminases are 
observed in about 0.5 to 2.0 percent of statin recipients and are usually dose-
dependent.124 It is not yet known, however, whether these elevations with statin therapy 
constitute true hepatotoxicity.  Hepatic transaminase elevations are reversible with a 
reduction of dose and usually do not reappear.  Elevations in liver enzymes are not 
 
120 Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann 
Pharmacother 2003;37:274-78. 
121 Gaist D, Garcia Rodriguez LA, Huerta C, et al. Are users of lipid-lowering drugs at increased risk of 
peripheral neuropathy? Eur J Clin Pharmacol 2001;56:931-3. 
122 Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase. Am J Cardiol 1994;73:3D-11D. 
123 Gotto AM, Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 
2003;163:657-9. 
124 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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unique to statins and have been observed with other classes of lipid lowering agents.  
This suggests that the increase may be due to changes in lipid metabolism induced by 
these drugs and not by drugs themselves.125 
Progression to liver failure specifically due to statins is very rare.  Nevertheless, 
statins have been associated with rare cases of hepatocellular toxicity and jaundice.126,127 
As result, patients with significant liver disease, heavy alcohol consumption, or chronic 
hepatitis should not receive statins. 
 The most clinically significant adverse reaction of statin therapy to date is 
myopathy and its progression to life-threatening rhabdomyolysis.  Muscle-related events 
and myopathy associated with statins are the focus of this dissertation and are described 
in detail in the next section. 
 
125 Gotto AM, Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med 
2003;163:657-9. 
126 Ibid. 






Myopathy is the most serious adverse effect associated with the statins.  
Although, the incidence of clinically important myopathy is low, the risk may increase in 
presence of many factors.  This section describes the various types of myopathy, its 
mechanism, risk factors for myopathy, and evidence from clinical trials and clinical 
practice settings. 
 
MYOPATHY: DEFINITION, SUBDIVISION AND CLASSIFICATION 
 The literature to describe muscle toxicity or myopathy associated with statins is 
not consistent, due to the lack of clear definitions.  Recently, the American College of 
Cardiology/American Heart Association/National Heart, Lung and Blood Institute 
(ACC/AHA/NHBLI) clinical advisory on the use and safety of statins classified muscle 
toxicity into four classes.128 These are as follows: 
 Myopathy – It is a general term referring to any disease of the muscles; 
myopathies can be acquired or inherited and can occur at birth or later in life. 
 Myalgia – It is defined as muscle aches or weakness without any elevation in 
creatine kinase (CK) levels.  Myalgia is the most common of the myotoxic effects 
of statins. 
 
128 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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 Myositis – It is defined as muscle symptoms with increased CK levels.  It is 
characterized by muscle weakness and is usually self-limiting. 
 Rhabdomyolysis – It is defined as muscle symptoms with an increase in CK 
levels greater than 10 times the upper limit of normal (ULN), and an elevated 
creatinine usually with brown urine and urinary myoglobin. 
Besdies statins some of the drugs that have been associated with myopathy include 
corticosteroids, antimalarials, colchicine, penicillamine, zidovudine, and drugs associated 
with abuse, such as alcohol and cocaine.129 The extent of muscle toxicitiy depends on 
many factors, and more than one mechanism of action has been proposed for the muscle 
damage. 
 
MECHANISM OF ACTION 
 There is little information on the mechanism by which statins cause myopathy.  
However, several theories have been proposed based on the biosynthetic pathways which 
were presented earlier in Figure 1.1.   
One theory suggests that inhibiting cholesterol synthesis reduces the cholesterol 
content of skeletal muscle cell membranes.  Alteration of skeletal muscle cell membrane 
content can lead to changes in the electrical properties of the membrane and instability of 
the cell membrane permeability of the myocyte.130,131 This may be responsible for the 
observed statin-associated myopathy. 
 
129 Krikorian S. Drug-induced myopathies. US Pharmacist 1999;24:33-34. 
130 Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16. 
131 Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann 
Pharmacother 2001;35:1096-107. 
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Another theory suggests that reduced levels of ubiquinone are responsible for 
muscle injury.132 Statins work by inhibiting the HMG-CoA reductase enzyme which is 
essential in the production of mevalonate (Figure 1.1).  Mevalonate is also a precursor for 
ubiquinone, also known as coenzyme Q10 (CoQ10).  Interruption in the synthesis of 
CoQ10 can lead to adverse effects of muscles.  CoQ10 is a steroid isoprenoid enzyme 
that helps in formation of adenosine triphosphate (ATP) through oxidation of nutrients 
within cells.133 CoQ10 serves as a powerful antioxidant and membrane stabilizer that is 
used by mitochondria for electron transport during oxidative phosphorylation.  CoQ10 
plays an important role in the functioning of skeletal and cardiac muscles.  Inhibition of 
CoQ10 synthesis by statins causes intracellular ubiquinone deficiency.  Futhermore, 
CoQ10 is transported in LDL particles.  Statins lower LDL levels, which further reduces 
ubiquinone levels.  As a result of this reduction in the CoQ10 levels, there is a decrease in 
the oxidative phosphorylation, which is needed for normal cellular respiration.  This 
causes instability of muscle cell membrane resulting in myopathy.134,135 A number of 
observations suggest that statin associated myopathy may be caused by CoQ10 
deficiency.  Mitochondrial dysfunction has been demonstrated in biopsy studies of 
patients treated with statins who experienced muscle symptoms.136 Similarly case reports 
of patients with myopathy who improved clinically after administration of CoQ10 
 
132 Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-
coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65. 
133 Ibid. 
134 Ibid. 
135 Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible 
mechanisms. Pharmacol Rep 2005;57:23-34. 
136 Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. 
Ann Intern Med 2002;137:581-5. 
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supplementation have been reported.137,138 However, no clinical study has yet provided 
support for this hypothesis. 
Yet another theory suggests that mevalonate production in the biosynthetic 
pathway of cholesterol leads to activation of regulatory proteins such as guanosine 
triphosphate (GTP)-binding proteins.139 These GTP-binding proteins are important in 
apoptosis or controlled cell death, which is a critical mechanism designed to assist in the 
remodeling and maintenance of tissue structure.140 Inhibition of mevalonate production 
by statins leads to inappropriate activation of these proteins.  As a result of inappropriate 
activation, apoptosis can cause pathological conditions.  It has been suggested that statin-
induced reductase inhibition triggers skeletal myocyte apoptosis and myopathy 
development.141,142,143 Also, a dose-dependent increase in apoptosis due to statin therapy 
has been observed in vascular smooth muscle cells.  Thus, it is possible that that same 
mechanism is involved in the inhibition of vascular smooth muscle cell’s proliferation 
and apoptic cell death in muscle fibers.144 
These are the theories that have been proposed for the mode of action statin-
induced myopathies.  Each of these theories continues to be investigated and additional 
 
137 Chariot P, Abadia R, Agnus D, et al. Simvastatin-induced rhabdomyolysis followed by a MELAS 
syndrome. Am J Med 1993;94:109-10. 
138 Walravens PA, Greene C, Frerman FE. Lovastatin, isoprenes, and myopathy. Lancet 1989;2:1097-8. 
139 Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther 2005;85:459-
65. 
140 Ibid. 
141 Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-
coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65. 
142 Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible 
mechanisms. Pharmacol Rep 2005;57:23-34. 
143 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
144 Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible 
mechanisms. Pharmacol Rep 2005;57:23-34. 
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work is required to support these theories.  Also it is possible that new theories may also 
evolve explaining the mechanism of myopathy due to statins. 
 
MYOPATHY IN RANDOMIZED CONTROLLED TRIALS OF STATIN 
THERAPY 
 Clinical trials that have assessed the safety and efficacy of statins support a low 
incidence of serious muscle problems with statin therapy.  Table 1.5 provides information 
on the rates of myopathy reported in seven clinical trials.145 
145 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
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Table 1.5: Percent of patients with myalgia, and number of patients with myositis and rhabdomyolysis in different
clinical trials of statin therapy as published by Thompson and colleagues
Drug Study No. of patients % with myalgia No. with myositisa No. with rhabdomyolysis
Statin Control Statin Control Statin Control Statin Control
Lovastatin AFCAPS/TexCAPSb 3304 3301 NA NA 21 21 1 2
Pravastatin CAREc 2078 2081 NA NA 0 4 0 0
WOSCOPSd 3302 3293 3.5 3.7 NA NA 0 0
LIPIDe 4512 4502 NA NA 8 10 0 0
Simvastatin 4Sf 2221 2223 NA NA 6 1 1 0
HPSg 10,269 10,267 32.9 33.2 11 6 5 3
Fluvastatin LCASh 214 215 NA NA 1 2 0 0
Atorvastatin MIRACLi 1538 1548 NA NA 0 0 0 0
Cerivastatin ENCOREj 114 119 NA NA 2 0 NA NA
Rosuvastatink 12,400 0 3.1 NA 2 NA 1 NA
Source: Thompson PD, Clarkson P, Karas RH. Statin-induced myopathy. JAMA 2003;289:1681-1690
NA-Not available
a. Myositis was defined as a CK elevation of greater than 10 times the upper limit of normal
b. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:
results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
c. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
d. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary
Prevention Study Group. N Engl J Med 1995;333:1301-7.
e. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
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Table 1.5: Percent of patients with myalgia, and number of patients with myositis and rhabdomyolysis in different
clinical trials of statin therapy as published by Thompson and colleagues (Continued)
f. The Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet
1994;344:1383-9.
g. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a
randomised placebo-controlled trial. Lancet 2002;360:7-22.
h. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations
(Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-86.
i. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL
study: a randomized controlled trial. JAMA 2001;285:1711-8.
j. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of
Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003;107:422-8.
k. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-8.
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As seen from Table 1.5, myopathy was not reported frequently during clinical 
trials, and there were few differences in the myopathy rates between the statin group and 
the control group.  The first generation statins (lovastatin, pravastatin, and simvastatin) 
have been well evaluated for their safety and efficacy in large clinical trials (Table 1.5).  
In the prospective pravastatin pooling project,146 which analyzed over 112,000 patient-
years of pravastatin exposure, three subjects had high creatine kinase concentrations and 
there were no cases of rhabdomyolysis.  In the 4S trial,147 there were six cases of mild 
myositis and one case of rhabdomyolysis.  In HPS trial,148 one of the largest statin trials 
to date (20,536 patients), 32.9% of the simvastatin and 33.2% of the placebo participants 
complained of muscle symptoms.  Rhabdodmyolysis occurred in five patients in the 
statin group and in the three placebo group patients.  Similarly, for trials of lovastatin, 
there was no difference in the myopathy rates between the statin and the control group. 
 As compared to first generation statins, there are fewer clinical trials for second 
generation statins (fluvastatin, atorvastatin, cerivastatin, and rosuvastatin).149 Fluvastatin 
and atorvastatin have demonstrated safety profiles similar to other statins in small studies 
(Table 1.5).150 Rosuvastatin is a much newer drug and the safety profile of this drug will 
have to be monitored.  Cerivastatin had similar safety profiles in clinical trials; however, 
 
146 Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: 
prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341-6. 
147 The Scandinavian Simvastatin Survival Study (4S) Group. Randomised trial of cholesterol lowering in 
4444 patients with coronary heart disease. Lancet 1994;344:1383-9. 
148 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering 
with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-
22. 
149 Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-
coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65. 
150 Ibid. 
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it was later withdrawn from the market due to high risk of rhabdomyolysis (discussed 
later). 
 In summary, the incidences of myopathy, mild or severe, reported in clinical trials 
are between 0.1 percent and 5.0 percent, depending on dose and type of statin.  However, 
many patients excluded from the trials receive these agents in clinical practice.  Also, 
patients in clinical trials are generally better informed, and monitored very closely as 
compared to those in a “real-world” setting.151,152 Therefore, these incidences may be 
underestimated in clinical trials compared to actual rates of myopathy in “real-world” 
situations.153,154,155 The case of cerivastatin is an example where the incidence was low in 
clinical trials but the drug was later withdrawn from market due to increased rates of 
rhabdomyolysis.  The next part looks at the life-cycle of cerivastatin from its marketing 
approval to its withdrawal. 
 
CERIVASTATIN: MARKETING APPROVAL TO WITHDRAWAL 
 Cerivastatin was developed as a highly potent lipophilic, pure enantiomeric agent 
and has been evaluated in studies since 1993.156 Cerivastatin is metabolized dually by 
two different isoenzymes in cytochrome P450 system (CYP 3A4 & CYP 2C9), and this 
 
151 Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk 
patients. Arch Intern Med 2003;163:553-64. 
152 Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-
coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65. 
153 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
154 Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-
coenzyme A reductase inhibitors. Am Heart J 2004;147:956-65. 
155 Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk 
patients. Arch Intern Med 2003;163:553-64. 
156 Stein E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am J 
Cardiol 1998;82:40J-46J. 
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dual mechanism was thought to improve its safety profile compared to other statins.157 
Based on the safety profile, the drug was marketed in 1998.  At the initial approved doses 
of 0.2 and 0.3 mg, cerivastatin reduced LDL levels lower than the other statins available 
at the time.  To achieve comparable levels of cholesterol lowering, new drug applications 
were made for 0.4 mg and 0.8 mg, which were approved subsequently in 1999 and 
2000.158 Premarketing clinical trials of cerivastatin up to doses of 0.4 mg, showed no risk 
of rhabdomyolysis.  However, there was a significant increase in adverse events 
including myotoxicity in doses higher than 0.4 mg.159 This was evident in the reports of 
post-marketing surveillance, which subsequently led to its withdrawal. 
 Psaty and colleagues160 reviewed unpublished manufacturer’s data on cerivastatin 
made available to public during lawsuit trials.  The authors reported that the company had 
received seven case reports of rhabdomyolysis within 100 days of marketing the drug.  
However, the company did not report this safety data to FDA.  Five of the seven cases 
had used gemfibrozil concomitantly with cerivastatin.  These reports continued to 
increase over time.  As a result, the FDA issued a specific contraindication of the use of 
cerivastatin and gemfibrozil.  In spite of this label change, there was continued use of the 
two drugs together, and then higher dose (0.8 mg) of cerivastatin was introduced in the 
 
157 Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the 
same? Drug Saf 2002;25:649-63. 
158 Psaty BM, Furberg CD, Ray WA, et al. Potential for Conflict of Interest in the Evaluation of Suspected 
Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis. JAMA 2004;292:2622-2631. 
159 Ose L, Luurila O, Eriksson J, et al. Cerivastatin gender effect: sub-analyses of results from a 
multinational, randomised, double-blind study. Cerivastatin Study Group. Curr Med Res Opin 2000;16:80-
7. 
160 Psaty BM, Furberg CD, Ray WA, et al. Potential for Conflict of Interest in the Evaluation of Suspected 
Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis. JAMA 2004;292:2622-2631. 
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market.161,162 During this period, the incidence of rhabdomyolysis continued to increase, 
and 52 worldwide deaths were recorded with the use of cerivastatin.163 After these 
reports, cerivastatin was withdrawn from the market.  The US accounted for 31 of the 52 
deaths, and 12 of the case fatalities involved a combination of cerivastatin and 
gemfibrozil.  In the majority of the cases where cerivastatin was used alone and a death 
occurred, the dose was 0.8 mg.164 Thus, severe myopathy appeared to occur at higher 
doses and in cases where patients took the drug with gemfibrozil. 
 The experience with cerivastatin emphasizes the need to continuously monitor 
adverse drug reactions after marketing of the drug, even though the drug has been proven 
safe in clinical trials.  This is because, as mentioned before, clinical trial settings are 
different from “real-world” practice settings, and many factors come into play in the 
actual setting.  Postmarketing surveillance is one way to monitor adverse reactions after 
marketing of the drug. 
 
POSTMARKETING SURVEILLANCE: REPORTS OF MYOPATHY/ 
RHABDOMYOLYSIS TO THE FOOD AND DRUG ADMINISTRATION 
 Postmarketing surveillance of drug-related events is one method that plays a 
valuable role in early identification of adverse events associated with drug therapy.  
 
161 Ibid. 
162 Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the 
same? Drug Saf 2002;25:649-63. 
163 Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-5. 
164 Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the 
same? Drug Saf 2002;25:649-63. 
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Postmarketing surveillance begins when the drug enters the market.  This monitoring of 
drug safety helps promote safe drug therapy, and therefore protects the health of public. 
 In the US, FDA is responsible for postmarketing surveillance.  The Office of 
Drug Safety (ODS) of the FDA receives voluntary spontaneous reports of adverse drug 
reactions, primarily from physicians and pharmacists, and through drug companies, and 
rarely from consumers.165 FDA’s Adverse Event Reporting System (AERS) is a 
repository of reports of adverse drug reactions.  This database can be used to identify 
drug-related events that occur in clinical practice.166,167 
Case-reports of myopathy associated with statin use began to appear in the 
literature as early as 1988; some of them involved potentially interacting medications.168 
The FDA database has been reviewed multiple times, with varying time periods, to 
identify cases of statin-associated rhabdomyolysis.  Omar and colleagues169 reviewed the 
database first, and found 601 cases of statin-associated rhabdomyolysis from November 
1997 through March 2000.  Thompson et al.170 reviewed the FDA database to identify 
cases of statin-associated rhabdomyolysis from January 1, 1990, through March 31, 2002.  
The authors found 3339 cases of statin-associated rhabdomyolysis.  Chang et al.171 
165 Adverse event reporting system. US Food and Drug Administration, 2005. Available at: 
http://www.fda.gov/cder/aers/default.htm. Accessed on: August 18 
166 Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann 
Pharmacother 2001;35:1096-107. 
167 Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and 
gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26. 
168 Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk 
patients. Arch Intern Med 2003;163:553-64. 
169 Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann 
Pharmacother 2001;35:1096-107. 
170 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
171 Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and 
gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26. 
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reviewed the database from the initial date of marketing for each of the statins until July 
2001, and extensively examined the cases of rhabdomyolysis and calculated the reporting 
rates for this event.  Table 1.6 summarizes the results of this study.  Table 1.7 illustrates 
the reporting rates for rhabdomyolysis. 
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Table 1.6: Mean age, gender, number of days to onset, mean dose, and outcomes of patients who had
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Source: Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Pharmacoepidemiol Drug Saf 2004; 13:417-426.
a. Data for all cases was not available. Due to incomplete data, means and number of cases for selected characteristics may be less than actual reported
number.
b. More than one outcome is possible.
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Table 1.7: Years analyzed, number of prescriptions dispensed, number of cases and crude reporting rates/100,000
prescriptions of rhabdomyolysis for different statin therapies as published by Chang and colleagues
Lovastatin Pravastatin Simvastatin Fluvastatin Atorvastatin Cerivastatin
Years analyzed 1988-July 2001 1992-July 2001 1992-July 2001 1994-July 2001 1997-July 2001 1998-July 2001
# of Rx’s (000’s)a 99,485 83,673 120,188 38,119 149,706 11,172
Cases 180 19 136 1 51 479
Crude reporting
rate/100,000 Rx
0.18 0.02 0.11 0.00 0.03 4.29
Source: Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Pharmacoepidemiol Drug Saf 2004; 13:417-426.
a. All dispensed Rxs for all years the drug was marketed, excluding long term care (Source: IMS Health)
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As seen from Table 1.6, a total of 866 cases of rhabdomyolysis were reported to 
the FDA from 1988 through July 2001.  More than 80% of the cases for each of the statin 
drug product resulted in hospitalization.  Also, the number of cases of rhabdomyolysis 
was much higher for cerivastatin as compared to any other statins.   Of the 866 reported 
cases, 482 (56%) cases were associated with monotherapy and 384 (44%) cases were 
associated with combination therapy of statin and gemfibrozil.172 In an earlier study by 
Omar and colleagues,173 rhabdomyolysis was associated with a combination of statins 
and other drugs (including gemfibrozil) that interfere with the metabolism of statins (e.g. 
CYP 3A4 inhibitors).  In addition to the statins mentioned in Table 1.6, rosuvastatin was 
marketed in October 2003.  Alsheikh-Ali and colleagues174 reviewed the FDA database 
for adverse events of rosuvastatin.  Within one-year of marketing the drug, there were 
145 reports of rosuvastatin-associated rhabdomyolysis.  As compared with the other 
statins, over the concurrent time frame and during their first year of marketing, 
rosuvastatin was several-fold more likely to be associated with rhabdomyolysis. 
 As shown in Table 1.7, the reporting rates for rhabdomyolysis were similar and 
much lower than one per 100,000 prescriptions for all statins, except cerivastatin.  The 
reporting rate for cerivastatin was 4.29/100,000 prescriptions but this rate was increased 
to 1249/100,000 prescriptions for a combination of cerivastatin and gemfibrozil.   
As discussed before, because of high rate of deaths due to cerivastatin-associated 
rhabdomyolysis, the drug was withdrawn from the market. 
 
172 Ibid. 
173 Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann 
Pharmacother 2001;35:1096-107. 
174 Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical 
practice: a postmarketing analysis. Circulation 2005;111:3051-57. 
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Although AERS is good source to monitor postmarketing rates of adverse events, 
it has many limitations.  The data used in the studies above reflect adverse event 
reporting rates, and not actual adverse event rates.175 Since AERS is a voluntary 
reporting system, it is left completely to the discretion of the health care professional 
whether or not to report an adverse event.  Also, it is known that most adverse drug 
reactions are severely underreported.176,177 Hence, the rates presented in Table 1.7 are 
likely underestimates of the true rate of the adverse events.    Therefore, it is important to 
scientifically design studies that can give true estimates of the risk of myopathy.  
Epidemiologic studies are one method that can provide true estimates of statin-associated 
myopathy. 
 
EPIDEMIOLOGICAL STUDIES OF MYOPATHY 
 The literature on epidemiologic studies of statin-associated myopathy is very 
sparse.  This may be because myopathy is such a rare event that a large population is 
required to do the study.  Four known studies have estimated the incidence of myopathy 
in patients using statins. Two of these studies were done on the population of United 
Kingdom using the General Practice Research Database (GPRD) database and two 
studies were done in the U.S. using large managed care databases. 
 
175 Ibid. 
176 Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and 
gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004;13:417-26. 
177 Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann 
Pharmacother 2001;35:1096-107. 
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Gaist and colleagues178 conducted a population-based cohort study to estimate the 
risk of myopathy associated with use of statins and fibrates.  This was one of the earliest 
studies done estimating the incidence of myopathy.  The authors utilized GPRD, which 
contains data from general practices in United Kingdom, to determine the risk of 
myopathy.  Three cohorts of individuals, aged 40 to 74, were identified from 1991 to 
1997.  The first cohort consisted of persons using a lipid lowering drug; the second 
included those patients who had a diagnosis of hyperlipidemia but did not use a lipid-
lowering drug; and the third cohort were persons from general population with no 
diagnosis of hyperlipidemia.  The authors identified myopathy cases using Oxford 
Medical Information System (OXMIS) codes and then verified the cases using patient 
charts.  The incidence rate of myopathy in the cohort of users of lipid-lowering drugs was 
2.3 per 10,000 person years (95% CI: 1.2-4.4) which exceeded the incidence rates 
observed in the non-treated hyperlipidemia cohort [0 per 10,000 person years (95% CI: 
0.0-0.4)] and the general population [0.2 per 10,000 years (95% CI: 0.1-0.4).  The 
relative risks of myopathy in current users of fibrates and statins as compared to non-
users were 42.4 (95% CI: 11.6-170.5) and 7.6 (95% CI: 1.4-41.3), respectively.  The 
authors concluded that although the absolute risk of myopathy for statin and fibrate users 
is small, the relative risk of myopathy associated with lipid-lowering drugs is high, with 
fibrates having the greatest risk. 
 
178 Gaist D, Garcia Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a 
population-based follow-up study. Epidemiology 2001;12:565-9. 
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Black and Jick also analyzed the GPRD database to estimate the risk of 
rhabdomyolysis with lipid lowering agents.  Among 2935 concurrent users of statin and 
fibrates, only one patient developed rhabdomyolysis.179 
Recently, a very extensive study was conducted estimating the risk and risk 
factors of rhabdomyolysis in users of statins and fibrates, alone or as a combination 
therapy.  Graham and colleagues180 determined the incidence of hospitalized 
rhabdomyolysis using claims data from health care plans across the US.  The average 
incidence for monotherapy with statins was 0.44 (95% CI: 0.20-0.84) per 10,000 years.  
This incidence rate increased for patients above 65 years of age and for patients with 
diabetes mellitus.  Cerivastatin was not included in this analysis.  The incidence for 
combined statin and fibrate users was 5.98 (95% CI: 0.72-216.0) per 10,000 patient-
years.  Statin-fibrate combination users had 12-fold increase in risk of myopathy as 
compared to statin users only (RR: 12.2; 95% CI: 2.59–57.44).  This risk was further 
increased in patients 65 years and older with diabetes mellitus (RR: 48; 95% CI: 5.2-
446.0).  The authors concluded that the risk of rhabdomyolysis was low for statin 
monotherapy.  However, the risk increased in patients using combination therapy and 
patients with certain risk factors. 
 A more recent study used administrative claims database from diverse regions in 
US to evaluate the incidences of hospitalizations related to adverse effects including 
myopathy for lipid lowering agents.  Incidence of hospitalizations for myopathy in 
 
179 Black C, Jick H. Etiology and frequency of rhabdomyolysis. Pharmacotherapy 2002;22:1524-26. 
180 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
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patients treated only with statins varied from 1.58 for fluvastatin to 3.84 for pravastatin 
per 10,000 person-years.   Risk of hospitalizations due to myopathy increased in presence 
of hypertension (RR: 5.13; 95% CI: 2.4 –10.85) and if patients received potentially 
interacting medications concurrently with statins (RR: 6.01; 95% CI: 2.08–17.38).181 The 
authors concluded that statin monotherapy is well-tolerated; however, the risk of 
myopathy increases in presence of PIMs. 
 Only one study has estimated the prevalence of myopathy in patients using statins 
alone or in combination with potentially interacting medications.182 This study estimated 
the prevalence of myopathy to be 0.12% in statin alone users and 0.22% in statins and 
potentially interacting medication users.  This difference in prevalence was statistically 
significant (p = 0.05).183 Most of the myopathy events were related to an increase in 
statin dose or addition of potentially interacting medication. 
 In summary all of these studies demonstrate that the risk of myopathy (mostly 
rhabdomyolysis) is low with statin monotherapy.  However, this risk may increase in 
presence of fibrates or other potentially interacting medications and patients with certain 
characteristics.  Presence of risk factors can greatly affect the risk of myopathy in 
patients.  The next section describes the risk factors of myopathy. 
 
181 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
182 Shanahan RL, Kerzee JA, Sandhoff BG, et al. Low myopathy rates associated with statins as 
monotherapy or combination therapy with interacting drugs in a group model health maintenance 
organization. Pharmacotherapy 2005;25:345-51. 
183 Ibid. 
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RISK FACTORS FOR MYOPATHY 
 The risk factors for myopathy can be divided into four main factors: demographic 
factors, health-related factors, treatment factors and physician-related factors.  The next 
part describes each of the factors that affect myopathy. 
 
Demographic factors 
Three demographic factors that may affect the risk of myopathy are age, gender, 
and ethnicity/race.  
Age  
Age is one of the risk factors for myopathy.184 The risk of myopathy increases 
with age due to the effect of aging on muscles.185 In two studies that estimated the risk of 
myopathy in statin users (mentioned above), people above the age of 65 had a higher risk 
of myopathy than younger patients.186,187 Therefore, increasing age is an important risk 
factor of myopathy. 
Gender  
Females have a higher risk of myopathy than males.188 This is based on evidence 
from case reports and spontaneous reporting systems.  However, in the two previous 
 
184 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
185 Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16. 
186 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
187 Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based 
follow-up study. Epidemiology 2001;12:565-9. 
188 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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studies done, there was no difference in the relative risk of myopathy based on gender.  
More research is needed to determine the effect of gender on the risk of myopathy. 
Ethnicity/race 
Ethnicity/race could have an impact on the risk of myopathy.  Most clinical trials 
did not incorporate different ethnicities/races to examine their safety profile in this 
population.  It is not very clear whether ethnicity/race has an impact of the risk of 
myopathy.  However, rosuvastatin pharmacokinetic studies show that there is a greater 
risk of myopathy in Asians than in other sub-populations.189 The difference in genetic 
makeup across ethnicities/races may play an important role in the risk of myopathy 
among patients. 
 
Health risk factors 
There are two main health risk factors: lifestyle factors and co-morbidity factors.  
These factors are known to increase the risk of myopathy.  Each of these factors is 
described in detail below. 
Lifestyle factors: 
Physical activity
Patients treated with statins may experience an increase in plasma creatine kinase 
(CK) levels following exercise.  This may be associated with disruption of muscle cell 
membrane.190 Among 14 men taking lovastatin, CK levels were increased in two, 24 
 
189 Crestor, [package insert]. Wlimington, Del: AstraZeneca Pharmaceuticals; 2005; 
190 Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 
2000;22:441-57. 
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hours after exercise.191 This increase in CK levels may result in increased risk of 
myopathy. 
Body size 
Small body size increases the risk of myopathy.192 This is related to volume of 
distribution of drug in thin or frail people.193 As a result, higher concentrations of drug 
may be present in the body increasing the risk of myopathy. 
Increased consumption of grapefruit juice 
Large quantities of grapefruit juice (usually more than 1 quart per day) greatly 
increase the risk of myopathy.194 Grapefruit inhibits an important enzyme (CYP450) in 
the metabolism of statins which increases the concentration of statins in the blood and 
thereby increases the risk of myopathy.195 
Alcohol abuse 
Excessive alcohol intake independently predisposes a patient to the risk 
myopathy.196 Statin use in such patients increases the risk of myopathy in these patients. 
 
191 Thompson PD, Gadaleta PA, Yurgalevitch S, et al. Effects of exercise and lovastatin on serum creatine 
kinase activity. Metabolism 1991;40:1333-6. 
192 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
193 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
194 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
195 Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J 
Cardiovasc Drugs 2004;4:281-97. 
196 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 




Diabetes is considered as a risk factor for myopathy.  This is based on case reports 
where many of the patients reporting myopathy/rhabdomyolysis had diabetes.  Graham et 
al.197 reported that the risk of rhabdomyolysis increased in patients with diabetes on statin 
monotherapy as well as on statin-fibrate combination.  It has been postulated that patients 
with diabetes have reduced drug metabolism which increases the concentration of statins 
in blood thereby increasing the risk of myopathy.198 
Renal insufficiency 
In patients with renal insufficiency the risk of myopathy is higher independent of 
statin use.  This is due to altered drug metabolism and polypharmacy in these patients.199 
In presence of statin use, the risk increases further.   
Hepatic dysfunction 
NCEP guidelines recommend preventing use of statins in patients with active or 
chronic liver diseases.200 Such diseases increase the risk of hepatotoxicity.  Presence of 
these diseases can also inhibit the metabolism of statins as liver is the primary path of 
metabolism.  This can lead to increase in statin blood levels and risk of myopathy.     
 
197 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
198 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
199 Sica DA, Gehr TW. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: 
considerations in the renal failure patient. Curr Opin Nephrol Hypertens 2002;11:123-33. 
200 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 




Hypothyroidism predisposes patients to myopathy independent of statin use.  
Clinical manifestations of hypothyroidism include proximal muscle weakness and 
elevation of creatine kinase levels.201 Such manifestations are increased when these 
patients use statins.   
 
Treatment-related factors 
 There are two main treatment-related factors: type and dose of statin, and receipt 
of potentially interacting medications with statins. 
 
Type and dose of statin 
 The type and dose of statin used may contribute to the risk of myopathy.  Factors 
that increase the concentration of statins in the blood enhance the risk of myopathy.  
According to the ACC/AHA/NHLBI clinical advisory on statins, myopathy is more likely 
to occur at higher statin doses than lower doses.202 This is because the higher the dose, 
the greater the concentration of statin in blood and greater the risk of myopathy. 
 In addition to the dose, the type of statin used can also affect the risk of 
myopathy.  As discussed, the pharmacokinetic properties of statins differ and this affects 
the risk of myopathy (Table 1.2).  The first metabolic property that differs across statins 
is the solubility of statins.  Lipophilic statins penetrate into the peripheral tissue more 
 
201 Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16. 
202 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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readily than hydrophilic statins, and therefore are more likely to produce the muscular 
effects.203 
The second metabolic property that differs across statins is the method of 
metabolism of statins.  The statins are metabolized mainly by CYP450 system, except 
pravastatin.  This cytochrome system is also responsible for the metabolism and 
elimination of many other pharmacologic agents.  This results in drug interactions with 
statins and may increase the concentration of statins in the blood which may lead to 
myopathy.204,205 
Statins and potentially interacting medications is the focus of this dissertation and 
is discussed in detail in the next section. 
 
203 Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-16. 
204 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 
205 Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase 
inhibitors. Clin Pharmacokinet 2002;41:343-70. 
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SECTION IV 
STATINS AND POTENTIALLY INTERACTING MEDICATIONS 
 
Myopathy is more likely to occur when statin drugs are administered with certain 
potentially interacting medications.  Drugs that interact with statins either increase the 
concentrations of statins in the blood or are themselves myotoxic.  Thus, the receipt of 
potentially interacting medications with statins is one of the factors that increase the risk 
of myopathy.  The ACC/AHA/NHLBI clinical advisory on statins has listed the 
following medications as increasing the risk of statin-associated myopathy: fibrates, 
nicotinic acid, cyclosporine, azole antifungals, macrolide antibiotics, HIV protease 
inhibitors, nefazodone, calcium channel blockers, and amiodarone.  This section gives a 
brief background on drug interactions followed by a description of prevalence and cost of 
co-prescription of statins with potentially interacting medications.  Finally, the rationale, 
efficacy, and safety of concurrent use of statins with each class of potentially interacting 
medication will be described.  
 
BACKGROUND ON DRUG INTERACTIONS 
 Drug-drug interactions are an important cause of adverse effects.  Drug-drug 
interactions were responsible for approximately 5% of adverse effects in hospitalized 
patients.206 Drug interactions can be either pharmacokinetic drug reactions or 
 
206 Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug-drug 
interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. 
Drug Saf 2005;28:263-75. 
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pharmacodynamic drug reactions.  Pharmacokinetic drug interactions occur when drugs 
cause an alteration in the concentration of unbound drug acting on the tissues.  These 
interactions result in changes in drug absorption, metabolism or elimination. 207 
Pharmacodynamic drug interactions are related to the pharmacologic activity of the 
interacting drug.  These interactions are frequently associated with synergism, 
antagonism, or altered cellular transport.  Pharmacodynamic interactions affect receptor 
sites and/or organ systems.208 
The consequences of drug interactions depend upon patient-related as well as 
drug-related factors.209 Figure 1.2 shows the factors that influence drug interactions. 
 
Figure 1.2: Patient-related and drug-related factors influencing drug interactions 
 
Source: Hansten PD.  Understanding drug-drug interactions.  Science & Medicine 1998;5:16-25. 
207 Herman RJ. Drug interactions and the statins. CMAJ 1999;161:1281-6. 
208 Brown CH. Overview of drug interactions. US Pharmacist 2000;25:25-35. 
209 Hansten PD. Understanding drug-drug interactions. Science & Medicine 1998;5:16-25. 
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As seen from Figure 1.2, the pharmacokinetic properties of a drug play a key role in 
occurrence of drug interactions.  In addition, the dose/dosing times of the drug and the 
therapeutic index of the drug are also important considerations when a drug interaction 
occurs.  Individual susceptibility to drug interactions (and thereby adverse reactions) 
because of age, genetics, or disease related factors (such as renal, hepatic) are also an 
important consideration.  In summary, a variety of factors play a role in drug interactions. 
 
STATINS AND DRUG INTERACTIONS 
 Drug interactions with statins can lead to serious adverse effects (rhabdomyolysis) 
which may result in death.  The use of statins with potentially interacting medications has 
a higher risk of myopathy than statin monotherapy.210 The mechanism of action of drug 
interaction involves CYP450 isoenzyme which is involved in metabolism of most statins  
as discussed earlier.  CYP450 isoenzymes are also involved in the metabolism of many 
other drugs.  Drug interactions occur when two or more drugs that are metabolized by the 
same CYP450 isoenzyme are given concurrently.  Most statins are metabolized by 
CYP450 isoenzymes and bind weakly to these isoenzymes.  As a result, drugs with 
stronger binding affinity for CYP450 isoenzymes will displace statins from these binding 
sites leading to increase in concentrations of statins in the blood.211 This increases the 
risk of myopathy.  In addition, pharmacodynamic interactions also can occur with statins 
leading to increase in the risk of myopathy. 
 
210 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
211 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 
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The possibility of drug interactions with statins is often unrecognized in clinical 
trials.212 The probability of drug interactions is a particularly important consideration 
because of the high rates of polypharmacy among patients taking statins. Also, drug 
interactions with statins may have clinical and economic consequences.  A few studies 
have been conducted that looked at the prevalence and cost of using statins with 
potentially interacting medications.  The next section describes these studies. 
 
PREVALENCE AND COST OF CO-PRESCRIPTION OF STATINS WITH 
POTENTIALLY INTERACTING MEDICATIONS 
 There have been very few studies that have described the prevalence and cost of 
use of statins with potentially interacting medications.  One of the earliest studies 
investigating the co-prescribing of statins with potentially interacting drugs was 
conducted in Ireland.  In this study, Heerey and colleagues used information from 
database from January to December 1998 to identify potentially interacting medications 
concurrently used with statins.213 The results of this study showed that 34% of patients 
on simvastatin, 28% on atorvastatin and 16% on fluvastatin received medications with 
the potential for drug interactions.  Recently, a Swiss study that assessed the prevalence 
of drug-statin interaction showed that about 6.9% of the population received potentially 
interacting medications that were harmful to the patients.214 
212 Fine DM. Statin-related muscle toxicity. Adv Stud Med. 2003;3:554-560. 
213 Heerey A, Barry M, Ryan M, et al. The potential for drug interactions with statin therapy in Ireland. Ir J 
Med Sci 2000;169:176-9. 
214 Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug-drug 
interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. 
Drug Saf 2005;28:263-75. 
67
Petropoulos et al. looked at the frequency of simvastatin prescriptions with 
potentially interacting medications in Veterans Affairs health care system.215 In this 
study, 10.5% of the patients were prescribed at least one potentially interacting 
medication.  Approximately 57% of simvastatin doses were above the maximum 
recommended daily dose when prescribed with potentially interacting medications. A 
combination of high statin doses with potentially interacting medications increases the 
risk of myopathy.   In another study conducted at a large U.S. managed care organization, 
approximately 32% of patients on simvastatin, 30% of patients on atorvastatin, and 3% of 
patients on pravastatin received a potentially interacting medication at some point.216 
The odds of receiving a potentially interacting medication were higher for both 
simvastatin and atorvastatin as compared to pravastatin.  All of these studies reveal that 
statins are prescribed with potentially interacting medications quite often. 
 The economic consequences of concurrent use of statins and potentially 
interacting medications have also been studied.  Einarson and colleagues217 examined the 
effect of drug interactions with statins on Canadian health care costs.  The results showed 
that the costs of hospital admissions, physician visits, and drugs were significantly higher 
for patients using statins and potentially interacting medications as compared to those 
using statins by themselves.  In a U.S. study, patients’ receiving potentially interacting 
 
215 Petropoulos JB, Bello-Quintero CE. Frequency of simvastatin prescriptions with potentially interacting 
medications in a Veterans Affairs health care system. J Manag Care Pharm 2004;10:239-43. 
216 Etemad LR, Fairchild C, Waldeck R. Prevalence and cost implications of potential interactions with 
statin medications in a managed care population. ISPOR Ninth Annual International Meeting 2004. 
Washington, D.C. 
217 Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug 
interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a 
Canadian population-based study. Clin Ther 2002;24:2126-36. 
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medications had 32% greater medical costs and 50% greater pharmacy costs than those 
who did not receive any potentially interacting medications.218 
In summary, all of the above-mentioned studies show that the prevalence and the 
costs of using statins with potentially interacting medications are high.  With the potential 
for a substantial increase in the number of patients treated with statins over the next 
several years, the potential of drug interactions may further increase leading to a further 
increase in clinical and economic consequences.  Therefore, it is important for health care 
professionals to be aware and prevent these interactions.  The ACC/AHA/NHLBI clinical 
advisory on statins has listed the following medications as increasing the risk of statin-
associated myopathy: fibrates, nicotinic acid, cyclosporine, azole antifungals, macrolide 
antibiotics, HIV protease inhibitors, nefazodone, calcium channel blockers, and 
amiodarone.  The next part provides detailed information on interaction of each of the 
above-mentioned drugs with statins. 
 
STATINS AND FIBRATES 
Statins and fibrates have shown efficacy in clinical trials for reducing LDL and 
triglyceride levels, respectively (discussed earlier).  Statins have also been shown to 
reduce the rate of cardiovascular events.  In spite of this evidence, it has been shown in 
the clinical trials that the maximum reduction of cardiac events has been 40% comparing 
 
218 Etemad LR, Fairchild C, Waldeck R. Prevalence and cost implications of potential interactions with 
statin medications in a managed care population. ISPOR Ninth Annual International Meeting 2004. 
Washington, D.C. 
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statin with a placebo.219 This means that there are a large number of people who in spite 
of being treated with statins experience a cardiac event.  This is highlighted in the 
Scandinavian Simvastatin Survival Study where over a 5-year period 19% of drug treated 
patients experienced recurrent myocardial infarction or coronary death.220 This may be 
due to increased triglycerides which also increase the risk of CHD.   
Epidemiological studies suggest that hypertriglyceridemia, due to elevations of 
VLDL and IDL, is an independent risk factor for CHD.221,222,223,224 The recent ATP III 
guidelines by NCEP recommend treatment beyond lowering LDL for patients with 
triglycerides of 200 mg/dl and above.225 Therefore, if the triglycerides are above the 
recommended levels, the treatment plan for patients should include controlling high 
triglyceride concentrations.  It is for this purpose that a combination therapy of statin with 
a fibrate is becoming a widely used treatment plan.  However, statin and fibrate 
combinations are associated with increased risk of myopathy.226,227,228 The following 
 
219 Guyton JR. Combination drug therapy for combined hyperlipidemia. Current Cardiology Reports 
1999;1:244-250. 
220 Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 
1994;344:1383-9. 
221 Austin M. Epidemiology of hypertriglyceridemia and cardiovascular disease. Am J Cardiol 
1999;83:13F-6F. 
222 Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an 
eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36. 
223 Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol 
and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. 
Implications for treatment. Circulation 1992;85:37-45. 
224 Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein 
particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8. 
225 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 
Circulation 2002;106:3143-421. 
226 Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and 
safety. Eur Heart J 1995;16:5-13. 
70
section will discuss studies that evaluated the efficacy and safety of statin-fibrate 
combination therapy. 
 
Studies evaluating the efficacy and safety of statin and fibrate combination therapy 
Many studies have assessed the efficacy and safety of combination therapy.  The 
study designs of the published reports include randomized controlled trials, prospective 
open-label studies, and retrospective studies.  Shek et al.229 performed a thorough 
literature review of all studies evaluating combination therapy from 1988-2000.  The 
authors reviewed 36 studies, of which 21 trials were open-label, six were retrospective, 
and 10 were prospective studies.  A total of 1,674 patients were treated with combination 
therapy from two to 184 weeks.  There were no cases of reported rhabdomyolysis; 
however, an incidence of 0.12% for myopathy (defined as CK levels greater than 10 
times upper limit of normal (ULN)) was reported. A total of 1.9% of patients developed 
muscle weakness, musculoskeletal pain, or myositis.  The authors pointed out that the 
true incidence might have been underestimated, because not all studies described the 
numbers or the reasons for discontinuation.  One of the other reasons for low incidence 
rate may have been the controlled environment of some studies and extensive exclusion 
criteria which did not include a lot of high risk patients.  
 
227 Shammas NW, Kapalis MJ, Deckert J, et al. Effectiveness of statin-gemfibrozil combination therapy in 
patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the 
literature. Prev Cardiol 2003;6:189-94. 
228 Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-
gemfibrozil combination therapy. JAMA 1990;264:71-5. 
229 Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17. 
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In a review of all randomized controlled trials, the author found an incidence rate 
of 1% of myopathy or rhabdomyolysis from such a combination. 230 Another study231 
pooled the data from prospective studies of statin-gemfibrozil combination therapy, and 
concluded that there was higher risk of myopathy in patients taking lovastatin-
gemfibrozil combination (3.9%) compared to simvastatin-gemfibrozil (0.4%) 
combination therapy.  Pierce et al.232 reported similar high incidence rate (5%) with the 
use of lovastatin and gemfibrozil.  Pravastatin-gemfibrozil combination seemed to be the 
safest among the three combinations with no reports of myopathy.233 
A few studies that conducted head-to-head comparisons of different statin-fibrate 
combinations also have been published.  Table 1.8 summarizes these studies that 
compared safety and efficacy of more than one statin-fibrate combination at the same 
time. 
 
230 Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and 
safety. Eur Heart J 1995;16:5-13. 
231 Shammas NW, Kapalis MJ, Deckert J, et al. Effectiveness of statin-gemfibrozil combination therapy in 
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literature. Prev Cardiol 2003;6:189-94. 
232 Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-
gemfibrozil combination therapy. JAMA 1990;264:71-5. 
233 Shammas NW, Kapalis MJ, Deckert J, et al. Effectiveness of statin-gemfibrozil combination therapy in 
patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the 
literature. Prev Cardiol 2003;6:189-94. 
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Table 1.8: Study design, type and dose of statin and fibrate used, percent decrease in LDL and triglyceride levels,
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Table 1.8: Study design, type and dose of statin and fibrate used, percent decrease in LDL and triglyceride levels,























35-41 48-56 1 1
LDL-low density lipoprotein; CK-creatine kinase; Retro-retrospective; R-randomized; DB-double-blind; Ator-atorvastatin; Sim-simvastatin; Prav-
pravastatin; Ceri-cerivastatin; Gem-gemfibrozil; Cipro-ciprofibrate; Feno-fenofibrate; Bez-bezafibrate; Trig-triglycerides; NA-not available.
a. Shammas NW, Kapalis MJ, Deckert J, et al. Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia:
experience of a community lipid clinic and safety review from the literature. Prev Cardiol 2003;6:189-94.
b. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin versus four statin-fibrate combinations in patients with familial combined
hyperlipidaemia. J Cardiovasc Risk 2002;9:33-9.
c. Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for
cardiovascular events. Am J Cardiol 2002;89:390-4.
d. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for
the treatment of mixed lipid disorders. Am Heart J 1999;138:151-5
e. Ellen RL, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol
1998;81:60B-65B.
f. Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory
familial combined hyperlipidemia. Am J Cardiol 1997;80:608-13.
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Although different statins were compared, none of the studies explicitly 
mentioned which statin-fibrate combination had more cases of myopathy.  Only severe 
cases of myopathy were attributed to statin-fibrate combination therapy.   A majority of 
the cases of rhabdomyolysis were associated with simvastatin and gemfibrozil.  The dose 
of the drugs was not specified in some of the studies.  But overall, these studies show that 
there are risks of muscle problems and an increase in CK levels. 
In summary, statin-fibrate combination therapy seems to be therapeutically 
effective; however, there seems to be increased risk of myopathy when the two drugs are 
taken together.  Due to different mechanisms of action, the interaction between statins 
and fibrates may appear to be pharmacodynamic but there is some evidence in the 
literature that the interaction may be due to pharmacokinetic interaction.  The next 
section describes the pharmacokinetics of statin-fibrate combination therapy.   
 
Effect of fibrates on pharmacokinetics of statins 
As discussed previously (in Section I), both statins and fibrates monotherapy are 
independently associated with risk of myopathy.  So a combination of two drugs together 
could explain the observed higher risk of muscle toxicity.  Therefore, initial evidence 
pointed towards a pharmacodynamic reaction between the two drugs.  In addition, 
fibrates are not known to inhibit CYP 450 mediated eliminations, and statins are not 
known to significantly inhibit any CYP pathways.  This suggests lack of pharmacokinetic 
interaction between statin and fibrates.  However, different pharmacokinetic studies 
evaluating the effect of fibrates on statins have had various conclusions.  There have been 
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two studies conducted on simvastatin, pravastatin, and rosuvastatin, and one each on 
cerivastatin, atorvastatin, fluvastatin, and lovastatin evaluating the effects of fibrates on 
statin concentrations. 
Bergman et al.234 determined the effect of fenofibrate on simvastatin and 
simvastatin acid, which is the active form of simvastatin.  Fenofibrate had no effect on 
pharmacokinetic parameters of simvastatin but the area under the curve (AUC) was 
decreased by 36% for simvastatin acid when the two were taken together.  The 
mechanism of action by which the plasma concentrations was decreased was not known 
but the authors concluded that it would be safe to take the two drugs together.  In 
contrast, the concurrent use of simvastatin with gemfibrozil increased the plasma 
concentrations of simvastatin.  In particular, gemfibrozil increased the plasma AUC of 
simvastatin by 35% and that of simvastatin acid by 185%.235 
Similar results have been observed with the administration of pravastatin with 
fenofibrate or gemfibrozil.  Concomitant administration of fenofibrate and pravastatin did 
not affect the pharmacokinetics of pravastatin; however, the concentration of one of its 
metabolite 3α-iso-PV was increased by 26%.236 The authors concluded that it was safe to 
take the two medications together even though there was a moderate increase in 
pravastatin metabolite.  This increase should not raise clinical concerns as the metabolites 
have much lower pharmacological potency than pravastatin and lack of toxicity.  On the 
 
234 Bergman AJ, Murphy G, Burke J, et al. Simvastatin Does Not Have a Clinically Significant 
Pharmacokinetic Interaction With Fenofibrate in Humans. J Clin Pharmacol 2004;44:1054-1062. 
235 Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are 
increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9. 
236 Pan WJ, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction 
between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316-23. 
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other hand, concomitant administration of gemfibrozil and pravastatin increased AUC of 
pravastatin by 202%.237 The authors attributed the increase, in part, to the decreased 
renal clearance of pravastatin in presence of gemfibrozil, and in part, to the increase of 
bioavailability of drug.  The authors hypothesized that this increase in bioavailability may 
be due to the effect of gemfibrozil on transporting proteins, which are involved in 
absorption, tissue uptake and elimination of pravastatin.238 
The concentration of rosuvastatin in presence of gemfibrozil increased 1.88-fold 
compared with placebo, and only minor increases in AUC of rosuvastatin were observed 
in presence of fenofibrate.239,240  The authors concluded that the increase in rosuvastatin 
concentration in presence of gemfibrozil is due to inhibition of hepatic uptake of the 
statin by gemfibrozil.241 
Most recently, Backman and colleagues242 assessed the effect of gemfibrozil on 
atorvastatin.  In a randomized crossover study, gemfibrozil increased the AUC of 
unchanged atorvastatin by 24%, and its active metabolites 2-hydroxyatorvastatin acid, 
and 4-hydroxyatorvastatin acid by 51% and by 82%, respectively. The authors concluded 
that only low doses of atorvastatin should be used with gemfibrozil, if necessary. 
 
237 Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma pravastatin concentrations 
and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003;73:538-44. 
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Two studies evaluated the effect of gemfibrozil on earlier statins, fluvastatin and 
lovastatin.  Contrary to most studies, gemfibrozil had no effect on plasma concentrations 
of fluvastatin,243 and the combination therapy appeared to be safe.  The plasma 
concentration of lovastatin acid, an active form of lovastatin, on the other hand, increased 
280% compared to the placebo.244 In the same study, bezafibrate had no effect on 
lovastatin concentrations, indicating it is safer to take lovastatin-bezafibrate combination 
than lovastatin-gemfibrozil combination.245 
Lastly, the greatest effect of gemfibrozil is seen on the pharmacokinetics of 
cerivastatin as compared to any other statin.  In a study conducted by Backman et al.,246 
gemfibrozil increased the plasma concentration of cerivastatin by 559%.  In this study, 
the plasma concentrations of its metabolites also were increased vastly.  The authors 
hypothesized that the increase in cerivastatin concentrations may be due to the effect on 
gemfibrozil on transporters that increase the absorption of cerivastatin, 
In summary, statin-gemfibrozil combination increases the plasma concentration of 
statins, thus, increasing the risk of myopathy.  In spite of this evidence, many clinicians 
continue to use this combination therapy together, and there have been many case reports 
of myopathy attributed to the use of statin and fibrates over the years.  The next section 
discusses the FDA reports of myopathy due to statin-fibrate combination therapy. 
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Myopathy/rhabdomyolysis reports in FDA database  
FDA maintains a database of adverse events which is collected through voluntary 
reporting, as mentioned earlier (in Section III).  Due to voluntary reporting by health care 
professionals, the quality of adverse event data may be inferior or incomplete as 
compared to clinical trials or well-controlled epidemiological studies; nevertheless, it 
may provide timely information about serious adverse events.  This information can then 
be further used to scientifically design studies to monitor the safety of drugs. 
Many researchers have analyzed FDA adverse event database to estimate reports 
on statin-fibrate associated rhabdomyolysis.  Thompson et al.247 did the most extensive 
study identifying all cases of rhabdomyolysis using FDA database between January 1, 
1990 and March 31, 2002.  A total of 3339 reports of rhabdomyolysis were related to 
statins of which 13% were due to statin-fibrate combination.  This study did not break 
down the case reports by the type of statin-fibrate combination. 
Chang et al.248 reported the cases of rhabdomyolysis associated with the use of 
statins and gemfibrozil.  The time period for this analysis was 1996 through July 31, 
2001.  Of a total of 866 cases of rhabdomyolysis, 482 cases (56%) were associated with 
statin monotherapy and 384 cases (44%) were associated with statin and gemfibrozil 
combination therapy.  Approximately 92% of patients on statin-fibrate combination 
therapy were hospitalized and 6% of patients died.  Little more than half the cases were 
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female.  Three-quarters of the rhabdomyolysis cases were associated with the use of 
cerivastatin and gemfibrozil. 
Recently, Jones et al.249 reviewed the database to determine the reporting rates of 
statins and fenofibrate versus statins and gemfibrozil.  Fenofibrate resulted in fewer cases 
of rhabdomyolysis than gemfibrozil in combination with statins.  This is not surprising as 
in-vitro studies have shown that gemfibrozil increases the plasma concentration of statins 
much more than fenofibrate.250,251,252,253 Another similar study that assessed the risk of 
adverse events of all fibrates reported similar rates of rhabdomyolysis for both 
gemfibrozil and fenofibrate statin combination except for cerivastatin.254 
These reporting rates using the FDA database may not reflect the true incidences 
of myopathy associated with statin-gemfibrozil therapy.  The most important limitation of 
using the AERS database is the voluntary reporting.  Therefore, it is important to conduct 
epidemiologic studies that can determine true incidence rates of myopathy due to statin-
fibrate combination therapy.  The next section describes these studies. 
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Epidemiologic studies estimating the risk of myopathy due to statin fibrate 
combination therapy 
The literature related to development of myopathy associated with the use statin 
and fibrates is sparse, with most attention on rhabdomyolysis.  Only two known study has 
estimated the risk of myopathy in statin-fibrate combination therapy users.   
Graham et al.255 estimated the incidence of hospitalized rhabdomyolysis in users 
of statin-fibrate combination.  The onset of symptoms occurred within 32 days of starting 
the combination therapy.  According to the authors, the incidence rates of 
rhabdomyolysis for statin-fibrate combination therapy were much higher than statin 
monotherapy.  The incidence rate for statin-fibrate combination therapy was 5.98 per 
10,000 patient years except for cerivastatin-fibrate combination therapy.  The risk of 
rhabdomyolysis with combined therapy was 12-fold higher than monotherapy.  This risk 
was further increased in patients above 65 years old having diabetes.  This study did not 
include lovastatin and fluvastatin users because there were very few users of these drugs. 
In another study, the incidence of myopathy was 0.0 (95% CI: 0-19.5) per 10,000 
person-years for statin-gemfibrozil combination and 5.19 (95% CI: 0.6-18.7) per 10,000 
person-years for statin-fenofibrate combination therapy.  Surprisingly, statin-fenofibrate 
combination had 4.32 times greater risk of myopathy than statin-only users.  The risk was 
much lower for statin-gemfibrozil combination therapy.256 
255 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
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256 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
81
In summary, there is evidence that the risk of myopathy increases with statin-
fibrate combination use.  Based on the literature review, there seems to be a difference in 
the risk of myopathy not only based on type of statin but also based on type of fibrate 
taken.  There is a need to continuously monitor the outcomes when these two therapies 
are taken together.  
 
STATINS AND NIACIN 
 Statins and niacin monotherapies are both effective in reducing cholesterol levels 
(discussed earlier).  However, statins have only modest effects on increasing HDL levels 
(5%-10%).257 This may be a problem in patients with high cholesterol and low HDL.  
Patients with combined hyperlipidemia have high LDL levels and/or high triglycerides 
and/or low HDL levels.  As discussed earlier in the literature review, there is an inverse 
relationship between HDL levels and occurrence of CHD.258,259 Therefore, it is important 
to raise HDL levels in patients with hyperlipidemia who have low HDL levels in addition 
to lowering LDL levels.  Combination therapy with statin and niacin offers an attractive 
option to treat patients because the combination therapy offers the benefits of statins 
coupled with elevation of HDL levels and supplemental lowering of LDL and 
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triglycerides due to niacin.  The next part describes the studies evaluating the efficacy 
and safety of combination therapy of statins and niacin. 
 
Efficacy of statin-niacin combination therapy 
 The efficacy of statin-niacin combination therapy has been well established in 
various trials.  In a multicenter randomized trial, combination therapy with simvastatin 
and niacin reduced LDL levels by 29% and triglycerides by 31%, and increased HDL 
levels by 31% after only 17 weeks of therapy.260 In a review of clinical trials of 
combination therapy with statin (fluvastatin, lovastatin, or pravastatin) plus niacin, 
similar results were observed.  The LDL levels were reduced by 25% to 57% and HDL 
levels were increased by 13% to 36%.261 More recently, the HDL-Atherosclerosis 
Treatment Study262 (HATS) showed a reduction in LDL levels by 42% and increase in 
HDL levels by 26% in patients with coronary disease, low HDL levels and normal LDL 
levels.  All of the above evidence shows that treatment with combination therapy is 
effective. 
 
Safety of statin-niacin combination therapy 
 The combination of statin and niacin is generally well-tolerated.  Data from 
clinical trials in which patients received combination therapy do not report any cases of 
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myopathy.263,264 However, the number of patients in these trials was low.  In another 
open-label study that evaluated the safety of the first combination drug containing 
extended-release niacin with lovastatin (Advicor®), there were no cases of myopathy; 
however, an increase in CK levels greater than five times upper limit of normal (ULN) 
occurred in 0.24% of patients.265 
Nevertheless, case reports of myopathy have been reported in the literature though 
this relationship has not been well established.  Niacin has been associated with 
rhabdomyolysis when administered with lovastatin, pravastatin or simvastatin but not 
with atorvastatin and fluvastatin.266,267,268,269 In a recent study on statin-induced 
rhabdomyolysis using FDA adverse event database, only a few cases of rhabdomyolysis 
were associated with use of niacin and statins.270 Despite the low rates of myopathy with 
concomitant use of niacin and fibrates, the ACC/AHA/NHBLI clinical advisory on use 
and safety of statins have recommended that health care professionals should use these 
two drugs together with caution until more evidence is available.271 
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STATINS AND CALCIUM CHANNEL BLOCKERS 
 Many patients with hyperlipidemia may also have hypertension and may be 
receiving calcium channel blockers as antihypertensive drug therapy.  Calcium channel 
blockers are weak inhibitors of CYP450 isoenzymes and may increase the plasma levels 
of statins, thereby increasing the risk of myopathy.272 This was brought into focus when 
mibefradil, a strong inhibitor of CYP 3A4, was withdrawn from the market because of 
serious drug-drug interactions.273 Several cases of statin-associated rhabdomyolysis were 
reported in patients receiving mibefradil.274 Verapamil and diltiazem, which are weak 
inhibitors of CYP 3A4 isoenzymes, may pose a similar risk of statin-associated 
myopathy. 
 
Pharmacokinetic effects of calcium channel blockers on statins 
 Drug interactions between statins and calcium channel blockers are 
pharmacokinetic drug interactions.  This has been shown in various pharmacokinetic 
studies.  In a randomized, double-blind, crossover study, the effects of verapamil, a 
calcium channel blocker, on the pharmacokinetics of simvastatin were studied in 12 
healthy volunteers.275 Verapamil increased the mean peak serum concentration of 
simvastatin 2.6-fold and the area under the plasma concentration-time curve (AUC) 4.6-
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fold. The AUC of simvastatin increased in each subject. In addition, verapamil increased 
the peak concentrations of the active simvastatin acid metabolite 3.4-fold and the AUC 
2.8-fold.  In another open label study, similar results were obtained when verapamil was 
administered with pravastatin or simvastatin.276 
The effects of diltiazem on the pharmacokinetics of lovastatin and pravastatin 
were studied in an open-label, 4-way crossover study in 10 subjects.277 Each individual 
received a single dose of lovastatin or pravastatin with and without sustained-release 
diltiazem 120 mg twice daily during the 2 preceding weeks. Diltiazem did not affect the 
pharmacokinetics of pravastatin. In contrast, the AUC of lovastatin increased 257%, and 
the peak concentration increased 333%.  In another study, diltiazem significantly 
increased the mean peak serum concentration of simvastatin by 3.6-fold (p < 0.05) and 
simvastatin acid by 3.7-fold (p < 0.05).278 Diltiazem also significantly increased the area 
under the serum concentration-time curve of simvastatin 5-fold (p < 0.05) and the 
elimination half-life 2.3-fold (p < 0.05). 
 These studies show that there is a possibility of interaction between verapamil and 
diltiazem, and statins probably by inhibiting CYP 450 mediated metabolism, leading to 
increase in concentrations of statins in the blood which increases the risk of myopathy. 
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Evidence of statin and calcium channel blocker associated myopathy from clinical 
trials and practice settings 
 There have been two clinical trials, the 4S and HPS trials, in which some patients 
randomized to the statin group were also taking a calcium channel blocker.  In the 4S 
trial, out of 668 patients in the simvastatin group who were taking a concomitant calcium 
channel blocker, only one patient developed myopathy after four years of therapy.279 In 
the HPS trial, approximately 3000 patients randomized to the simvastatin group were 
taking calcium blocker.  None of these patients developed myopathy.280 The clinical trial 
evidence shows there is low risk of myopathy with use of statins and calcium channel 
blockers. 
 However, there have been case reports of myopathy in patients receiving calcium 
channel blockers and statins.  At least six cases of rhabdomyolysis have been reported in 
patients receiving diltiazem and statins concurrently.   Two of these cases were with 
atorvastatin281,282 and four with simvastatin.283,284,285 In some cases, preexisting renal 
dysfunction was present. Acute renal failure developed in five cases and required 
hemodialysis.  Three patients died, and two patients recovered. Diltiazem was started one 
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to three weeks prior to development of rhabdomyolysis in two patients. In other cases, 
there was a recent increase in the statin dose.  In a review of the FDA database by Omar 
and Wilson,286 case reports of rhabdomyolysis were observed with use of any statins and 
mibefradil.  However, there were no reports from use of any other calcium channel 
blocker.  
 In summary, the evidence on the risk of myopathy associated with use of statins 
and calcium channel blockers is inconsistent and sparse.  Health care professionals need 
to be aware and cautious when statins and calcium channel blockers are used together 
until more evidence is available to determine which patients are more susceptible to such 
interactions. 
 
STATINS AND AMIODARONE 
 Amiodarone is an antiarrhythmic drug which is used to treat ventricular 
arrhythmias.  Patients receiving amiodarone may also receive statins to control their 
cholesterol levels.  Since amiodarone is mainly metabolized by CYP 450 isoenymes, it 
may decrease the metabolism of statins leading to an increase in concentration of statins 
in the blood, which may result in myopathy.287 However, there are no known 
pharmacokinetic studies that have evaluated the effects of amiodarone on statin 
concentration in the blood. The ACC/AHA/NHBLI advisory on clinical use and safety of 
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statins listed amiodarone as one of the drugs that increases the risk of statin-associated 
myopathy.288 
In an ongoing clinical trial, myopathy has been reported in 6% of patients 
receiving high dose simvastatin 80mg/day with amiodarone, according to the product 
information.289 However, there was no increase in the frequency of myopathy in patients 
receiving simvastatin 20mg/day and amiodarone.  Based on this information, the product 
labeling of simvastatin was changed, stating that dose of simvastatin should not exceed 
20mg/day in patients concomitantly treated with amiodarone.290 Similar drug 
interactions can be observed with other statins (as they are metabolized similarly) though 
there is no clear evidence of such interactions. 
 Recently, Alsheikh-Ali and colleagues291 reviewed the adverse events reported to 
the FDA to determine the frequency of adverse events associated with concomitant use of 
statins (simvastatin, pravastatin, & atorvastatin) and amiodarone.  The results showed that 
from 1990 through March 2002, there were 36 reports of adverse events related with 
simvastatin-amiodarone use, 29 reports of adverse events related to atorvastatin-
amiodarone use, and only six reports related to pravastatin-amiodarone use.  Most of 
these adverse events were muscle toxicity (76-77%), and occurred in older male patients 
who were on multiple other medications.  The authors concluded that even though the 
frequency of muscle-related events was low, health care professionals have to be careful 
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when these two drugs are given together.  Use of a statin not metabolized by CYP 450 
isoenzyme (e.g. pravastatin) may be more appropriate in this scenario.292 
As mentioned earlier, there are limitations to the AERS database and the results 
do not represent the true rates of myopathy.  There have been no epidemiologic studies 
done evaluating the actual rates of myopathy associated with amiodarone-statin use.  
However, it is important to be cautious when using these drugs together until more 
evidence is available. 
 
STATINS AND MACROLIDE ANTIBIOTICS 
 Macrolide antibiotics are used to treat a large number of bacterial infections.  
Patients receiving statins may obtain these antibiotics for short time period to treat 
infections.  Macrolide antibiotics increase the levels of statins in blood by blocking statin 
metabolism.293 This will increase blood levels of statin drugs and thus increase the risk 
of myopathy. 
 
Pharmacokinetic studies assessing the effect of macrolide antibiotics on statins 
 There have been several pharmacokinetic studies conducted evaluating the effects 
of various macrolide antibiotics on statins.  One of the earliest studies evaluated the 
effects of erythromycin on simvastatin in a randomized double-blind cross-over study.294 
The results of the study revealed that erythromycin increased the mean peak serum 
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concentration of simvastatin 3.4-fold and the AUC 6.2-fold.  In another study, the effects 
of azithromycin and clarithromycin on atorvastatin were assessed in randomized open-
label study.295 The data demonstrated that azithromycin did not significantly alter peak 
serum concentrations of atorvastatin.  Clarithromycin, on the other hand, increased the 
peak serum concentrations of atorvastatin by 56% and AUC by 88%.  A comparative 
pharmacokinetic study which compared the effects of clarithromycin on pravastatin, 
simvastatin, and atorvastatin showed that there was a two-fold increase in concentration 
of pravastatin, five-fold increase in concentration of atorvastatin, and eight-fold increase 
in concentration of simvastatin when administered concomitantly with clarithromycin.296 
All these studies show that macrolide antibiotics, especially erythromycin and 
clarithromycin, interact considerably with statins.  This is evident in case reports of 
myopathy due to concomitant use of statins and macrolide antibiotics. 
 
Case reports of myopathy  
 There have been at least six published reports that provide evidence of interaction 
between various macrolide antibiotics and statins.  Patients in three of the six case reports 
used clarithromycin,297,298,299 two used erythromycin,300,301 and one used azithromycin.302 
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Prior to initiation of antibiotic therapy, patients did not report any signs or symptoms of 
myopathy.  Following initiation of macrolide therapy, all patients had myopathy and 
elevated CK levels.  Most of these patients were taking high doses of statins and some of 
them had renal impairment.  These factors in addition to concomitant use of the two 
drugs together may have precipitated myopathy in these patients.  In a review of the FDA 
database of adverse events over a 29-month time frame, 42 cases of rhabdomyolysis were 
associated with concomitant use of statins and macrolide antibiotics.303 Based on this 
evidence, the ACC/AHA/NHLBI advisory on clinical use and safety of statins 
recommended avoiding the use of these two drugs together as it increases the risk of 
myopathy.304 
STATINS AND AZOLE ANTIFUNGALS 
 Azole antifungals are used to treat fungal infections. Patients being treated with 
statins may simultaneously receive antifungals for treatment of such infections.  The 
ACC/AHA/NHLBI advisory on clinical use and safety of statins states that use of statins 
with azole antifungals increases the risk of statin-associated myopathy.305 Azole 
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antifungals inhibit CYP 450 isoenzymes and thus decrease the metabolism of statins.306 
This can lead to increased concentrations of statins increasing the risk of myopathy. 
 
Pharmacokinetic studies evaluating the effect of azole antifungals on statins 
 Pharmacokinetic studies have been conducted to assess the effects of azole 
antifungals on statins.  In 12 healthy subjects, itraconazole increased the average serum 
concentrations of lovastatin acid (the active metabolite of lovastatin) 13-fold and the 
AUC 20-fold as compared to the placebo.307 One subject experienced a 10-fold increase 
in plasma creatine kinase within 24 hours of lovastatin administration. Itraconazole 
increased the AUC of simvastatin 19-fold in 10 healthy subjects.308 In contrast, the AUC 
of pravastatin increased less than 2-fold.309 Itraconazole increased the AUC of 
atorvastatin and atorvastatin lactone between 2.5- and 4-fold.310,311 Itraconazole had no 
effect on fluvastatin.312 In 12 healthy volunteers, fluconazole increased the mean AUC of 
fluvastatin 81% and the mean C max 44% but had no effect on pravastatin.313 There have 
 
306 Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-Fluconazole Causing Rhabdomyolysis. Ann 
Pharmacother 2003;37:1032-1035. 
307 Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and 
lovastatin acid. Clin Pharmacol Ther 1996;60:54-61. 
308 Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction 
with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41. 
309 Ibid. 
310 Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. 
Clin Pharmacol Ther 1998;64:58-65. 
311 Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to 
a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400. 
312 Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of 
fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53. 
313 Kantola T, Backman JT, Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin 
concentrations. Eur J Clin Pharmacol 2000;56:225-9. 
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been no known studies that have assessed the effect of ketoconazole on statins; however, 
case-reports of myopathy with all azole antifungals have been reported. 
 
Case reports of myopathy 
 Rhabdomyolysis has been reported when statins have been taken with 
fluconazole,314 itraconazole,315,316 and ketoconazole.317,318 Most of these patients were 
older patients with a history of multiple comorbidities and multiple medications.  These 
factors may have further increased the risk of myopathy.  Omar and Wilson reported 12 
cases of statin-associated rhabdomyolysis in their review of FDA’s adverse event 
database.319 Thus, caution should be exercised when prescribing these two drugs 
together as it increases the risk of myopathy. 
 
STATINS AND ANTIDEPRESSANT DRUGS 
 The antidepressant drugs such as fluxoetine, fluvoxamine, sertraline, and 
nefazodone inhibit CYP3A isoenzymes, and therefore should be cautiously used with 
 
314 Shaukat A, Benekli M, Vladutiu GD, et al. Simvastatin-Fluconazole Causing Rhabdomyolysis. Ann 
Pharmacother 2003;37:1032-1035. 
315 Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent 
itraconazole. N Engl J Med 1995;333:664-5. 
316 Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in 
healthy individuals. Arch Dermatol 1996;132:1254. 
317 Itakura H, Vaughn D, Haller DG, et al. Rhabdomyolysis from cytochrome p-450 interaction of 
ketoconazole and simvastatin in prostate cancer. J Urol 2003;169:613. 
318 Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin 
Neuropharmacol 1999;22:295-7. 
319 Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann 
Pharmacother 2002;36:288-95. 
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statins.320 The clinical advisory on use and safety of statins listed only nefazodone as an 
antidepressant drug that may increase the risk of statin-associated myopathy.321 This is 
because only case-reports of rhabdomyolysis associated with concurrent use of 
nefazodone and statins are known.   
 A pharmacokinetic study examined the potential for drug interaction when 
atorvastatin, simvastatin and pravastatin were each administered with nefazodone.322 The 
results revealed a significant increase in the AUC of atorvastatin and simvastatin by 3.4-
fold and 20-fold respectively.  However, pravastatin concentrations were unaffected.    
There have been some published case-reports of rhabdomyolysis associated with 
statin and nefazodone use.323,324,325 All of these reports were due to concurrent use of 
simvastatin with nefazodone.  However, in a study that reviewed the adverse events 
reported to FDA, a total four cases of rhabdomyolysis were reported, two of which were 
due to lovastatin.326 Therefore, other statins metabolized the same way as simvastatin 
and lovastatin may also be susceptible to drug interaction with nefazodone.  Therefore, 
health care professionals should be aware of this interaction until more evidence is 
available regarding patients at high risk. 
 
320 Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J 
Psychiatry 1996;153:311-20. 
321 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
322 Serzone (nefazodone). [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2004. 
323 Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of 
simvastatin and nefazodone. JAMA 1997;277:296-7. 
324 Thompson M, Samuels S. Rhabdomyolysis with simvastatin and nefazodone. Am J Psychiatry 
2002;159:1607. 
325 Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone 
therapy. South Med J 2003;96:1034-5. 
326 Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann 
Pharmacother 2002;36:288-95. 
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STATINS AND OTHER POTENTIALLY INTERACTING MEDICATIONS 
 Besides the interactions described above, there are published reports of 
interactions with thiazolidinediones,327 phenytoin,328 digoxin,329 antithrombotic agents 
like warfarin,330 and clopidogrel.331 However, there is not enough evidence about the 
effects of co-administration of statins with these drugs to exclude their combination.  
Therefore, the ACC/AHA/NHBLI advisory on clinical use and safety of statins has not 
listed these medications as increasing the risk of myopathy when taken with statins.332 
However, patients should be started at low doses of statins and should be closely 
monitored until more evidence is available. 
Cyclosporine and HIV protease inhibitors are other drugs that increase the risk of 
myopathy.  A brief description of interactions of these potentially interacting medications 
with statins is outlined; however, these drugs will not be included in the study. 
 
Statins and cyclosporine 
 Cyclosporine is used in patients with transplantation.  In post-transplantation 
patients treating dyslipidemia is crucial because cardiovascular disease is a major cause 
 
327 Alsheikh-Ali AA, Karas RH. Adverse events with concomitant use of simvastatin or atorvastatin and 
thiazolidinediones. Am J Cardiol 2004;93:1417-18. 
328 Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug 
interactions. Circulation 2004;109:50-57. 
329 Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin 
concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40:91-
98. 
330 Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann 
Pharmacother 2002;36:288-95. 
331 Serebruany VL, Malinin AI, Callahan KP, et al. Statins do not affect platelet inhibition with clopidogrel 
during coronary stenting. Atherosclerosis 2001;159:239-41. 
332 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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of death in these patients.333 Dyslipidemia often worsens during post-transplantation 
period, with increases in LDL levels and triglyceride levels.  Because of the clinical 
benefit of statins, statin therapy is recommended with close follow-up.  It is 
recommended low doses of statin therapy be used.334 
The ACC/AHA/NHBLI advisory on clinical use and safety of statins lists 
cyclosporine as one of the medications that increases the risk of myopathy when taken 
with statins.335 Cases of rhabdomyolysis have been reported in patients after 
transplantation taking cyclosporine with all statins except fluvastatin and 
pravastatin.336,337,338,339 Texas Medicaid covers only very few transplantations that are 
deemed medically necessary.  Therefore, there was very limited data on patients taking 
cyclosporine.  Therefore, this drug was not included in the study. 
 
Statins and HIV protease inhibitors 
 Dyslipidemia is a common problem in patients infected with HIV and receiving 
antiretroviral therapy.  Abnormalities of lipid levels are associated with HIV infection 
 
333 Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk 
patients. Arch Intern Med 2003;163:553-64. 
334 Ballantyne CM, Bourge RC, Domalik LJ, et al. Treatment of hyperlipidemia after heart transplantation 
and rationale for the Heart Transplant Lipid Registry. Am J Cardiol 1996;78:532-35. 
335 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
336 Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of 
two cases in cardiac transplant recipients. JAMA 1988;260:239-41. 
337 Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and 
cyclosporine. Ann Pharmacother 1999;33:1176-9. 
338 Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins 
safer than others? Nephrol Dial Transplant 2001;16:873-4. 
339 Rodriguez JA, Crespo-Leiro MG, Paniagua MJ, et al. Rhabdomyolysis in heart transplant patients on 
HMG-CoA reductase inhibitors and cyclosporine. Transplant Proc 1999;31:2522-3. 
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itself as well as to antiretroviral therapy.  The risk of coronary events appears to be 
increased in HIV-infected patients.  Therefore, it is important to control dyslipidemia.340 
Statins could be used effectively to control increased cholesterol levels.  
However, there is a potential for interaction between statins and protease inhibitors.  
Most protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir) inhibit CYP3A 
metabolism.341 This increases the risk of myopathy in patients receiving both drugs.  
Despite the increased risk, it is important to control the dyslipidemia to reduce the risk of 
coronary events.  Therefore, statins and protease inhibitors are used together.  To reduce 
the risk of myopathy the preferred statins are pravastatin or fluvastatin or change to non-
CYP3A inhibitors antiretroviral therapy.342 This study did not analyze the interaction 
between statins and protease inhibitors. 
 
In summary, combination of statins with all the above-mentioned potentially 
interacting medications can increase the risk of myopathy.  The concentration of statins in 
blood increases when potentially interacting medications are used together with statins.  
This increases the risk of myopathy.  However, the magnitude of the risk varies 
depending on type of statin and potentially interacting medication used.  Nevertheless, 
 
340 Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in 
human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of 
the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical 
Trials Group. Clin Infect Dis 2003;37:613-27. 
341 Davidson MH. Does differing metabolism by cytochrome p450 have clinical importance? Curr 
Atheroscler Rep 2000;2:14-9. 
342 Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in 
human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of 
the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical 
Trials Group. Clin Infect Dis 2003;37:613-27. 
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caution should be exercised when using statins and potentially interacting medications 
together until more evidence is available. 
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SECTION V 
RATIONALE FOR THE STUDY 
 
Statins have become increasingly important in the management and prevention of 
coronary artery disease (CAD).  Many clinical studies have shown the benefits of statin 
therapy for both primary and secondary prevention of CAD (as discussed in Section I).  
Statins are generally well-tolerated; however, the major side effect related to statin 
therapy is myopathy. 
 Myopathy is a general term referring to disorders of the muscles ranging from 
mild myalgia to severe rhabdomyolysis.  The incidence of myopathy is between 0.1 
percent and 5.0 percent depending on type and dose of statin, and severity of the 
condition.343 However, this risk increases in presence of a number of factors. 
 The ACC/AHA/NHBLI advisory on the clinical use and safety of statins has 
identified a number of factors that increase the risk of statin-associated myopathy.344 
These include age, female gender, low body mass index, hypothyroidism, renal or hepatic 
dysfunction, diabetes mellitus, consumption of alcohol or grapefruit juice, and use of 
certain concomitant medications.  Most of these risk factors were identified based on 
review of case reports.  There have been very few studies, either clinical or 
epidemiological, that have confirmed these risk factors as being related to myopathy. 
 
343 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
344 Ibid. 
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The recent guidelines recommend more aggressive treatment of elevated 
cholesterol levels.345 This means that there will be a substantial increase in the number of 
people with the above-mentioned risk factors who will be treated with statin therapy over 
the next several years.  Also, more people will receive higher statin doses and 
combination therapies to lower their cholesterol levels.  In addition, many patients who 
are on statin therapy may also receive other medications to control their comorbidities.  
All of these factors increase the risk for statin-associated myopathy.  However, the 
magnitude of the risk in the above-mentioned scenario is unknown.  Therefore, it is 
important to conduct studies to identify the patients who are at higher risk of myopathy. 
The general purpose of this study was to estimate the incidence and identify the 
risk factors for myopathy in patients receiving statins with and without potentially 
interacting medications using the Texas Medicaid database.  The advantages and 
disadvantages of using databases for outcomes and pharmacoepidemiology studies are 
described in Appendix A.  One study described the prevalence of myopathy in patients 
using statins with potentially interacting medications as 0.22%.346 Cziarky and 
colleagues estimated the risk of myopathy to be six times higher in patients using statins 
and PIMs.347 Another epidemiologic study estimated the risk of myopathy to be 12-fold 
 
345 Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National 
Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. 
346 Shanahan RL, Kerzee JA, Sandhoff BG, et al. Low myopathy rates associated with statins as 
monotherapy or combination therapy with interacting drugs in a group model health maintenance 
organization. Pharmacotherapy 2005;25:345-51. 
347 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
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higher in patients using fibrates and statins than those who used only statins.348 Most 
other studies have assessed only the relationship between myopathy and use of statins.   
Given the sparse information in the literature about the risk and risk factors of 
myopathy, the current study aimed to fill this gap by identifying the risk factors for 
myopathy in the Texas Medicaid population.  This information can be used by health care 
professionals to identify patients who are at higher risk of myopathy, and thus better 
manage their patients who are on multiple medications and have certain risk factors that 
predispose them to the risk of myopathy.  By identifying patients early-on, health care 
professionals can improve clinical outcomes, and reduce the economic and humanistic 
burden associated with myopathy. 
 
348 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
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SECTION VI 
GOALS, OBJECTIVES, AND HYPOTHESES OF THE STUDY 
 
STUDY GOALS 
The goals of this study were two-fold: 1) to evaluate trends in prescribing patterns 
of potentially interacting medications with statins and to identify factors that are 
associated with the receipt of potentially interacting medications; and 2) to evaluate the 
incidence and risk factors for myopathy in patients using statins and potentially 
interacting medications as compared to those using statins without potentially interacting 
medications.  For the purpose of this study, patients who use statins and potentially 
interacting medications were called as statin interacters and patients who use statins 
without potentially interacting medications were called statin users (described in detail 
in the methodology chapter).   
 
STUDY OBJECTIVES 
The specific objectives for the above-mentioned goals were as follows: 
Evaluation of trends in prescribing patterns of potentially interacting medications with 
statins
1) To provide descriptive statistics on type and dose of statins. 
2) To provide descriptive statistics on the type and dose of potentially interacting 
medications. 
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3) To describe demographic characteristics of study population based on whether or 
not they receive potentially interacting medications. 
4) To identify demographic, health-related, treatment, and physician-related factors 
that are associated with the receipt of potentially interacting medications with statins. 
 
Evaluation of incidence and risk factors for myopathy in patients receiving statins with 
and without potentially interacting medications
5) To estimate the overall incidence of myopathy among study population. 
6) To describe demographic characteristics of study population based on presence or 
absence of myopathy. 
7) To describe the “time to occurrence of myopathy” in statin users and statin 
interacters. 
8) To assess the relationship between the development of myopathy and use of 
potentially interacting medications with statins, while controlling for other risk 
factors for myopathy. 
9) To determine the risk factors (demographic factors, health risk factors, and 
treatment factors) for myopathy. 
 
STUDY HYPOTHESES 
The specific study hypotheses for each of the goals were as follows: 
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Evaluation of trends in prescribing patterns of potentially interacting medications with 
statins
Ho1 There will be no difference in the odds of receipt of potentially interacting 
medication based on type of statin, while controlling for other factors. 
Ho2 There will be no difference in the odds of receipt of potentially interacting 
medication based on dose of statin, while controlling for other factors. 
H3 The odds of receipt of potentially interacting medication will increase with 
increasing age, while controlling for other factors. 
Ho4 There will be no difference in the odds of receipt potentially interacting 
medication based on gender, while controlling for other factors. 
Ho5 There will be no difference in the odds of receipt of potentially interacting 
medication based on ethnicity/race, while controlling for other factors. 
H6 The odds of receipt of potentially interacting medication will increase with 
increasing number of comorbidities, while controlling for other factors. 
Ho7 There will be no difference in the odds of receipt of potentially interacting 
medications based on physician specialty, while controlling for other 
factors. 
 
Evaluation of incidence and risk factors for myopathy in patients receiving statins with 
and without potentially interacting medications
H8 The odds of developing myopathy will be higher for statin interacters as 
compared to statin users, while controlling for other factors. 
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H9 The odds of developing myopathy will increase with increasing age, while 
controlling for other factors. 
H10 The odds of developing myopathy will be higher for females than males, 
while controlling for other factors. 
Ho11 There will be no difference in the odds of developing myopathy based on 
ethnicity/race, while controlling for other factors. 
H12 The odds of developing myopathy will be higher for patients with diabetes 
than those without diabetes, while controlling for other factors. 
H 13 The odds of developing myopathy will increase with increasing number of 
comorbidities, while controlling for other factors. 
H14 The odds of developing myopathy will be higher for patients using 
simvastatin as compared to pravastatin, while controlling for other factors. 
H15 The odds of developing myopathy will be higher for patients using 
atorvastatin as compared to pravastatin, while controlling for other factors. 
H16 The odds of developing myopathy will be higher for patients using 
fluvastatin/lovastatin as compared to pravastatin, while controlling for 
other factors. 
H17 The odds of developing myopathy will be higher for patients on higher 
doses of statins than lower doses of statins, while controlling for other 
factors. 
H18 The odds of developing myopathy will increase with increasing duration 
of use of statin, while controlling for other factors. 
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H19 The odds of developing myopathy will increase with increasing level of 
significance of drug interaction, while controlling for other factors. 
Ho20 There will be no difference in the odds of developing myopathy based on 
whether the potentially interacting medication was given at the start of 
statin therapy or at a later date, while controlling for other factors. 
H21 The odds of developing myopathy will increase with increased duration of 
potentially interacting medication use, while controlling for other factors. 
Ho22 There will be no difference in the odds of developing myopathy based on 






There were two main goals of this study: 1) to evaluate trends in prescribing 
patterns of potentially interacting medications with statins and to identify factors that are 
associated with the receipt of potentially interacting medications; and 2) to evaluate the 
incidence and the risk of myopathy in patients using statins with and without potentially 
interacting medications.  This chapter describes the methodology of the study.  First, the 
study design is described followed by description of the patient population and patient 
selection criteria, study timeframe, study cohorts, and sample size calculations.  Finally, 
the study variables and statistical analyses used for the study are outlined. 
 
STUDY DESIGN 
 The current study utilized a retrospective cohort study design to address the goals.  
In a retrospective cohort study, cohorts of population are identified through a data source 
and followed over time looking for differences in the outcomes.  A retrospective cohort 
study using an existing database is an efficient method for determining incidence rates.349 
349 Strom BL. Study designs available for pharmacoepidemiology studies. In: Strom BL, ed. 
Pharmacoepidemiology. London: John Wiley & Sons, Ltd., 2000:17-29. 
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PATIENT POPULATION AND PATIENT SELECTION CRITERIA 
This study included patients enrolled in Texas Medicaid who received their 
prescription and medical benefits through this agency.  The study cohort included 
patients between the ages of 21 years and 64 years.  Patients 65 years and older were not 
included in this study since some patients may have dual eligibility (Medicaid and 
Medicare) resulting in incomplete medical information for these patients. 
The patients selected were those who received their first statin prescription (new 
statin users) and were continuously enrolled for at least one year.  Patients should not 
have used statin drug six months prior to their first pharmacy claim for a statin 
prescription.    Patients using cerivastatin were excluded from the study due to market 
withdrawal of this drug.  Patients who switched either a statin drug or dose or a 
potentially interacting medication during follow-up period were excluded from the study 
to obtain clean groups.  Patients having renal insufficiency, hypothyroidism, and hepatic 
dysfunction were also excluded from the study because these patients have higher risk of 
myopathy associated with these conditions independent of statin use.  Patients having 
HIV were excluded from the study.  Also, patients having myopathy within six months 
prior to start of statin therapy or three months before index date (defined later) were 
excluded from the study in order to avoid attributing pre-existing myopathy to statin use. 
The inclusion criteria for the study can be summarized as follows: 
 Age group: 21-64 years; 
 New statin users (no use of statin drug six months before the first statin 
prescription); 
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 At least one year continuous enrollment; 
 No cross-over of statins or potentially interacting medication (i.e., no use of any 
other statin or PIM); 
 No prescription for cerivastatin; 
 No diagnosis of myopathy as identified by ICD-9-CM codes (Appendix B) within 
three months prior to index date ro six months before statin therapy; 
 No diagnosis of renal insufficiency or hepatic dysfunction as identified by ICD-9-
CM codes (Appendix B); and  
 No diagnosis of hypothyroidism or HIV as identified by ICD-9-CM codes or use 
of hypothyroid or HIV drugs (Appendix B). 
 
TIMEFRAME FOR THE STUDY 
 The overall timeframe of the study was from September 1, 1998 to August 31, 
2003.  A description of the study timeline is presented in Figure 2.1. 
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Figure 2.1:  Timeline for the study 
 
A wash-out period of six months was used to identify eligible patients based on 
the patient selection criteria mentioned above.  Thus, the earliest observation date was 
March 1, 1999.  The patients were followed six months from their index date.  As 
discussed in literature review, most patients developed myopathy within two to four 
months of starting statin therapy with or without potentially interacting medications.  
Therefore, a time window of six months was chosen to capture the maximum number of 
cases of myopathy.  The last follow-up date was August 31, 2003.  The follow-up period 
will likely differ for each patient, as they enter or exit cohorts at different times.  
 Follow-up times were defined for each individual in person-months.  The 
reporting of exposure time in aggregate person-months is considered meaningful as it 
takes into account the variable times of follow-up into estimating the incidence rate of 





09/01/98 03/01/99 03/01/03 
Subject identification period 
Follow-up period
08/31/03 
Earliest index date Latest 
follow-up date 
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myopathy; 2) discontinued statin (a gap of 45 days or greater) therapy or PIM use; or 3) 
end of the six-month follow-up from the index date.   
 
STUDY COHORTS 
 In the current study, two cohorts of patients were assembled.  The first cohort 
consisted of patients who received statins without potentially interacting medications 
labeled as statin users. The second cohort consisted of patients who received statins 
with potentially interacting medications labeled as statin interacters. The list of 
potentially interacting medications is shown in Table 2.1.   
 
Table 2.1:  List of potentially interacting medications by therapeutic class 
contraindicated with statins used in the study 
Therapeutic Class Drugs 
Fibrates Gemfibrozil, Fenofibrate, Clofibrate 
Nicotinic Acid Niacin 
Calcium Channel Blockers Diltiazem, Verapamil 
Antidepressant Nefazodone 
Antiarrthymic Amiodarone 
Azole Antifungals Fluconazole, Ketoconazole, Itraconazole 
Macrolide Antibiotics Erythromycin, Clarithromycin, 
Azithromycin 
Source: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the 
use and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
 
As described in the literature review, the risk of myopathy increases when 
patients take the drugs listed in Table 2.1 along with statins.  The reason is that the 
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interacting drug increases the concentration of statins in the blood, thereby increasing the 
risk of myopathy. 
 
Cohort 1, the statin user 
For the purpose of this study, a patient who received a statin drug without any 
potentially interacting medication was defined as a statin user. A statin user could 
receive any other medications besides the list of potentially interacting medications listed 
in Table 2.1.   
The index date for statin user was defined as the date of the first pharmacy claim 
for any statin starting from March 1, 1999.  As mentioned before, only patients with no 
statin medication use six months prior to the first pharmacy claim for statin were 
included.  The patients were followed until they experienced myopathy, discontinued 
statin therapy (a gap of 45 days or greater) or the follow-up period ended.  A gap of 45 
days was used to account for adherence and gaps between drug refills.  Studies on 
compliance with statins have used similar gaps.350,351,352 A sensitivity analysis was 
conducted using 60-day gap between drug refills. 
 
350 Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs--do rates 
reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-31. 
351 Sung JC, Nichol MB, Venturini F, et al. Factors affecting patient compliance with antihyperlipidemic 
medications in an HMO population. Am J Manag Care 1998;4:1421-30. 
352 Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. 
JAMA 2002;288:455-61. 
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Cohort 2, the statin interacter 
 In this study, a patient who received a statin drug and potentially interacting 
medication (as listed in Table 2.1) simultaneously was defined as a statin interacter.
The index date for a statin interacter was the date statin drug and potentially interacting 
medication were first received together.  A PIM can be received at different time periods 
during the duration of statin use.  Figure 2.2 demonstrates different scenarios when a 
potentially interacting medication can be received and a description of the different 
scenarios. 
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Figure 2.2: Description of scenarios based on the time a PIM was received
New statin user +
PIM (Index Date) Patient is on PIM when he starts statin therapy.
This patient was in cohort 2 provided there was






Patient receives PIM 3 months after start of statin
therapy. This patient was in cohort 2 provided







Patient receives PIM 6 months after start of statin
therapy. This patient was in cohort 2 provided









Patient receives PIM 9 months after start of statin
therapy. This patient was in cohort 2 provided









As seen from Figure 2.2, patients received PIMs at different times during the 
duration of statin use.  As mentioned earlier, there should be no myopathy event three 
months before the index date, which for cohort two was the date the statin and potentially 
interacting medication were first received together.  This is to be sure that the myopathy 
event was attributed to the concurrent use of statins and potentially interacting 
medications, and was not a carry-over effect from previous statin use.  Statin interacters 
were followed from the index date until the patients experienced myopathy, or 
discontinued statin therapy (a gap of 45 days or more) or PIM use, or end of the follow-
up period.  A separate sub-group analysis was conducted on the statin interacter group to 
determine whether the risk of myopathy differed based on whether both statin and  
potentially interacting medication were received at the start of statin therapy or at a later 
date.  
 In summary, two multivariate analyses (discussed later) were conducted 
evaluating the risk factors of myopathy.  In Model 1, statin users who never received any 
potentially interacting medications throughout the study period were compared with 
statin interacters.  In Model 2, only the statin interacter group was included to evaluate 
the association of the level of significance of drug interaction and time/duration of 
potentially interacting medication and risk of myopathy. 
 In the original proposal, the method of assembling the two cohorts and the 
statistical analysis plan was different from what was conducted in the study.  However 
this methodology was not followed.  An explanation of this method and the reasons for 
not implementing the methodology has been described in Appendix C.   
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SAMPLE SIZE 
 To calculate sample size for a cohort study, information is required on the 
following five factors: 1) type I error rate (and whether it used for one-tailed or two-tailed 
statistical analysis); 2) power; 3) minimum relative risk; 4) incidence of outcome in the 
control group; and 5) ratio of cases to controls.353 
Type I error rate (alpha level) was set at 0.05 level for all statistical analyses of 
the study.  The power was set at 80% (a type II error rate of 20%).  As discussed in the 
literature review, there has been only one known study directly comparing the risk of 
myopathy between statin users and statin interacters.354 However, that study did not 
include all PIMs that were included in the current study.  Therefore, on the basis of 
available epidemiological studies (as described earlier in literature review), and 
pharmacokinetic studies of statins with potentially interacting medications, a minimum 
relative risk of five was assumed when comparing the myopathy incidences between 
statin users and statin interacters.   
 The incidence of myopathy has been reported between <0.1-5.0 percent in clinical 
trials.  For the purpose of this study, an incidence rate of 0.5% was assumed in the statin 
user group which is the comparator group for the statin interacter group and hence the 
control group in this study.  The ratio of the control (statin user group) to the cases (statin 
interacter group) was set at 1:1. 
 
353 Strom BL. Sample size considerations for pharmacoepidemiological studies. In: Strom BL, ed. 
Pharmacoepidemiology. London: John Wiley & Sons, Ltd., 2000:31-39. 
354 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
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Given the above information, the minimum required sample size can be 
calculated.  The following formula was used to calculate sample size in cohort studies:355 
Where p = the incidence of the disease in the unexposed (statin user group); 
R = the minimum relative risk to be detected; 
α = type I error rate; 
β = type II error rate; 
 Z1- α and Z1- β = normal deviances from alpha and beta;  
K = the ratio of controls to cases; and 
U = K p + p R where K, p, and R are as defined before. 
 K + 1
Based on the values of variables specified earlier and using the above equation, 
the number of subjects needed in the comparison groups was approximately 579 in a two-
tailed analysis for the cohort study.  Thus, a total minimum size of 1,158 was required for 
the study spilt equally between the two groups. 
 
355 Strom BL. Sample size considerations for pharmacoepidemiological studies. In: Strom BL, ed. 
Pharmacoepidemiology. London: John Wiley & Sons, Ltd., 2000:31-39. 
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INVESTIGATIONAL REVIEW BOARD APPROVAL 
 The investigational review board (IRB) of the University of Texas at Austin 
provided approval for the current study.  The study did not involve direct contact with 
patients and the information was de-identified.  However, since health information of 
patients enrolled in Texas Medicaid was used for the study, a petition was filed with the 
IRB to obtain a waiver of informed consent and was approved.  As per the requirements 
of the waiver, the use of health information for this study involved minimal risk to the 
privacy of individuals as the study was a retrospective analysis of claims database and the 
researcher did not have access to personal names, social security numbers or addresses of 
the Medicaid patients. 
 
DATA SOURCES 
 The data needed to conduct this study was collected from four data files.  These 
files were obtained from the Texas Medicaid program and included the Texas Medicaid 
Eligibility File, the Texas Medicaid Medical Claims File, the Texas Medicaid 
Prescription Claims File, and the Texas State Board of Medical Examiners database.  The 
databases were used to extract information on Medicaid eligibility of statin users, their 
demographic characteristics, statins and other potentially interacting medication use, 
diagnosis of myopathy as identified by ICD-9-CM codes and specialty of prescribing 
physician.   
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The Texas Medicaid Eligibility File 
The Texas Medicaid Eligibility File contained information as presented in Table 
2.2. 
 
Table 2.2:  Texas Medicaid eligibility file information 
 
Data Fields 
1. Unique client identification number 
2. Date of birth 
3. Gender of the patient 
4. Ethnicity/race of the patient 
5. Eligibility start date 
6. Eligibility end date 
The unique client identification number is a number that is assigned to each Medicaid 
patient and was used to link the eligibility file to the prescription and medical claims 
files.  This number is unique for each patient and does not change from file to file. 
 
The Texas Medicaid Prescription Claims File 
The Texas Medicaid Vendor Drug program prescription claims file contained 
information about every prescription paid for by Texas Medicaid.  Table 2.3 presents the 
data fields included in the prescription claims files.  
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Table 2.3:  Texas Medicaid Prescription Claims File Information 
 
Data Fields (Description) 
1.  Unique client identification number 
2.  Pharmacy provider number 
3.  Date prescription filled 
4.  Number of refills authorized 
5.  Prescribing physician number 
6.  Amount reimbursed by Medicaid 
7.  National Drug Code (NDC) (unique code for drugs that identifies 
the vendor, product, and package size) 
8.  Generic product sequence code (unique product code provided 
 by First DataBank and assigned to all products having the same  
 active ingredient and dosage form regardless of manufacturer) 
9.  Generic product identifier (classified drugs with respect to the  
 compound indicator regardless of the strength) 
10. Quantity dispensed 
11. Days supply 
12. Strength 
13. Age of patient at prescription dispensing 
14. Gender of patient 
The prescribing physician number was used to link the prescription file with the 
Texas State Board of Medical Examiners database to identify the specialty of the 
physician. 
 
The Texas Medicaid Medical Claims File 
Medical resources used by Medicaid recipients who had medical claims from fee-
for-service (FFS) and primary care case management (PCCM) are found in the Medicaid 
Medical Claims File.  Data for only these FFS and PCCM patients were used in this 
study.  Medicaid patients enrolled in plans that are paid on a capitation basis have 
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incomplete medical use data and thus were not employed in this study.  Table 2.4 
presents the information included in the medical claims file. 
 
Table 2.4  Texas Medicaid Medical Claims File Information 
 
Data Fields (Description/Definition) 
1.  Unique client identification number 
2.  Performing provider number 
3.  Diagnosis 1 (as identified by ICD-9-CM code) 
4.  Diagnosis 2 (as identified by ICD-9-CM code) 
5.  Diagnosis 3 (as identified by ICD-9-CM code) 
6.  Diagnosis 4 (as identified by ICD-9-CM code) 
7.  Diagnosis 5 (as identified by ICD-9-CM code) 
8.  Procedure code (as identified by CPT code) 
9.  Beginning date of service for the claim 
10. Last date of service covered by the claim 
11. Place of service (e.g., emergency room, inpatient hospital,  
 physician’s office, etc.) 
12. Type of service (e.g., surgery, consultation, anesthesia, etc.)
13. Admit date 
14. Admit diagnosis 
15. Type of admission (e.g., emergency, newborn, etc.) 
16. Days of service 
17. Medicaid payment for the service 
18. County code 
19. DRG code of provider 
STUDY VARIABLES 
 This section describes the study variables.  First, the dependent variables are 
defined followed by the independent variables.  Figure 2.3 and Figure 2.4 illustrate the 
conceptual models used in this study.   
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Figure 2.3:  Study Model: Risk factors determining the risk of myopathy 
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Figure 2.4:  Study model: Factors determining the odds of receiving a potentially 
interacting medication  
 














Type of statin 





Dependent variables / Study outcomes 
 The primary outcome of this study was the development of myopathy.  The 
development of myopathy was a dichotomous variable (1 = presence of myopathy and 0 
= absence of myopathy) and the log-likelihood of developing myopathy was the 
dependent variable.  In addition, the duration of time to develop myopathy served as the 
study outcome in survival analysis.   
Patients developing myopathy were identified using ICD-9-CM codes based on 
the following criteria: 
 Primary or secondary diagnosis of myoglobinuria (ICD-9-CM code: 791.3); 
 Primary diagnosis of myopathy (ICD-9-CM code: 359.4, 359.8, 359.9), myositis 
(ICD-9-CM code: 729.1), polymyositis (ICD-9-CM code: 710.4), muscle 
weakness (ICD-9-CM code: 728.9), other disorders of muscle, ligament, and 
fascia (ICD-9-CM code: 728.89), musculoskeletal symptoms of the limbs (ICD-9-
CM code:729.81, 729.82, 729.89) or adverse effect from antihyperlipidemic 
agents (ICD-9-CM code:E942.2); 
 A secondary diagnosis of muscle-related disorder (as mentioned above) plus a 
laboratory claim for serum creatine kinase measurement within seven days of the 
diagnosis; and  
 A primary diagnosis of acute renal failure (ICD-9-CM code: 584.0) plus a 
secondary diagnosis of muscle-related disorder or a laboratory claim of serum 
creatine kinase measurement within seven days of the diagnosis. 
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The identification of cases of myopathy based on the above criteria has been 
validated before.  Andrade et al.356 conducted a retrospective study and evaluated positive 
predictive values (PPVs) for identification of cases of myopathy and rhabdomyolysis 
based on ICD-9-CM codes.  The criteria used to identify cases of myopathy were the 
same as used in this study. PPV was calculated as percentage of confirmed cases 
identified using administrative databases.  A composite PPV of 74% was estimated using 
the first three criteria.  The authors concluded that the ICD-9-CM codes and laboratory 
claims data can facilitate identification of myopathy cases. 
The other study outcome was whether or not a patient received potentially 
interacting medications (receipt of potentially interacting medication).  The receipt of 
potentially interacting medication was a dichotomous variable (1 = receipt of PIM and 0 
= no receipt of PIM) and the log-likelihood of receiving a potentially interacting 
medication served as a dependent variable. 
 
Independent variables 
Risk factors for developing myopathy and receipt of potentially interacting 
medication were included in the analysis as covariates.  These risk factors have been 
discussed in detail in the literature review.  The risk factors were classified into four main 
categories: demographic factors, health risk factors, treatment factors, and physician-
related factors.  Each of these risk factors are operationally defined in the next section. 
 
356 Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify 
serious myopathy and rhabdomyolysis. J Clin Epidemiol 2005;58:171-4. 
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Demographic factors: 
Three demographic factors that were included in the study were age, gender, and 
ethnicity/race.  The demographic factors are explained in Table 2.5. 
 
Table 2.5:  Explanation of demographic factors used in the study 
 
Variable Explanation/Definition 
Age Age was defined as the age of person in years at the index date.  
Age was analyzed as a continuous variable. 
Gender  Gender was a dichotomous variable and was indicated as male or 
female.  Male was used as the reference category. 
Ethnicity/race Ethnicity/race was coded as Whites, Blacks, Hispanics, Asians, 
and others. Whites was used as the reference category. 
Health risk factors 
 There are two main health risk factors that may increase risk of myopathy: 
lifestyle factors and comorbidity factors.  For the purpose of this study, information on 
lifestyle factors such as physical activity, body size, and consumption of grape-fruit juice 
and alcohol were not available for the study, which was a limitation of the study.  In this 
study, two factors related to comorbidities of patients were included in the analysis. 
 
Health comorbidity factors 
 The presence of renal insufficiency, hypothyroidism, and hepatic dysfunction 
poses a risk of myopathy independent of statin use.  Therefore, patients with these 
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conditions were excluded from the study.  The two health comorbidity variables included 
in the study were presence of diabetes and number of comorbid conditions. 
Diabetes
Diabetes is considered to be a risk factor for myopathy.  As mentioned in the 
literature review, diabetes patients have reduced drug metabolism thereby increasing the 
concentration of statin drug in the blood.  This increases the risk of myopathy.   
 Presence or absence of diabetes was coded as a dichotomous variable where 
1=diabetes and 0= no diabetes.  ICD-9-CM codes (ICD-9-CM codes: 250.xx) and use of 
anti-diabetic drugs were used to identify patients having diabetes. 
Number of comorbidities
Presence of comorbid conditions may increase the likelihood of receiving 
potentially interacting medications, which in turn, can increase the risk of myopathy.  
Therefore, it is important to include a covariate that controls for the number of comorbid 
conditions in patients. 
 The total number of comorbidities present at or prior to start of statin use was 
calculated.  The list of clinical conditions and the ICD-9-CM codes are shown in Table 
2.6.  The list of clinical conditions and the ICD-9-CM codes were adapted from the Deyo 
et al. version of Charlson comorbidity index using ICD-9-CM codes.357,358 Patients with 
renal disease, liver disease and HIV infection were excluded from the current study.  
Therefore, these clinical conditions were not included in the calculation of the number of 
 
357 Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. 
358 Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM 
administrative databases. J Clin Epidemiol 1992;45:613-9. 
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comorbidities.  Also, diabetes was controlled for separately as a covariate and was not 
included in the list of comorbid conditions. 
 
Table 2.6:  Major clinical conditions and ICD-9-CM codes used to define 
comorbidities based on the Charlson comorbidity index 
 
Clinical Conditions ICD-9-CM codes 
Myocardial infarction 410.xx, 412 
Congestive heart failure 428.xx, 404.01, 404.03, 404.11, 404.13, 
404.91, 404.93 
Peripheral vascular disease 441.x, 443.9, 785.4, V43.4, 38.48 
Cerebrovascular disease 430-437.x, 438 
Dementia 290.x 
Chronic pulmonary disease 490-496, 500-505, 506.4 
Connective tissue disease 710.0-710.1, 710.4, 714.0-714.2, 714.81, 725 
Ulcer disease 531.0x-531.7x, 532.0x-532.7x, 533.0x-533.7x, 
534.0x- 534.7x, 531.9, 532.9, 533.9, 534.9 
Hemiplegia 342.x, 344.1 
Any tumor, including 
lymphoma, leukemia 
140.x-172.x, 174.x-195.x, 200.xx-208.xx 
Metastatic solid tumor 196.x-199.x 
Sources: 1) Charlson ME, Pompei P, Ales KL, et al.  A new method of classifying prognostic comorbidity 
 in longitudinal studies: Development and validation.  J Chron Dis 1987;40:373-383. 
2) Deyo RA, Cherkin DC, Ciol MA.  Adapting a clinical comorbidity index for use with  
 ICD-9-CM administrative databases.  J Clin Epidemiol 1992;45:613-619. 
 
Treatment factors 
 Treatment factors are important factors in evaluating the risk of myopathy.  Both 
characteristics of statins as well as PIMs were included in the study models; however, 
only statin characteristics (type of statin therapy and dose of statin therapy) were included 
in determining the odds of receiving a potentially interacting medication.  Operational 
definitions and explanation of these variables are described below. 
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Receipt of potentially interacting medication
As discussed in section four of the literature review, the risk of myopathy greatly 
increases with concurrent administration of statin and potentially interacting medications.  
The list of potentially interacting medications is shown in Table 2.1.  This is an important 
variable among treatment factors that influences the risk of myopathy.  As described 
before, there were two study cohorts: statin users (defined as patients who received 
statins without potentially interacting medication), and statin interacters (defined as 
patients who received statins with potentially interacting medication). This variable was 
a dichotomous variable where 1 = someone who received potentially interacting 
medication (statin interacter) and 0 = someone who did not receive a potentially 
interacting medication (statin user).  The statin user cohort was the reference category. 
 
Level of significance of drug interaction
The risk of myopathy may vary based on the type of potentially interacting 
medication received.  Interactions of some potentially interacting medications with statins 
may be more severe than the others.  The reference, Drug Interaction Facts, was used to 
assign a level of significance to drug interactions.359 The following scale was used:  
 Level 1 was defined as a potentially severe or life-threatening interaction, and 
was coded as 0 and was the reference category. 
 Level 2 was defined as an interaction that may cause detoriation in patients’ 
clinical status, and was coded as 1. 
 
359 Drug Interaction Facts. Wolters Kluwer Health, Inc, 2003-2005. Available at: 
http://www.efactsonline.com/Fac/servlet/MainPage. Accessed on: January 2005 
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 Level 3 was defined as an interaction that may cause moderate to minor side 
effects, and was coded as 2. 
Table 2.7 provides the list of PIMs based on level of drug interaction significance. 
 
Table 2.7: List of PIMsa by level of drug interaction significance  
 
Level of Significance of Drug 
Interaction 
Type of PIMa
Level 1b Fibrates, Antidepressants, Antibiotics 
Level 2c Calcium Channel Blockers, Antifungals 
Level 3d Nicotinic acid, Amiodarone 
a. PIM – Potentially Interacting Medication 
b. Level 1 is defined as potentially severe or life threatening interaction. 
c. Level 2 is defined as interaction that causes detoriation in patients’ clinical status. 
d. Level 3 is defined as moderate to minor side effects.   
 
Type and dose of statin
As discussed in the literature review, the pharmacokinetic properties and doses 
differ across statins and this affects the risk of myopathy.  Therefore, it is vital to include 
these variables in the analysis.  The type of statin was coded into five categories where 0 
= pravastatin, 1 = atorvastatin, 2 = simvastatin, 3 = lovastatin and 4 = fluvastatin.  
Pravastatin was the reference category as it is the only statin which is not metabolized by 
the cytochrome P450 system. 
 The doses of statins were categorized into two groups.  Table 2.8 shows the two 
groups which are formed based on the comparative efficacy of the statins on lipid levels.  
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All the doses in group I were lower (coded as 0) and have lower reduction in lipid levels 
as compared to doses of statins in group II (coded as 1). 
 
Table 2.8:  Grouping of statin doses based on statin efficacy 
 
Group Statin Drug and Dose (mg)a, b 
Atorvastatin Simvastatin Pravastatin Lovastatin Fluvastatin
- 10 mg 20 mg 20 mg 40 mg I
10 mg 20 mg 40 mg 40 mg 80 mg 
20 mg 40 mg - 80 mg - 
40 mg 80 mg - - - 
II 
80 mg - - - - 
Source: Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. 
a Rosuvastatin was not included because the drug was not approved for the time period of this study. 
b Cerivastatin was not included, because the drug was withdrawn and these patients are excluded in this 
study. 
 
Duration of statin treatment
Duration of statin use may affect the risk of myopathy.  This variable captured the 
time period a patient was exposed to statin treatment before experiencing an event.  
Duration of statin treatment was defined as the number of days of statin treatment in the 
observation period.  The formula to calculate duration of statin use was as follows: 
Duration of statin treatment = Σ Days supply (as listed on Rx claim) 
The date for the first statin prescription was the date to start calculating days 
supply.  The last date of statin prescription was defined as: 1) discontinuation of statin 
therapy (a gap of 45 days or greater); or 2) patient experiences myopathy; or 3) end of 
study’s follow-up period.  Duration of statin use was the sum of days’ supply between the 
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first and last date of statin prescription.  A sensitivity analysis was conducted using a 60-
day gap between refills. 
 
Time/Duration of PIM use
Time/Duration of PIM use may also affect the risk of myopathy.  These variables 
were included in a separate analysis which included only statin interacters to determine if 
these variables affect myopathy.  Time of PIM use was a dichotomous variable where 1 = 
PIM use at start of statin therapy and 0 = PIM use at a date later than the date of start of 
statin therapy.  Duration of PIM use was defined as the number of days of PIM use in the 
observation period before a patient experiences an event or end of PIM use. 
 
Physician-related factors 
There was only one variable included in this factor, namely physician specialty. 
 
Physician specialty
Physician specialty is an important factor to be included in the models.  Some 
physicians may be more aware of drug interactions than others.  It may also happen that 
patients of certain physician specialties may experience fewer myopathy events than 
others due to greater awareness of risk factors.  Therefore, this variable was included in 
the second model too.  Physician specialty was defined as the prescribing physician at 
index date.  The specialty was coded into three groups: 0 = general practice/family 
practice and internal medicine, 1 = cardiologists and 2 = others. 
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In summary, a number of independent variables were included in the two models.  
Some of the variables were continuous whereas others were categorical variables.  Table 
2.9 illustrates the coding scheme and definition of all the dependent and independent 
variables. 
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a. 0 is the code for the reference category 
b. Formula to calculate duration discussed in study variables section 
c. All other specialty except those mentioned above. 
 
STATISTICAL ANALYSES 
 Based on whether a patient receives a potentially interacting medication with a 
statin, patients were categorized into two groups, statin users and statin interacters, as 
described previously in the study cohort section.  These two groups were compared to 
determine the factors that influence the odds of receiving a potentially interacting 
medication, and the incidence and risk factors for development of myopathy. 
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Data manipulation and statistical analyses were conducted using SAS version 9.1 
and Statistical Packages for the Social Sciences (SPSS) v. 12.0.  The a priori level of 
significance was 0.05 for all statistical tests.  All tests were two-tailed unless otherwise 
specified. 
Descriptive analyses (frequencies, means, and standard deviations) were used to 
examine the demographics (age, gender, and ethnicity/race) of the subjects.  Similarly, 
frequency distributions of the type and dose of statins and potentially interacting 
medications used were conducted.  Descriptive analyses were used to evaluate the overall 
incidence (incidence density) of myopathy among Medicaid patients.  Time to 
development of myopathy was estimated using the Kaplan-Meier procedure. 
 Logistic regression was used to assess the factors that influence the receipt of 
potentially interacting medications.  In order to evaluate the risk factors of myopathy, two 
separate multivariate models were tested as mentioned earlier in study cohort section.  In 
Model 1, statin users who never received any potentially interacting medications 
throughout the observation period were compared with statin interacters.  In Model 2, 
only the statin interacter group was included to evaluate the effect of time/duration of 
potentially interacting medication on the risk of myopathy.  For both of these models, 
logistic regression was used.   
 
Analyses for the study objectives 
 There were two main goals of the study: 1) to evaluate trends in prescribing 
patterns of potentially interacting medications with statins and to identify factors that are 
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associated with the receipt of potentially interacting medications; and 2) to evaluate the 
incidence and the risk of myopathy in patients using statins with and without potentially 
interacting medications.  The statistical analyses used for the objectives of each of the 
goals are described below. 
 
Evaluation of trends in prescribing patterns of potentially interacting medications 
with statins 
Objective 1: To provide descriptive statistics on the type and dose of statins. 
 Frequencies and percentages were used to describe the type and dose of statin 
used.   
 
Objective 2: To provide descriptive statistics on the type of potentially interacting 
medications 
 Frequencies were calculated to address Objective 2.  In addition, the potentially 
interacting medications were classified based on level of significance of drug interaction 
with statins, as described previously.  Frequencies were used to classify the drug 
interactions into three levels of significance. 
 
Objective 3: To describe demographic characteristics of the study population based on 
whether or not they receive potentially interacting medications. 
 Descriptive statistics (frequencies, mean, variance) were calculated for the 
analysis of Objective 3.  Demographic characteristics such as age, gender, and 
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ethnicity/race were described using means, frequencies and standard deviations.  Patients 
were classified separately based on whether or not they receive potentially interacting 
medications and descriptive statistics for each group were presented separately. 
 
Objective 4: To determine demographic, health-related, treatment, and physician-related 
factors are associated with the receipt the potentially interacting medications with 
statins. 
 Seven hypotheses were tested for Objective 4.  A logistic regression model was 
used to test the hypotheses.  The association between various demographic, health risk, 
treatment, and physician-related factors and odds of receiving a potentially interacting 
medication were assessed in a regression equation simultaneously.  The regression 
coefficients obtained for the independent variables were logits which were converted to 
odds by exponentiation of the logits.  The logistic model for the odds of receiving a 
potentially interacting medication i.e. Y = 1 for an any given subject i was 
Yi =  exp (g(xi))______
1 + exp (g (xi)) 
Where  g(xi) is the usual linear equation: 
g(xi) = β0 + β1 X1 +…..+ βkXk
With constant β0, coefficients βj, and predictors Xj for k predictors (j = 1, 2, 3 … k).360 In 
this study the predictors to be included were age, gender, ethnicity/race, number of 
comorbidities, type and dose of statin, and physician specialty. 
 
360 Tabachnick BG, Fidell LS. Logistic Regression. In: Tabachnick BG, Fidell LS, eds. Using Multivariate 
Statistics. Boston: Allyn & Bacon, 2001:517-581. 
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Evaluation of incidence and the risk of myopathy in patients using statins with and 
without potentially interacting medications 
Objective 5: To estimate the overall incidence of myopathy in the study population. 
 Descriptive analysis was used to evaluate the overall incidence (incidence 
density) of myopathy among Medicaid patients.  As mentioned earlier (in the timeframe 
of the study section), incidence density takes into account different follow-up times for 
each patient.  The formula to calculate incidence density is as follows:361 
Incidence density =  New myopathy events over observation period____________
Time spent by the study population at risk during observation 
period (person-months)  
 
Or 
 = Myopathy occurrences
Sum of time periods 
 
Myopathy incidence was calculated separately for the statin user and statin 
interacter groups.  After the incidences were obtained, chi-square analysis was conducted 
for comparing the incident cases of myopathy between the two groups. 
 
361 Bhopal R. The concept of risk and measures of disease frequency. In: Bhopal R, ed. Concepts of 
Epidemiology: An integrated introduction to the ideas, theories, principles and methods of epidemiology. 
New York: Oxford University Press Inc., 2002:163-190. 
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Objective 6: To describe the demographic characteristics of the study population based 
on presence or absence of myopathy. 
 Frequencies, means, and standard deviations were used to address Objective 6.  
The patients were classified based on presence or absence of myopathy, and descriptive 
statistics were provided for each group separately. 
 
Objective 7: To describe the “time to occurrence of myopathy” in patients receiving 
statins and potentially interacting medications, and patients receiving statins without 
potentially interacting medications. 
 Survival analysis was utilized to address Objective 7.  Specifically, Kaplan-Meier 
analysis was used to estimate time to development of myopathy.  Kaplan-Meier survival 
curves describe the length of time it takes for an event to occur in context of incomplete 
(censored) information.  Using the Kaplan-Meier method, the time to myopathy was 
estimated and graphically described from the cumulative probability of surviving each of 
the time intervals that preceded development of myopathy.  Statin users were compared 
with statin interacters on time taken to develop myopathy. 
 
Objective 8: To assess the relationship between the development of myopathy and use of 
potentially interacting medications with statins, while controlling for other risk factors 
for myopathy. 
 Logistic regression was used to address Objective 8.  There was one hypothesis 
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associated with this objective.  Receipt of PIM was the independent variable.  All the 
othe independent variables were controlled for in the model.   
 
Objective 9: To determine the risk factors (demographic factors, comorbidity factors, 
treatment factors and physician-related factors) for myopathy. 
 There were 13 hypotheses that were tested in Objective 9.  Two models were 
analyzed to answer Objective 9, as mentioned earlier.  In Model 1, the statin interacter 
group was compared with the statin user group.  In Model 2, only the statin interacter 
group was analyzed to determine PIM characteristics associated with risk of myopathy.  
Both models were analyzed using logistic regression.  The regression coefficients were 
logits, and were exponentiated to obtain odds.  Thus, the regression coefficient was 
interpreted as “odds of developing myopathy.”  The risk factors to be analyzed included 
age, gender, ethnicity/race, diabetes, number of comorbidities, receipt of potentially 
interacting medication, type and dose of statin, duration of statin use, level of significance 
of drug interaction, time and duration of use of potentially interacting medication, and 
physician specialty. 
 
In summary, 22 hypotheses were tested in this study.  The specific statistical tests 
for each of these hypotheses are shown in Table 2.10. 
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Description Statistical Tests 
Evaluation of factors that are associated with the receipt of potentially interacting medication
Ho1 There will be no difference in the odds of receipt of 
potentially interacting medication based on type of statin, 
while controlling for other factors. 
 
Logistic Regression 
Ho2 There will be no difference in the odds of receipt of 
potentially interacting medication based on dose of statin, 




H3 The odds of receipt of potentially interacting medication 




Ho4 There will be no difference in the odds of receipt of 
potentially interacting medication based on gender, while 




H6 The odds of receipt of potentially interacting medication 
will increase with increasing number of comorbidities, 
while controlling for other factors. 
 
Logistic Regression 
Ho7 There will be no difference in the odds of receipt of 
potentially interacting medication based on physician 
specialty, while controlling for other factors. 
 
Logistic Regression 
Evaluation of risk factors that are associated with the development of myopathy
H8 The odds of developing myopathy will be higher for 
statin interacters than for statin users, while controlling 
for other factors 
.
Model 1: Logistic Regression 
 
H9 The odds of developing of myopathy will increase with 
increasing age, while controlling for other factors. 
Model 1: Logistic Regression 
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Description Statistical Tests 
H10 The odds of developing myopathy will be higher for 
females than males, while controlling for other factors. 
Model 1: Logistic Regression 
 
Ho11 There will be no difference in the odds of developing 
myopathy based on ethnicity/race, while controlling for 
other factors. 
 
Model 1: Logistic Regression 
 
H12 The odds of developing myopathy will be higher for 
patients with diabetes than those without diabetes, while 
controlling for other factors. 
 
Model 1: Logistic Regression 
 
H13 The odds of developing myopathy will increase with 
increasing number of comorbidities, while controlling for 
other factors. 
 
Model 1: Logistic Regression 
 
H14 The odds of developing myopathy will be higher for 
patients using simvastatin as compared to pravastatin, 
while controlling for other factors. 
 
Model 1: Logistic Regression 
 
H15 The odds of developing myopathy will be higher for 
patients using atorvastatin as compared to pravastatin, 
while controlling for other factors. 
 
Model 1: Logistic Regression 
 
H16 The odds of developing myopathy will be higher for 
patients using fluvastatin/lovastatin as compared to 
pravastatin, while controlling for other factors. 
 
Model 1: Logistic Regression 
 
H17 The odds of developing myopathy will be higher for 
patients on higher doses of statins than lower doses of 
statins, while controlling for other factors. 
 
Model 1: Logistic Regression 
 
H18 The odds of developing myopathy will increase with 
increasing duration of statin use, while controlling for 
other factors. 
 
Model 1: Logistic Regression 
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Description Statistical Tests 
H19 The odds of developing myopathy will increase with 
increasing level of significance of drug interaction, while 
controlling for other factors. 
 
Model 2: Logistic Regression 
 
Ho20 There will be no difference in the odds of developing 
myopathy based on whether the potentially interacting 
medication was given at the start of statin therapy or on a 
later date, while controlling for other factors. 
 
Model 2: Logistic Regression 
H21 The odds of developing myopathy will increase with 
increasing duration of PIM use, while controlling for 
other factors. 
 
Model 2: Logistic Regression 
Ho22 There will be no difference in odds of developing 
myopathy based on physician specialty, while controlling 
for other factors. 






This chapter presents the results of this study.  First, the sample size is discussed 
after implementation of inclusion/exclusion criteria.  This is followed by descriptive 
analysis of the variables included in the study, and finally the results for each objective 
are presented.  The results of the objective analyses are presented in the order of 
objectives listed in Section VI of Chapter 1. 
 
PATIENT SELECTION CRITERIA AND SAMPLE SIZE 
The study population was followed from March 1, 1999 to August 31, 2003 as 
depicted in Figure 2.1 of Chapter 2.  The study sample consisted of 8,822 patients who 
were enrolled in Texas Medicaid and were eligible for this study.  Of these, 5,817 
patients were statin users who never received potentially interacting medications (PIMs) 
during the observation period.  The remaining 3,005 patients were statin users who 
received a potentially interacting medication.   
Patient inclusion/exclusion criteria for the study were: 1) continuous enrollment 
for one year; 2) new statin user; 3) no diagnosis of myopathy six months before the start 
of statin therapy and three months before the index date; 4) no diagnosis of renal 
insufficiency, hepatic dysfunction or hypothyroidism throughout the study period; 5) no 
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diagnosis of HIV throughout the study period; 6) no use of cerivastatin throughout the 
study period; 7) no switch in dose or type of statins throughout the study period, 8) age 
between 21 and 64 years; 8) did not receive PIMs during the duration of statin use 
(Figure 3.1), and  9) no switch in PIM use. Table 3.1 shows the patient inclusion criteria 
with the corresponding sample size after implementation of each criterion. 
 
Table 3.1:   Patient inclusion criteria and sample size 
 
Patient Inclusion Criteria Exclusion Number Sample Size
1.Patients using statins 48,320
2. New statin user and continuous enrollmenta 14,353 33,967
3. No prior myopathy eventb 985 32,982
4. No diagnosis of renal insufficiency, hepatic 
dysfunction or hypothyroidismc
7,794 25,188
5. No HIV diagnosisc 409 24,779
6. No cerivastatin usec 966 23,813
7. No switch in dose and type of statinsc 9,266 14,547
8. Age between 21 and 64 years 29 14,518
9. No receipt of PIMsd concurrently with statins 5,182 9,336
10. No switch in PIMd use 514 8,822
a. At least six months continuous enrollment before and after start of statin therapy 
b. Six months prior to start of statin therapy and three months before index date 
c. Throughout the study period 
d. PIM – potentially interacting medication 
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Figure 3.1: Inclusion and exclusion number of patients receiving PIMsa
DESCRIPTIVE STATISTICS 
 The risk factors that affect the study outcomes are shown in Figure 2.3 and Figure 
2.4 in Chapter 2.  These factors include demographic factors (age, gender, and race), 
health risk factors (presence of diabetes and number of comorbid conditions), treatment 
factors which include PIM characteristics (receipt of PIM, level of significance of 








during the duration 
of statin therapy 
N = 2,538
PIMa received 




ended PIMa use 
before start of 
statin therapy 
N = 2,305
Started PIMa use 
before start of 
statin therapy and 
ended it after start 






a. PIM- Potentially interacting medication 
b. End of statin therapy is when there is a gap of greater than 45 days between two refills 




of statin, and duration of statin use), and finally physician-related factors (physician 
specialty).  Descriptive statistics are provided for each of the above-mentioned variables 
in the following section.  
 
Demographic factors 
 Objective 3 was related to description of demographic characteristics of study 
population.  This section describes in detail the characteristics of the patient population. 
Data is presented based on whether or not patients received PIMs. 
 Table 3.2 shows the gender distribution for statin user and statin interacter groups. 
A total of 5,193 patients were females (58.9%).  The statin interacter group had a higher 
percent of females (65.3%, N = 1,961) than the statin user group (55.6%, N = 3,232).  
There was a statistically significant difference in gender distribution between the statin 
user and statin interacter groups (χ2 = 76.93; d.f. = 1; p <0.0001). 
 
Table 3.2: Frequency and percent of statin users and statin interacters by gender 
 






Females 3,232 (55.6) 1,961 (65.3) 5,193 (58.9)
Males 2,585 (44.4) 1,044 (34.7) 3,629 (41.1)
Total 5,817 (100.0) 3,005 (100.0) 8,822 (100.0)
χ2 = 76.93; d.f. = 1; p <0.0001 
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Table 3.3 presents the ethnic/race distribution for the statin user and statin 
interacter groups.  A total of 3,386 (38.4%) of the sample were Whites, 2,148 (36.9%) 
were in the statin user group and 1,238 (41.2%) were in the statin interacter group.  Statin 
user group had more percent of Hispanics (N = 1,948, 33.6%) than statin interacter group 
(N = 818, 27.2%).  There was a statistically significant difference between two groups 
based on ethnicity/race (χ2 =38.09; d.f. = 5; p <0.0001). 
 









White 2,148 (36.9) 1,238 (41.2) 3,386 (38.4)
Black 1,266 (21.8) 681 (22.7) 1,947 (22.1)
Hispanic 1,948 (33.5) 818 (27.2) 2,766 (31.3)
Native Indian 24  (0.4) 16 (0.5) 40 (0.5)
Asian 125  (2.2) 71 (2.4) 196 (2.2)
Othera 306  (5.3) 181 (6.0) 487 (5.5)
Total 5,817 (100.0) 3,005 (100.0) 8,822 (100.0)
χ2 =38.09; d.f. = 5; p <0.0001 
a. Other includes all other ethnicities except those mentioned above 
 
The mean age for statin user group was 51.1 years (Standard Deviation (S.D.) = 
9.9 years) while the mean age for statin interacter group was 51.4 years (S.D. = 9.7 
years).  There was no statistical difference in age between groups (t-value = -1.26; p = 
0.20).  Table 3.4 gives the frequency and percent of patients for statin users and statin 
149
interacters by age groups.  Patients aged 51 to 60 years represented 41.8% (N = 3,690) of 
the eligible population.  The next largest group was comprised of patients aged between 
41 and 50 years accounting for 24.1% (N = 2,123) of the eligible population.  
 
Table 3.4:  Frequency and percent of statin users and statin interacter by age 
groups 
 






21-30 275  (4.7) 113  (3.8) 388  (4.4)
31-40 659 (11.3) 341 (11.3) 1,000 (11.3)
41-50 1,380 (23.7) 743 (24.7) 2,123 (24.1)
51-60 2,434 (41.9) 1,256 (41.8) 3,690 (41.8)
61-64 1,069 (18.4) 552 (18.4) 1,621 (18.4)
Total 5,817 (100.0) 3,005 (100.0) 8,822 (100.0)
Table 3.5 provides information on frequency and percent of statin users and statin 
interacters by gender and age groups.  The statin user group had greater percent of males 
(6.0%) in the 21-30 age groups than statin interacter group (3.8%).  Furthermore, there 
were a greater proportion of females in the older age categories.  Overall, a χ2 analysis 
revealed that there was a statistically significant difference between age groups for males 
and females for the statin user group (χ2 = 88.29; d.f. = 4; p < 0.0001).  However, there 
was no such difference for the statin interacter group (χ2 = 4.59; d.f. = 4; p = 0.33). 
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Table 3.5: Frequency and percent of statin users and statin interacters by age 
groups and gender 
 
Age Group Statin Users Statin Interacters 
Females N (%) Males N (%) Females N (%) Males N (%)
21-30 120 (3.7) 155 (6.0) 73 (3.7) 40 (3.8)
31-40 304 (9.4) 355 (13.7) 207 (10.6) 134 (12.8)
41-50 697 (21.6) 683 (26.4) 479 (24.4) 264 (25.4)
51-60 1,443 (44.7) 991 (38.3) 833 (42.5) 423 (40.5)
61-64 668 (20.6) 401 (15.6) 369 (18.8) 183 (17.5)
Total 3,232 (100.0) 2,585 (100.0) 1,961 (100.0) 1,044 (100.0)
χ2 = 88.29; d.f. = 4; p < 0.0001 χ2 = 4.59; d.f. = 4; p = 0.33 
Health risk factors 
 The two health risk factors that were included in the study were presence of 
diabetes and number of comorbidities. 
 
Diabetes 
 A total of 4,272 (48.4%) patients had a diagnosis of diabetes as identified by ICD-
9-CM codes or use of anti-diabetes drugs.  A little more than half the patients (N = 4,550, 
51.6%) had no diagnosis for diabetes.  When broken down by cohorts, statin interacters 




Number of comorbidities 
 The major clinical conditions and ICD-9-CM codes used to define comorbidities 
are as shown in Table 2.6 in Chapter 2.  Table 3.5 shows the number and percent of statin 
users and statin interacters by number of comorbidities.  A total of 3,630 (41.1%) patients 
had at least one comorbidity.  The remaining 5,192 (58.9%) patients had no 
comorbidities.  The statin interacter group had significantly (χ2 =198.58; d.f. = 5; p 
<0.0001) higher percentage of patients with comorbidities (N = 1,507; 40.1%) than statin 
user group (N = 2,123; 36.5%).   
 
Table 3.5: Frequency and percent of statin users and statin interacters by 










0 3,694 (63.5) 1,498 (49.9) 5,192 (58.9)
1-2 1,966 (33.8) 1,325 (44.1) 2,375 (26.9)
3-4 149  (2.6) 169  (5.6) 318 (36.0)
> 5 8 (0.1) 13  (0.4) 21  (0.2)
Total 5,817 (100.0) 3,005 (100.0) 8,822 (100.0)
χ2 =198.58; d.f. = 5; p <0.0001 
Treatment factors 
 The treatment factors that were included in this study were characteristics of statin 
used and characteristics of PIM used by the eligible patients.  The next section describes 
these variables in detail. 
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Statin characteristics 
 Objective 1 was related to providing descriptive statistics on type and dose of 
statins.  Table 3.6 presents information on frequency and percent of type and dose of 
statin prescribed to patients for the first time.  Patients used atorvastatin (N = 4,894; 
55.5%) most frequently, followed by simvastatin (N = 2,219; 25.2%), pravastatin (N = 
1,159; 13.1%), fluvastatin (N = 465; 5.3%) and lovastatin (N = 85; 0.9%).   
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Table 3.6: Frequency and percent of patients based on statin type and dose 
prescribed for first time 
 



















































































As seen from the Table 3.6, most patients (N = 7,066; 80.1%) were started on low 
doses of statins, as recommended by package inserts of these statins.  A total of 3,494 
patients (40%) were started on 10mg of atorvastatin and 1,144 (13%) patients were 
started on 20mg of simvastatin.  Based on categorization of doses (as shown in Table 2.7 
of Chapter 2) where Group I consists of lower doses of statins and group II consists of 
higher doses of statins, a total of 6,601 patients (74.8%) were started on lower doses of 
statin and 2,221 (25.2%) patients were started on high doses of statins. 
 Table 3.7 shows the frequency and percent of statin users and statin interacters by 
statin type used for the first time.  Table 3.8 shows the frequency and percent of statin 
users and statin interacters by statin dose.  Both cohorts were comparable in the type and 
dose of statin used.  However, the statin interacter group had a slightly greater use of 
pravastatin (14. 2%) and higher percent of high dose fluvastatin users than the statin user 
group (12.6%). 
 
Table 3.7: Frequency and percent of statin users and statin interacters by type of 
statin used 




Atorvastatin 3,220 (55.3) 1,674 (55.7)
Simvastatin 1,483 (25.5) 736 (24.5)
Pravastatin 732 (12.6) 427 (14.2)
Fluvastatin 319 (5.5) 146 (4.9)
Lovastatin 63 (1.1) 22 (0.7)
Total 5,817 (100.0) 3,005 (100.0)
χ2 =8.8; d.f. = 5; p = 0.06 
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Table 3.8: Frequency and percent of statin users and statin interacters by dose of 
statin 
 

























































































a. 38% of the cells have expected counts less than 5 
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Duration of statin treatment was defined as the time period a patient is exposed to 
statin treatment before the end of observation period.  The end of observation period 
occurs when any one of the following three criteria are met: 1) diagnosis of myopathy; 2) 
discontinued statin therapy (a gap of greater than 45 days between refills); or 3) end of 
six month follow-up period.  The time period was then calculated as sum of days’ supply 
between the first and last prescription.  Based on these criteria, the average duration of 
statin use was 154 days (S.D. = 137 days) with a minimum use of one day and a 
maximum use of 1,661 days.  When both cohorts were compared, the duration of statin 
use was statistically greater for statin interacters than for statin users (t-value = -26.77; 
p<0.0001 ) (Table 3.9). 
 
Table 3.9: Mean, standard deviation, minimum, and maximum duration of 
statin use (no gap greater than 45 days between refills) for statin users and statin 
interacters 
 






Mean  120 221
Standard Deviation 62 202
Minimum 3 1
Maximum 180 1661
t-value = -26.77; p < 0.0001 
Table 3.10 provides descriptive statistics on duration of statin use for statin users 
and statin interacters with 60-day gap between refills was used.  When this criterion for 
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discontinuation of statin was changed, a total of 8,911 patients were included in study, 
the details of which are discussed in Appendix D.  Based on this criterion, the average 
duration of statin use was 164 days (S.D. = 146 days) with a minimum of 1 day and 
maximum of 1661 days.  There was a statistically significant difference in the duration of 
statin use between statin interacters and statin users (t-value = -28.73; p<0.0001). 
 
Table 3.10: Mean, standard deviation, minimum, and maximum duration of 
statin use (no gap greater than 60 days between refills) for statin users and statin 
interacters 
 






Mean  125 238
Standard Deviation 61 214
Minimum 3 1
Maximum 180 1661
t-value = -28.73; p < 0.0001 
PIM characteristics 
 A total of 3,005 patients received potentially interacting medications along with 
statin medications.  These patients formed the statin interacter group.  A total of 2,207 
(73.4%) patients received PIMs after the start of statin therapy whereas a total of 798 
(26.6%) patients were using PIMs before start of statin therapy.   
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Objective 2 aimed at providing descriptive statistics on type of potentially 
interacting medications.  Table 3.11 shows the frequency and percent of patients by type 
of PIM used. 
 
Table 3.11: Frequency and percent of patients using PIMs 
 
Type of PIM Frequency Percent
Fibratesa 379 12.6%
Nicotinic Acid 65 2.2%
Antiarrthymicb 59 2.0%
Calcium Channel Blockersc 879 29.2%
Antidepressantsd 90 2.9%
Macrolide Antibioticse 1,225 40.8%
Azole Antifungalsf 308 10.3%
Total 3,005 100.0%
a. Fibrates include gemfibrozil and fenofibrate 
b. Antiarrthymics include amiodarone 
c. Calcium Channel Blockers include diltiazem and verpamil 
d. Antidepressants include nefazodone 
e. Macrolide antibiotics include erythromycin, clarithromycin, and azithromycin 
f. Azole Antifungals include fluconazole, ketoconazole and itraconazole 
 
A total of 1,225 (40.8%) patients used macrolide antibiotics and a total of 308 
(10.3%) patients used azole antifungals.  These products are normally used for a short 
period.  Among the remaining patients, calcium channel blockers (N = 879; 29.2%) and 
fibrates (N = 379; 12.6%) were the most often used potentially interacting medication. 
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Based on type of PIM used, the level of significance of drug interaction were 
characterized into following three levels: 1) Level 1 is defined as potentially severe or life 
threatening interaction; 2) Level 2 is defined as interaction that causes detoriation in 
patients’ clinical status and; 3) Level 3 is defined as moderate to minor side effects.  
Table 3.12 provides information on frequency and percent of patients based on level of 
significance of drug interaction.  A total of 1,694 patients (56.4%) were classified as 
receiving a PIM which was defined as severe or life-threatening. 
 
Table 3.12: Frequency and percent of patients by level of drug interaction 
significance based on type of PIMa used 
 
Level of Significance 
of Drug Interaction 
Type of PIMa Frequency Percent
Level 1b Fibrates, Antidepressants, 
Antibiotics 
1,694 56.4%
Level 2c Calcium Channel 
Blockers, Antifungals 
1,187 39.5%
Level 3d Nicotinic acid, 
amiodarone 
124 4.1%
Total  3,005 100.0%
a. PIM – Potentially Interacting Medication 
b. Level 1 is defined as a potentially severe or life threatening interaction. 
c. Level 2 is defined as interaction that causes detoriation in patients’ clinical status. 
d. Level 3 is defined as moderate to minor side effects.   
 
Duration of PIM use was defined as the number of days of PIM use before the end 
of the observation period.   The end of the observation period occurs when any one of the 
following three criteria are met: 1) diagnosis of myopathy; 2) discontinued statin therapy 
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(a gap of greater than 45 days between refills) or PIM use; or 3) end of six month follow-
up period. The average duration of PIM use was 58 days (S.D=67 days) with a minimum 
of one day and a maximum of 253 days.  Table 3.13 provides descriptive statistics on 
duration of PIM use based on type of PIM.  Calcium channel blockers had the highest 
mean number of days (121 days) whereas macrolide antibiotics had the shortest (8 days). 
 
Table 3.13: Mean, standard deviation, minimum and maximum of duration of 
PIM use before end of observation period based on therapeutic class of PIM 
 








Fibrates 379 92 57 20 226
Nicotinic Acid 65 95 59 30 180
Antiarrthymic 59 111 66 9 200
Calcium Channel 
Blockers 
879 121 60 9 253
Antidepressants 90 92 58 20 184
Macrolide 
Antibiotics 
1,225 8 9 1 161
Azole Antifungals 308 12 23 1 150
Physician specialty 
 Information on the specialty of the prescribing physician at index date was 
obtained from Texas State Board of Medical Examiners (TSBME) database.  The 
physician’s unique license number was used to link the Medicaid file with the database 
obtained from TSBME.  Overall, physician specialty was available for 7,519 patients 
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(85.2%) out of a total of 8,822 patients.  A total of 3,450 prescriptions (45.9%) were 
written by family practice/general practice physicians.  However, the statin user group 
had more patients (N = 2,331; 48.0%) whose prescription was written by family 
practice/general practice than the statin interacter group (N = 1,119; 42.1%) (Table 3.14).  
There was a statististically significant difference in physician specialty when comparing 
statin interacters with statin users (χ2 =32.1; d.f. = 3; p <0.0001). 
 
Table 3.14: Frequency and percent of patients by physician specialty who wrote 
statin prescription at index date 
 








2,331 (48.0) 1,119 (42.1) 3,450 (45.9)
Internal Medicine 1,479 (30.4) 841 (31.7) 2,320 (30.8)
Cardiologists 328 (6.7) 189 (7.1) 517 (6.9)
Othera 725 (14.9) 507 (19.1) 1,232 (16.4)
Totalb 4,863 (100.0) 2,656 (100.0) 7,519 (100.0)
χ2 =32.1; d.f. = 3; p <0.0001 
a. Other category includes all physician specialties except those mentioned above. 
b. Data on physician specialty were missing for 1,303 patients. 
 
ASSESSING BASELINE CHARACTERISTICS 
 The above section provided descriptive statistics for both cohorts on all variables 
involved in the study.  In order to assess potential differences in baseline characteristics, 
the demographic, health risk, treatment and physician-related factors were compared 
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between statin users and statin interacters.  For continuous variables namely age and 
duration of statin use t-tests were used.  For categorical variables, chi-square was used to 
evaluate the differences between the groups.   
The baseline characteristics of the two cohorts were different on some variables.  
There was no statistically significant difference in the age groups between the two 
groups.  However, there were significantly more females (Table 3.2) and a greater 
percent of Whites (Table 3.3) in the statin interacter group than statin user group.  The 
statin user group had a greater percent of Hispanics than the statin interacter group (Table 
3.3). 
 The doses and type of statin used in both groups were similar (Tables 3.7 and 
3.8).  However, the duration of statin use was significantly higher in the statin interacter 
group than the statin user group.  Also, the statin interacter group had significantly more 
proportion of patients with diabetes (51.6% vs. 46.8%) and higher proportion of 
comorbidities (40.1% vs. 36.4%) than the statin user group.  Finally, the statin user group 
had significantly more percent of family practice/general practice physicians who had 
written prescriptions than the statin interacter group (Table 3.14). 
 In summary, there were differences in the characteristics of patients in the two 
cohorts.  However, these differences in baseline characteristics were controlled for in the 




 Two major statistical tools were used in assessing the study objectives: Kaplan-
Meier survival analysis and logistic regression analyses. The Kaplan-Meier technique 
was used for unadjusted description and graphical representation of survival data.  
Therefore, assumptions regarding the distribution of covariates and survival times were 
not required.  There are assumptions that are related to logistic regression which are 
reviewed in the next section.  First, the general data cleaning and assessment step are 
discussed.   
 
Accuracy of data file and distribution of variables 
 Descriptive statistics of the study variables have been described in the previous 
section of the chapter.  Frequencies were calculated for all variables to check for coding 
errors, outliers and distribution of variables.   There were no coding errors for any of the 
variables of the study.  Normality plots, means and standard deviations were calculated 
for continuous variables age, duration of statin use and duration of PIM use.  Age was 
negatively skewed whereas duration of statin use and PIM use were positively skewed 
(Appendix E).  However since logistic regression is used as method of analysis, which 
does not make assumptions about shape of predictors, deviation from normality was not 
likely to pose a problem.362 Also, the sample size was large enough not to cause 
problems in the analysis.363 
362 Tabachnick BG, Fidell LS. Logistic Regression. In: Tabachnick BG, Fidell LS, eds. Using Multivariate 
Statistics. Boston: Allyn & Bacon, 2001:517-581. 
363 Tabachnick BG, Fidell LS. Cleaning up your act: Screening data prior to analysis. In: Tabachnick BG, 
Fidell LS, eds. Using Multivariate Statistics. Boston: Allyn & Bacon, 2001:56-100. 
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Assessment of missing data 
 The data were complete for all variables except physician specialty.  There were 
1,303 (14.8%) missing values for physician specialty.  It has been suggested that the 
pattern of missing data is more important than the amount of missing data.364 This is 
because data missing in a systematic manner may cause more problems in the analysis 
than missing data scattered across dataset.  Missing data were scattered across dataset; 
however, since a large percent of values are missing for physician specialty this variable 
was excluded from the main analyses.  
 
Assumptions of logistic regression analysis 
 Although logistic regression makes no assumptions about the distribution of 
independent variables, assumptions such as sampling adequacy, linearity among 
predictors, absence of multicollinearity and outliers, and independence of errors are 
critical to logistic regression.365 All observations were mutually exclusive.  Therefore, 
the assumption of independence of errors was not violated.  All other assumptions were 
tested as part of the analysis for all logistic regression models and the results are 
presented in Appendix F. 
 
364 Ibid. 
365 Tabachnick BG, Fidell LS. Logistic Regression. In: Tabachnick BG, Fidell LS, eds. Using Multivariate 
Statistics. Boston: Allyn & Bacon, 2001:517-581. 
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Adequacy of expected frequencies and power 
 A goodness-of-fit test compares observed frequencies with expected frequencies 
formed by combinations of discrete variables.  If the expected frequencies are too small, 
the analysis may lack power.  Therefore, it is important to evaluate the expected cell 
frequencies for all variables including outcome variables.  The requirement of sampling 
adequacy is that no more than 20% of cells should have expected frequency less than 5 
and no cell should have expected frequency less than one.366 
This assumption was violated in two of the three logistic regression models.  In 
logistic regression models, evaluating the odds of developing myopathy, the expected call 
count for ethnicity Asian was less than one.  Hosmer and Lemeshow367 recommend 
collapsing the categories in order to increase the cell size of expected frequencies.  Based 
on this recommendation, the category for Asian ethnicity was collapsed with the category 
for “Other” ethnicities.   Also, 25% of cells had expected frequency less than 5 for 
lovastatin and fluvastatin users.  Therefore, these two categories were collapsed to form a 
new category called “other statins”. 
 
Linearity among predictors 
 Although there are no assumptions about linear relationships among predictor 
variables themselves in logistic regression, there is an assumption of linearity between 
continuous predictor variables and the logit transformation of the outcome variable.  This 
 
366 Ibid. 
367 Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Hosmer DW, Lemeshow S, eds. Applied 
Logistic Regression. New York: John Wiley & Sons, 1989:135-173. 
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linearity assumption between predictor variables and the logit of dependent variable can 
be tested using Box-Tidwell approach.368 In this approach, an interaction term of the 
continuous variable and its natural logarithm is added along with other variables to the 
logistic regression model.  The assumption is violated if one or more of added interaction 
terms are statistically significant.  The interaction terms were not statistically significant 
in any of the logistic regression models (Appendix F).  Therefore, linearity in the logit 
assumption was not violated. 
 
Assessment of multicollinearity 
 Logistic regression is sensitive to high correlations among predictor variables.  If 
two predictor variables are highly correlated, the estimate of its effect on the dependent 
variable will be unstable.  This will be indicated with high standard errors.369 In order to 
assess multicollinearity you can evaluate standard errors but more formal testing is 
recommended.  Therefore in addition to evaluating standard errors, bivariate correlations 
among all variables, and tolerance and variance inflation factor for each parameter 
estimate was also evaluated.  Tolerance and variance inflation factor measure the 
inflation in the variances of the parameter estimates due to multicollinearities that exist 
among the variables.  There are no formal cutoff values to indicate multicollinearity. 
 
368 Tabachnick BG, Fidell LS. Logistic Regression. In: Tabachnick BG, Fidell LS, eds. Using Multivariate 
Statistics. Boston: Allyn & Bacon, 2001:517-581. 
369 Allison PD. Logistic Regression: Using the SAS system - Theory and application. Cary: SAS Institute 
Inc. and John Wiley & Sons, 1999. 
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However, tolerances below 0.40 or variance inflation factor greater than 5.0 may indicate 
multicollinearity.370 
The standard errors of parameter estimates in all the logistic regression models 
were low as shown in tables later.  All of the bivariate correlations among explanatory 
variables were low.  An examination of tolerance and variance inflation factor of 
parameter estimates revealed that none of the tolerance values were below 0.4 and none 
of variance inflation values were above five (Appendix F).  All these tests indicate that 
there was no problem of multicollinearity in any of the logistic regression models. 
 
Assessment of outliers 
 The presence of outliers is problematic as it may lead to Type I and Type II errors 
and the results may be only generalizable to populations with similar outlier 
characteristics.  Frequency distributions were reviewed for each of the three continuous 
variables.  Additionally, histograms for continuous variables were evaluated for each 
group.  No outliers were detected from visual evaluation.  Additionally, minimum and 
maximum standardized z-scores were calculated using the following formula371 
Z = (Y – Y`)/ SD where 
Y = each variable’s minimum or maximum value 
Y` = mean of the variable 
SD = standard deviation. 
 
370 Ibid. 
371 Tabachnick BG, Fidell LS. Cleaning up your act: Screening data prior to analysis. In: Tabachnick BG, 
Fidell LS, eds. Using Multivariate Statistics. Boston: Allyn & Bacon, 2001:56-100. 
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Those cases with z-scores in excess of 3.3 were considered as outliers.372 Based 
on these assessments age and duration of PIM use had no univariate outliers.  However 
duration of statin use (Zmax = 10.99) had univariate outliers.  Although the discrepancies 
were statistically significant, given the large sample size, they did not appear to be 
extreme.  Therefore, no cases were deleted from the analyses. 
 Another way to assess the effect of outliers is to assess the goodness-of-fit 
indices.  The chi-square statistic is the sum of Pearson’s residuals.373 Therefore if the 
model shows an adequate fit there is no need to search for outliers.  All of the logistic 
regression models showed adequate fit.  These fits are discussed later in detail in 
objective analyses.  Therefore, outliers are not an issue in any of the models. 
 
ANALYSES OF STUDY OBJECTIVES 
 There were nine objectives in this study addressing two main goals: 
1) Evaluation of trends in prescribing patterns of potentially interacting medications 
with statins and; 
2) Evaluation of incidence and risk factors of myopathy in patients receiving statins 
with and without potentially interacting medications. 
There were four objectives addressing the first goal, and five objectives 
addressing the second goal of the study.  Objectives one to three addressing the first goal 
of the study were exploratory in nature with no corresponding hypotheses.  This has been 
 
372 Ibid. 
373 Tate R. An introduction to modeling outcomes in the behavioral and social sciences. Edina, MN: 
Burgess International Group, Inc., 1998. 
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discussed in detail under demographic factors, statin characteristics and PIM 
characteristics.  A summary of these objectives is presentedin the following section. 
Objective four, which was aimed at identifying factors that are associated with receipt of 
PIMs with statins, had seven hypotheses.  Logistic regression was used to address 
objective four.  The second goal of the study had five objectives of which the first three 
were exploratory in nature.  Survival analysis was used to address objective seven.  The 
remaining two objectives that assessed the relationship between myopathy and receipt of 
PIMs with statins as well as association between myopathy and risk factors had 15 
hypotheses associated with it.  Logistic regression was used to address objectives eight 
and nine.   
The independent variables in the logistic regression were either continuous 
variables or categorical variables.  Some of the categorical variables such as ethnicity, 
level of significance of drug interaction, and type of statin had more than two categories. 
These variables had to be dummy coded to convert them into a set of dichotomous 
variables with categories being one less than total number of discrete categories.  The 
variable physician specialty was excluded from the analysis due to missing data.  
Therefore, hypotheses related to this variable could not be tested.  In total, 21 hypotheses 
were tested.  The variables were entered simultaneously in the regression analysis.   
The model fit of logistic regression models was assessed using global chi-square 
test and the Hosmer and Lemeshow statistic.  The global chi-square statistic tests the null 
hypothesis that is there is no difference between a model with no predictors (constant-
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only model) and a model with predictors (constant + predictors).374 A significant chi-
square (p < 0.05) indicates rejection of the null (i.e., there is a difference between the two 
models) and thus, there is an acceptable model fit. 
The Hosmer and Lemeshow statistic calculates predicted probabilities, divides 
them into approximately 10 intervals and then computes a chi-square statistic based on 
observed and expected frequencies within those intervals.  The Hosmer and Lemeshow 
statistic tests the null hypothesis that there is no difference between observed and 
predicted frequencies over the 10 intervals for a model that fits the data well.  A non-
significant chi-square (p > 0.05) indicates that the null hypothesis is not rejected 
supporting the assumption of correct model fit.375 
Goal 1: Evaluation of trends in prescribing patterns of potentially interacting 
medications with statins 
 Objectives one to four corresponded to the above-mentioned goal.  A summary of 
objectives one to three is presented here.  These objectives have been discussed in detail 
in the descriptive section of this chapter. 
 
Summary of objectives 1 to 3 
 Objective 1 aimed to provide descriptive statistics on type and dose of statin used.  
The most commonly used statins by patients was atorvastatin (N = 4,894; 55.5%), 
 
374 Tabachnick BG, Fidell LS. Logistic Regression. In: Tabachnick BG, Fidell LS, eds. Using Multivariate 
Statistics. Boston: Allyn & Bacon, 2001:517-581. 
375 Tate R. An introduction to modeling outcomes in the behavioral and social sciences. Edina, MN: 
Burgess International Group, Inc., 1998. 
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followed by simvastatin (N = 2,219; 25.2%), pravastatin (N = 1,159; 13.1%), fluvastatin 
(N = 465; 5.3%) and lovastatin (N = 85; 0.9%).  A total of 7,066 patients (80.1%) were 
started on low doses of statins, as recommended by package inserts of these statins.  Of 
these, 3,494 (40%) patients were started on 10mg of atorvastatin and 1,144 (13%) 
patients were started on 20mg of simvastatin. 
 Objective 2 addressed the frequency and percent of the type of potentially 
interacting medication.  A total of 3,005 patients used potentially interacting medications.  
The most frequently used PIM was macrolide antibiotics (N = 1,225; 4.0.8%), followed 
by calcium channel blockers (N = 879; 29.2%) and fibrates (N = 379; 12.6%). 
 Objective 3 aimed to describe demographic characteristics of study population 
based on whether or not they receive potentially interacting medications.  Table 3.15 
provides a summary of demographic characteristics of both cohorts. 
 
Table 3.15: Percent, means and standard deviation of demographic 
characteristics by statin users and statin interacters 
 
Variable Statin Users Statin Interacters
Age (years): Mean (SD) 
 



























Objective 4: To identify demographic, health-related, treatment, and physician-
related factors that are associated with the receipt of potentially interacting 
medications. 
 The association between the receipt of potentially interacting medications and 
various risk factors was evaluated using logistic regression.  The physician specialty 
factor was not included in the analysis due to missing data.  The logistic model for the 
odds of receiving a potentially interacting medication (i.e., Y = 1) for any given subject i 
is 
Yi =  exp (g (xi))______
1 + exp (g (xi)) 
 
Where  g(xi) is the usual linear equation: 
g(xi) = β0 + β1 X1 +…..+ βkXk
With constant β0, coefficients βj, and predictors Xj for k predictors (j = 1, 2, 3 … k). 
 The logistic regression model showed an improvement in fit based on the global 
chi-square test (χ2 = 312.5; df = 12; p < 0.05) and an acceptable functional form based on 
the Hosmer and Lemeshow statistic (χ2 = 5.1; df = 8; p > 0.05).  The results of the 
regression analyses are shown in Table 3.16. 
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Table 3.16: Logistic regression analyses to identify risk factors associated with 












Age -0.005 0.002 5.000 1 0.025* 0.995 0.990 0.999 
Gender (Female)a 0.429 0.048 81.084 1 <0.0001* 1.536 1.399 1.686 
Ethnicity (Black)b -0.080 0.061 1.731 1 0.188 0.923 0.819 1.040 
Ethnicity 
(Hispanic)b
-0.281 0.055 25.326 1 <0.001* 0.755 0.676 0.842 
Ethnicity (Asian)b 0.094 0.155 0.367 1 0.544 1.099 0.810 1.490 
Ethnicity (Other)b 0.012 0.099 0.015 1 0.901 1.012 0.834 1.229 
Comorbidities 0.355 0.026 183.334 1 <0.001* 1.427 1.355 1.502 
Fluvastatinc -0.221 0.119 3.450 1 0.063 0.801 0.634 1.012 
Atorvastatinc -0.113 0.070 2.562 1 0.109 0.893 0.777 1.026 
Lovastatinc -0.494 0.258 3.653 1 0.055 0.610 0.367 1.013 
Simvastatinc -0.183 0.079 5.328 1 0.021* 0.832 0.712 0.973 
Dose of statind -0.033 0.055 0.372 1 0.541 0.967 0.867 1.078 
* p<0.05 
a. Reference category is male 
b. Reference category is Whites 
c. Reference category is pravastatin 
d. Reference category is low dose of statin 
 
Among all the risk factors that were evaluated, increasing age, being Hispanic, 
and receiving simvastatin had lower odds of receiving potentially interacting medication.  
Being female and having a greater number of comorbidities had higher odds of receiving 
potentially interacting medications.  The odds of receipt of PIM was greatest for females 
(Odds ratio (OR): 1.536; 95% CI: 1.399-1.686) and those with increasing number of 
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comorbidities (OR: 1.427; 95% CI: 1.355-1.502).  Based on the results of the analyses, 
hypotheses one to seven are presented in following section. 
 
Results of hypotheses tests 
Hypothesis 1:  There will be no difference in the odds of receipt of potentially interacting 
medication based on type of statin, while controlling for other factors. 
 Based on the results of the logistic regression (Table 3.16), patients on simvastatin 
had significantly lower odds (OR: 0.832; 95% CI: 0.712-0.973) of receiving PIMs than 
patients on pravastatin.  However, there was no difference in the odds of receiving PIMs 
for the remaining categories of statins.  Thus, hypothesis 1 was rejected. 
 
Hypothesis 2: There will be no difference in the odds of receipt of potentially interacting 
medication based on dose of statin, while controlling for other factors. 
 The doses of statins were categorized into two groups based on the comparative 
efficacy of the statins on lipid levels (Table 2.7 in Chapter 2).  All the doses in group I 
are lower and have lower reduction in lipid levels as compared to doses of statins in 
group II .  Based on the results shown in Table 3.16, hypothesis 2 was not rejected.  
There was no difference in odds of receiving PIM based on dose of statin (OR:0.967; 
95% CI: 0.867-1.078), controlling for all other factors. 
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Hypothesis 3: The odds of receipt of potentially interacting medication will increase with 
increasing age, while controlling for other factors. 
 Based on the results of the regression analysis (Table 3.16), increasing age had 
lower odds of receiving a PIM (OR: 0.995; 95% CI: 0.990-0.999), controlling for all 
other factors.  The odds ratio is so close to one that even though the results are 
statistically significant, the difference between two groups is minimal.  Nevertheless, 
hypothesis 3 is rejected. 
 
Hypothesis 4: There will be no difference in the odds of receipt of potentially interacting 
medication based on gender,while controlling for other factors. 
 Based on the results of the logistic regression (Table 3.16), hypothesis 4 was 
rejected.  Females had a 53.6% (OR: 1.536; 95% CI: 1.399-1.686) higher odds of 
receiving PIM than males, controlling for all other factors. 
 
Hypothesis 5: There will be no difference in the odds of receipt of potentially interacting 
medication based on ethnicity/race, while controlling for other factors. 
 Based on the results of the logistic regression presented in Table 3.16, being 
Hispanic had statistically significant lower odds (OR:0.755; 95% CI: 0.676-0.842) of 
receiving a PIM as compared to Whites.  Blacks had lower odds whereas Asians and 
other ethnicities had higher odds of receiving PIM than Whites, but the results were not 
statistically significant.  Based on these results, hypothesis 5 was rejected. 
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Hypothesis 6: The odds of receipt of potentially interacting medication will increase with 
increasing number of comorbidities, while controlling for other factors. 
 The odds of receipt of potentially interacting medication increased 42% (OR: 
1.427; 95% CI: 1.355-1.502) with increasing number of comorbidities, controlling for all 
other factors.  Based on these results, hypothesis 6 was not rejected. 
 
Hypothesis 7: There will be no difference in the odds of receipt of potentially interacting 
medications based on physician specialty, while controlling for other factors. 
 It was not possible to test this hypothesis, as the physician specialty variable was 
not included in the analysis due to missing data. 
 
Goal 2: Evaluation of incidence and risk factors for myopathy in patients receiving 
statins with and without potentially interacting medications 
 As mentioned earlier, objectives 5 to 9 corresponded to goal two.  Objectives 5 to 
7 were exploratory in nature.  Descriptive statistics were used to answer objectives 5 to 7.  
Objectives 8 and 9 were assessed using logistic regression.  A total of 15 hypotheses were 
associated with objectives 8 and 9.  The results of each of the objective analyses are 
discussed in the following section. 
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Objective 5: To estimate the overall incidence of myopathy among study population. 
 The main outcome of this study was to determine the incidence of myopathy in 
the study population.  The patients were followed from the index date until one of the 
following endpoints: 
1) diagnosis of myopathy as identified by ICD-9-CM codes as discussed in 
methodology chapter;  
2) discontinued statin therapy (a gap of 45 days or greater) or PIM use; or  
3) end of the six-month follow-up from the index date.   
 Follow-up times were calculated in terms of person-months where person-month 
was duration of time between index date and one of the above-mentioned endpoints.  The 
cumulative incidence rate or incidence density was then calculated using following 
formula: 
Incidence density =  Myopathy Occurrences X 100 
 Sum of time periods 
 
A total of 113 patients developed new cases of myopathy during the average 
follow-up of 3.9 months.  The cumulative incidence rate for the overall population was 
0.32 per 100 person-months based on the above formula. 
The incidence density was then calculated for the statin user and the statin 




Table 3.17: Number of patients, sum of follow-up months, number of myopathy 
cases, and incidence of myopathy per 100 person-months by statin users and statin 
interacters 
 
Statin Users Statin Interacters 
Number of patients 5,817 3,005
Sum of follow-up months (person-months) 23,369 11,656
Number of myopathy cases (%) 49 (0.8) 64 (2.1)
Incidencea 0.21 0.54
a. New myopathy cases per 100 person-months 
 
As seen from Table 3.17, statin interacters had higher incidence density of 
myopathy (0.54 per 100 person-months) than statin users (0.21 per 100 person-months).  
When the two groups were compared using chi-square analysis, there was a statistically 
significant (χ2 = 25.97; df = 1; p < 0.001) difference in the number of myopathy cases 
between two groups.  The odds of myopathy within the two groups controlling for a 
variety of risk factors will be discussed in objective eight. 
 
Objective 6: To describe demographic characteristics of the study population based 
on presence or absence of myopathy. 
 Tale 3.18 provides information on age, sex, and ethnicity/race based on whether 
the patient has experienced myopathy for each of the two cohorts. 
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Table 3.18: Age, gender, and ethnicity/race by presence or absence of myopathy 
















Age (Years) Mean (SD) 50.3 (9.6) 51.1 (10.0) 54.0 (9.3) 51.3 (9.7)
Gender 
Female (%) 



































a. Others includes all other ethnicities besides those mentioned above 
 
The proportion of females was greater for patients experiencing myopathy than 
those with no myopathy for both groups (Table 3.18).  The percent of Blacks, Asians and 
other ethnic groups was lower for patients with myopathy compared to those without 
myopathy; but the percent of Whites was higher for those patients experiencing 
myopathy than those without myopathy for both groups.  In the statin user group, the 
proportion of Hispanics was smaller for patients with myopathy (28.6%) than those 
without myopathy (33.5%).  Also, the patients with myopathy were slightly younger than 
patients without myopathy.  However, in the statin interacter group, not only was the 
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percent of Hispanics greater for patients having myopathy (29.7%) compared to those 
without myopathy (27.2%), also patients with myopathy were older than those without 
myopathy.  The association of these demographic variables with risk of myopathy will be 
discussed in objective 9. 
 
Objective 7: To describe the “time to occurrence of myopathy” in patients receiving 
statins and potentially interacting medications, and patients receiving statins 
without potentially interacting medications. 
 This objective was addressed using Kaplan-Meier survival analysis.  Kaplan-
Meier survival analysis describes the time to survival without myopathy in context of 
incomplete (censored) information.  Figure 3.2 shows the survival curves for the statin 
user and statin interacter groups. 
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As seen from the Figure 3.2, the probability of 180 days survival (without 
myopathy) was higher for statin user group (0.45) compared to statin interacters (0.42).  
There was a statistically significant difference (χ2 = 10.77; df = 1; p < 0.05) in survival 
times between two groups.  As seen from the graph, for a short time period, 
approximately between 100 and 120 days, the probability of survival is higher in the 
statin interacter group than the statin user group.  Table 3.19 provides information on the 
probability of survival without myopathy and the mean survival times for the statin user 
and statin interacter groups. 
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Table 3.19: Probability of survival without myopathy and mean survival time for 
statin users and statin interacters 
 
Statin User Statin Interacter 












Mean (SE)a Survival, daysb 120 (0.81) 115 (1.19) 
a. S.E. – Standard Error.  Standard Error was reported in the output instead of standard deviation 
b. The mean survival time and its standard error were underestimated because the largest observation was 
censored and the estimation was restricted to the largest event time. 
 
Objective 8: To assess the relationship between the development of myopathy and 
use of potentially interacting medications with statins, while controlling for other 
risk factors for myopathy 
 The relationship between presence or absence of myopathy and use of potentially 
interacting medications with statins was assessed using logistic regression.  The 
dependent variable was a dichotomous variable where 1 = presence of myopathy and 0 = 
absence of myopathy.   The risk factors that were controlled for included age, gender, 
ethnicity/race, presence of diabetes, number of comorbidities, type of statin used, dose of 
statin and duration of statin treatment.   As mentioned earlier in the testing of logistic 
regression assumptions section, the Asian ethnicity/race category was collapsed with the 
other ethnicities/races category because the expected cell count was less than one.  Also, 
lovastatin and fluvastatin users were collapsed into one single category of other statins as 
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25% of cells had an expected count of less than five.  The physician specialty variable 
was not included in the analysis due to missing data. 
The logistic model for the odds of developing myopathy (i.e., Y = 1) for an any 
given subject i is 
Yi =  exp (g(xi))______
1 + exp (g (xi)) 
 
Where  g(xi) is the usual linear equation: 
g(xi) = β0 + β1 X1 +…..+ βkXk
With constant β0, coefficients βj, and predictors Xj for k predictors (j = 1, 2, 3 … k). 
 The logistic regression model showed an improvement in fit based on the global 
chi-square test (χ2 = 61.2; df = 13; p < 0.0001) and an acceptable functional form based 
on the Hosmer and Lemeshow statistic (χ2 = 15.1; df = 8; p > 0.05).  Table 3.20 provides 
information on the results of the regression analysis for odds of developing myopathy. 
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Table 3.20: Logistic regression analysis results to assess the relationship between 












Receipt of PIMa 1.000 0.200 24.87 1 < 0.0001* 2.720 1.83 4.03 
Age 0.008 0.011 0.65 1 0.419 1.009 0.988 1.030 
Gender (Female)b 0.275 0.205 1.79 1 0.179 1.317 0.881 1.970 
Ethnicity (Black)c -0.385 0.264 2.12 1 0.145 0.681 0.406 1.142 
Ethnicity 
(Hispanic)c
-0.214 0.230 0.867 1 0.352 0.807 0.514 1.268 
Ethnicity (Other)c -0.507 0.409 1.537 1 0.215 0.602 0.270 1.342 
Diabetesd 0.140 0.197 0.511 1 0.475 1.151 0.783 1.692 
Comorbidities 0.320 0.088 13.202 1 0.0003* 1.377 1.159 1.637 
Atorvastatine 0.271 0.302 0.800 1 0.3710 1.311 0.725 2.372 
Simvastatine 0.068 0.341 0.040 1 0.8410 1.071 0.549 2.091 
Other statinse -1.085 0.759 2.04 1 0.153 0.388 0.076 1.497 
Duration of statin 
use 
-0.002 0.000 9.62 1 0.001* 0.997 0.995 0.999 
Dose of statinf -0.159 0.228 0.489 1 0.484 0.853 0.545 1.333 
* p<0.05 
a. PIM – Potentially interacting medication 
b. Reference category is male 
c. Reference category is Whites 
d. Reference category is absence of diabetes 
e. Reference category is pravastatin 
f. Reference category is low doses of statin 
 
As seen from Table 3.20, the odds of myopathy increases when a patient is using 
statins and potentially interacting medications compared to those who use statins without 
potentially interacting medications.  The 95% CI showed that the odds had a range of 
1.83 to 4.03 times greater if the patient used a potentially interacting medication.  In 
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addition, comorbidities and duration of statin use were statistically significant, which is 
discussed under objective 9.   
 
Hypothesis 8: The odds of developing myopathy will be higher for statin interacters as 
compared to statin users, controlling for other factors.
Based on results of logistic regression (Table 3.20), the odds of developing 
myopathy was significantly higher (OR: 2.72; 95% CI: 1.83–4.03) for statin interacters 
than statin users.  Statin interacters had two times higher odds of developing myopathy 
than statin users, while controlling for other factors.  Based on these results, hypothesis 8 
was not rejected.  
 
Objective 9: To determine the risk factors (demographic factors, health risk factors, 
treatment factors and physician-related factors) for myopathy. 
 Logistic regression analysis was conducted to determine the risk factors 
associated with developing myopathy.  Two logistic regression models were analyzed.  In 
the first model, the analysis included all patients and all factors except those involving 
PIM characteristics as statin users never received PIMs and therefore, that information 
was not available for them.  In order to evaluate PIM characteristics as risk factors for 
myopathy, a separate logistic analysis was done only on statin interacters.  The variable 
physician specialty was not included in the analysis due to missing data, as mentioned 
before.  Therefore, hypothesis 23 could not be evaluated.  The results of logistic 
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regression analysis that included all the patients are discussed first followed by the results 
of the analysis of statin interacters. 
 Table 3.20 provides information on the results of logistic regression analysis.  As 
seen from the Table 3.20, the odds of developing myopathy were significantly associated 
with the number of comorbidities and duration of statin use.  The odds of developing 
myopathy increased with an increasing number of comorbidities (OR: 1.377; 95% CI: 
1.159–1.637).  Even though decreasing duration of statin use was significantly associated 
with odds of developing myopathy, the difference was only minimal (OR: 0.997; 95% 
CI: 0.995-0.999).  Based on the results of this analysis, hypotheses 9 to 19 are discussed. 
 
Hypothesis 9: The odds of developing myopathy will increase with increasing age, while 
controlling for other factors. 
 Based on the results of logistic regression analysis (Table 3.20), increasing age 
had higher odds of developing myopathy (OR: 1.009; 95% CI: 0.988 –1.030); however, 
these results were not statistically significant.  Therefore, hypothesis 9 was rejected. 
 
Hypothesis 10: The odds of developing myopathy will be higher for females than males, 
while controlling for other factors. 
 Based on the results shown in Table 3.20, hypothesis 10 was rejected.  There was 
no statistically significant difference in odds of developing myopathy between females 
and males (OR: 1.317; 95% CI: 0.881-1.970). 
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Hypothesis 11: There will be no difference in the odds of developing myopathy based on 
ethnicity/race, while controlling for other factors. 
 Logistic regression analysis revealed that there was no statistically significant 
difference in odds of developing myopathy based on ethnicity/race (Blacks - OR: 0.681; 
95% CI: 0.406-1.142, Hispanics - OR: 0.807; 95% CI: 0.514-1.268, Other - OR: 0.602; 
95% CI: 0.270-1.342).  Therefore, hypothesis 11 was not rejected.  
 
Hypothesis 12: The odds of developing myopathy will be higher for patients with diabetes 
than those without diabetes, while controlling for all other factors. 
 There was no statistically significant difference in the odds of developing 
myopathy (OR: 1.151; 95% CI: 0.783 – 1.692) between patients with diabetes and those 
without diabetes.  Based on these results, hypothesis 12 was rejected. 
 
Hypothesis 13: The odds of developing myopathy will increase with increasing number of 
comorbidities, while controlling for other factors 
 Based on the results shown in Table 3.20, there was statistically significant 
increase in the odds of developing myopathy with an increasing number of comorbidities.  
Specifically, the odds of developing myopathy increased 1.37 times with an increasing 
number of comorbidities (OR: 1.377; 95% CI: 1.159 - 1.637).  Therefore, hypothesis 13 
was not rejected. 
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Hypothesis 14: The odds of developing myopathy will be higher for patients using 
simvastatin as compared to pravastatin, while controlling for other factors. 
Based on the results of logistic regression analysis (Table 3.20), there was no 
statistically significant difference in the odds of developing myopathy for patients on 
simvastatin compared to those on pravastatin (OR: 1.071; 95% CI: 0.549–2.091).  Thus, 
hypothesis 14 was rejected. 
 
Hypothesis 15: The odds of developing myopathy will be higher for patients using 
atorvastatin as compared to pravastatin, while controlling for other factors. 
 The results of the regression analysis (Table 3.20) revealed there was no 
difference in the odds of developing myopathy for patients using atorvastatin as 
compared to those using pravastatin (OR: 1.311; 95% CI: 0.725–2.372).  Based on these 
results, hypothesis 15 was rejected. 
 
Hypothesis 16: The odds of developing myopathy will be higher for patients using 
fluvastatin/lovastatin as compared to pravastatin, while controlling for other factors 
 Fluvastatin and lovastatin users were combined to form one group.  This was done 
to increase the cell count due to the small number of fluvastatin and lovastatin users.  
Based on the results of the logistic regression (Table 3.20), after combining both users, 
there was no statistically significant difference in the odds of developing myopathy for 
patients using fluvastatin and lovastatin compared to patients using pravastatin (OR: 
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0.388; 95% CI: 0.076–1.497).  Therefore, both hypothesis 16 and hypothesis 17 were 
rejected. 
 
Hypothesis 17: The odds of developing myopathy will be higher for patients on higher 
doses of statins than lower doses of statins, controlling for other factors. 
 The doses of statins were categorized into two groups based on the comparative 
efficacy of the statins on lipid levels (Table 2.7 in Chapter 2).  All the doses in group I 
are lower and have lower reduction in lipid levels as compared to doses of statins in 
group II.  Based on the logistic regression analysis results shown in Table 3.20, there was 
no statistically significant difference in the odds of developing myopathy between 
patients on higher doses of statins and those on lower doses of statins (OR: 0.853; 95% 
CI: 0.545-1.333).  Therefore, hypothesis 18 was rejected. 
 
Hypothesis 18: The odds of developing myopathy will increase with increasing duration 
of use of statin, while controlling for other factors. 
 Based on the results shown in Table 3.20, hypothesis 19 was rejected.  The odds 
of developing myopathy decreased with increasing duration of statin use (OR: 0.997; 
95% CI: 0.995–0.999).  Even though the results were statistically significant, the 
difference was minimal.  Nevertheless, hypothesis 19 was rejected.  
 
In order to evaluate the association between PIM characteristics and risk of 
myopathy, logistic regression analysis was conducted only on statin interacters.  Table 
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3.21 provides information on logistic regression analysis conducted on statin interacters 
to determine PIM characteristics that are risk factors for myopathy. 
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Table 3.21: Logistic regression analysis results to determine PIM characteristics 











Age 0.034 0.016 34.15 1 <0.001* 1.035 1.004 1.067 
Gender (Female)a 0.029 0.277 0.011 1 0.916 1.030 0.598 1.773 
Ethnicity (Black)b -0.233 0.355 0.432 1 0.511 0.792 0.394 1.589 
Ethnicity 
(Hispanic)b
0.027 0.312 0.008 1 0.930 1.028 0.558 1.893 
Ethnicity (Other)b -0.299 0.497 0.363 1 0.547 0.741 0.280 1.963 
Diabetesc 0.056 0.264 0.045 1 0.832 1.058 0.631 1.774 
Comorbidities 0.299 0.113 7.047 1 0.008* 1.349 1.081 1.682 
Atorvastatind 0.275 0.403 0.465 1 0.495 1.316 0.597 2.902 
Simvastatind 0.384 0.440 0.759 1 0.383 1.468 0.619 3.481 
Other statinsd -1.101 1.067 1.063 1 0.302 0.332 0.041 2.696 
Duration of statin 
use 
-0.001 0.000 3.959 1 0.047* 0.998 0.997 1.000 
Dose of statine -0.409 0.324 1.599 1 0.206 0.664 0.352 1.252 
Significance of 
drug interaction 
 Level 2f, g 























Time of receipt of 
PIMi,  j 
0.240 0.345 0.485 1 0.486 1.272 0.647 2.500 
Duration of PIMj
use 
-0.002 0.002 1.029 1 0.310 0.997 0.992 1.002 
* p<0.05 
a. Reference category is male 
b. Reference category is Whites 
c. Reference category is absence of diabetes 
d. Reference category is pravastatin 
e. Reference category is low doses of statin 
f. Reference category is Level 1 which is defined as severe or potentially life-threatening. 
g. Level 2 is defined as an interaction that causes detoriation in patients’ clinical status. 
h. Level 3 is defined as moderate to minor side effects.   
i. Reference category is PIM received after start of statin therapy 
j. PIM – Potentially interacting medication 
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A sub-group analysis on statin interacters as shown in Table 3.21 revealed the 
same risk factors as shown in Table 3.20 to be significantly associated with odds of 
developing myopathy.  In addition, increasing age was associated with higher odds of 
developing myopathy (OR: 1.035; 95% CI: 1.004-1.067).  Based on the results of this 
sub-group analysis, hypotheses 20 to 22 are discussed. 
 
Hypothesis 19: The odds of developing myopathy will increase with increasing level of 
significance of drug interaction, while controlling for other factors. 
Based on the results of logistic regression shown in Table 3.21, there was no 
statistically significant difference in the odds of developing myopathy based on level of 
significance of drug interaction. Therefore, hypothesis 19 was rejected. 
 
Hypothesis 20: There will be no difference in the odds of developing myopathy based on 
whether the potentially interacting medication was given before or after the start of statin 
therapy, while controlling for other factors. 
 The results of regression analysis revealed that there was no difference in the odds 
of developing myopathy based on whether the potentially interacting medication was 
given before or after the start of statin therapy  (OR: 1.272; 95% CI: 0.647–2.500).  
Therefore, hypothesis 20 was not rejected. 
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Hypothesis 21: The odds of developing myopathy will increase with increased duration of 
potentially interacting medication use, while controlling for other factors. 
 Logistic regression analysis (Table 3.21) revealed that there was no statistically 
significant difference in the odds of developing myopathy with increased duration of PIM 
use (OR: 0.997; 95% CI: 0.992-1.002).  Therefore, hypothesis 21 was rejected. 
 
SUMMARY OF THE STUDY HYPOTHESES TESTS 
Table 3.22 provides a summary of the results of study hypotheses tests. 
 





Description Rejected/Not Rejected 
Evaluation of factors that are associated with the receipt of potentially interacting medication
Hypothesis 1 There will be no difference in the odds of receipt of 
potentially interacting medication based on type of statin, 
while controlling for other factors. 
 
Rejected 
Hypothesis 2 There will be no difference in the odds of receipt of 
potentially interacting medication based on dose of statin, 
while controlling for other factors. 
.
Not Rejected 
Hypothesis 3 The odds of receipt of potentially interacting medication 




Hypothesis 4 There will be no difference in the odds of receipt of 
potentially interacting medication based on gender, while 









Description Rejected/ Not Rejected 
Hypothesis 5 There will be no difference in the odds of receipt of 
potentially interacting medication based on ethnicity/race, 
while controlling for other factors. 
 
Rejected 
Hypothesis 6 The odds of receipt of potentially interacting medication 
will increase with increasing number of comorbidities, 
while controlling for other factors. 
 
Not rejected 
Hypothesis 7 There will be no difference in the odds of receipt of 
potentially interacting medication based on physician 
specialty, while controlling for other factors. 
 
Did not test 
Evaluation of risk factors that are associated with the development of myopathy
Hypothesis 8 The odds of developing myopathy will be higher for 
statin interacters than for statin users, while controlling 
for other factors. 
 
Not rejected 
Hypothesis 9 The odds of developing of myopathy will increase with 
increasing age, while controlling for other factors. 
 
Rejected 
Hypothesis 10 The odds of developing myopathy will be higher for 




Hypothesis 11 There will be no difference in the odds of developing 




Hypothesis 12 The odds of developing myopathy will be higher for 
patients with diabetes than those without diabetes, while 
controlling for other factors. 
 
Rejected 
Hypothesis 13 The odds of developing myopathy will increase with 




Hypothesis 14 The odds of developing myopathy will be higher for 
patients using simvastatin as compared to pravastatin, 
while controlling for other factors. 
Rejected 
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Description Rejected/Not Rejected 
Hypothesis 15 The odds of developing myopathy will be higher for 
patients using atorvastatin as compared to pravastatin, 
while controlling for other factors. 
 
Rejected 
Hypothesis 16 The odds of developing myopathy will be higher for 
patients using fluvastatin/lovastatin as compared to 
pravastatin, while controlling for other factors. 
 
Rejected 
Hypothesis 17 The odds of developing myopathy will be higher for 
patients on higher doses of statins than lower doses of 
statins, while controlling for other factors. 
 
Rejected 
Hypothesis 18 The odds of developing myopathy will increase with 




Hypothesis 19 The odds of developing myopathy will increase with 
increasing level of significance of drug interaction, while 
controlling for other factors. 
 
Rejected 
Hypothesis 20 There will be no difference in the odds of developing 
myopathy based on whether the potentially interacting 
medication was given before/ after the start of statin 
therapy, while controlling for other factors. 
 
Not Rejected 
Hypothesis 21 The odds of developing myopathy will increase with 




Hypothesis 22 There will be no difference in odds of developing 
myopathy based on physician specialty, while controlling 
for other factors. 
Did not test 
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SENSITIVITY ANALYSIS 
A sensitivity analysis was conducted on the duration of statin use variable.  
Duration of statin use was originally defined as the time period a patient was exposed to 
statin before the end of observation period.  The end of the observation period is defined 
when any one of the following three events occur: 1) diagnosis of myopathy; 2) 
discontinues statin therapy or PIM use; 3) end of 180 days follow-up period.  
Discontinuation of statin therapy was defined as a gap of greater than 45 days between 
two refills.  In the sensitivity analysis, the criterion for discontinuation of statin therapy 
was defined as a gap of greater than 60 days between two refills.   
Based on this criterion, a total of 8,911 patients were included in the study of 
which 5,817 patients were statin users and 3,094 were statin interacters.  Objectives four, 
five, seven, eight and nine were re-analyzed with this new end-point.  Results are 
presented in Appendix D.  The results of all objectives when a gap greater than 60 days 
was allowed between refills were similar to the original results when a gap of greater than 




DISCUSSION AND CONCLUSIONS 
 
The present study examined the risk of myopathy associated with the use of 
statins and potentially interacting medications in Texas Medicaid population.  This 
chapter discusses the results of the study by comparing and contrasting them with 
previous research, and finally presenting the conclusion.  First, the background for the 
study is reviewed, followed by the present study overview, discussion of the objectives, 
study limitations, and finally study implications and conclusions. 
 
STUDY BACKGROUND 
 The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins as 
they are commonly called are the most widely used drugs for the management of 
hyperlipidemia.  The management of hyperlipidemia is essential in the prevention of 
CHD.  Primary, secondary, and angiographic trials have demonstrated the beneficial 
effects of statins in treatment of hyperlipidemia and in reduction of CHD-related 
morbidity and mortality (as discussed in Section I). 
 Statins as a class of drugs are generally well tolerated; however, adverse events 
have been associated with statins both as monotherapy and in combination therapy with 
other agents.  Concern over the safety of statins was heightened by the worldwide 
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withdrawal of cerivastatin in 2001, a drug that was thought to be relatively free of 
adverse effects over the four years it was marketed.376,377 The major side-effect 
associated with cerivastatin as well as other statins is myopathy. 
 Myopathy is a general term referring to disorders of muscles ranging from mild 
myalgia to severe rhabdomyolysis.  The risk of statin-associated myopathy further 
increases in the presence of a number of risk factors.378 One of the most important risk 
factors is concurrent use of PIMs with statins.  Statins in combination with PIMs which 
inhibit their metabolism, increase the blood levels of statins, thereby increasing the risk 
of myopathy.  One study estimated the risk of myopathy to be 12-fold higher in patients 
using a statin-fibrate combination versus those using statins by themselves.379 There is 
very limited information on the risk of myopathy when statins are taken with other 
potentially interacting medications and the risk factors that increase the probability of 
myopathy.  The next section discusses the studies that have estimated the risk of 
myopathy. 
 
Observational studies evaluating the risk of myopathy 
 Four known observational studies estimated the incidences of myopathy.  Two of 
these studies were conducted using the GPRD database and focused on rhabdomyolysis, 
 
376 Psaty BM, Furberg CD, Ray WA, et al. Potential for Conflict of Interest in the Evaluation of Suspected 
Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis. JAMA 2004;292:2622-2631. 
377 Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 
2002;346:539-540. 
378 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
379 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
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and the other two studies were conducted on the US population using data from managed 
care and included hospitalized cases of myopathy.   
 The earliest study conducted using the UK population estimated the incidence of 
myopathy as 2.3 per 10,000 person-years for patients using lipid lowering drugs.380 The 
relative risk was of myopathy was 7.6 (95% CI: 1.4–41.3) for statin users and 42.4 (95% 
CI: 11.6–170.5) for fibrate users compared with non-users.  Another study that used the 
same database identified only one case of rhabdomyolysis among 52,000 patients 
receiving lipid lowering agents.381 This patient was on statin-fibrate combination 
therapy. 
 Graham and colleagues382 used claims data from 11 managed care organizations 
to establish the incidence of hospitalized rhabdomyolysis across US.  The incidence of 
myopathy was 0.44 per 10,000 person-years for statin users (excluding cerivastatin) and 
5.98 per 10,000 person-years for statin-fibrate combination users.  The relative risk of 
myopathy increased for patients aged 65 years and older, and for patients with diabetes 
mellitus.  As compared to statin users, fibrate users had a 5.5-fold greater risk of 
myopathy and statin-fibrate combination users had a 12.2-fold increase in risk of 
myopathy.383 
A more recent study used administrative claims database from diverse regions in 
the US to evaluate the incidences of hospitalizations related to adverse effects including 
 
380 Gaist D, Garcia Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a 
population-based follow-up study. Epidemiology 2001;12:565-9. 
381 Black C, Jick H. Etiology and frequency of rhabdomyolysis. Pharmacotherapy 2002;22:1524-26. 
382 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
383 Ibid. 
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myopathy for lipid lowering agents.  Incidence of hospitalizations for myopathy in 
patients treated only with statins varied from 1.58 for fluvastatin to 3.84 for pravastatin 
per 10,000 person-years.   Risk of hospitalizations due to myopathy increased in the 
presence of hypertension (RR: 5.13; 95% CI: 2.42–10.85) and if patients received 
potentially interacting medications concurrently with statins (RR: 6.01; 95% CI: 2.08–
17.38).384 
Only one known study has evaluated the risk of myopathy in patients using PIMs 
concurrently with statins.385 However, not all drugs listed by the ACC/AHA/NHLBI 
clinical advisory on safety of statins were included in the analysis.  The study findings 
were also limited by lack of control for other important risk factors that increase the 
probability of myopathy and included only hospitalized cases of myopathy.  Most other 
studies evaluated only the association between risk of myopathy and use of statins with a 
secondary focus on statin-fibrate combination use and risk of myopathy.386,387 Given the 
sparse information about risk and risk factors of myopathy in patients using statins and 
PIMs, this study aimed to fill this gap in literature. 
 
PRESENT STUDY OVERVIEW 
 The purpose of this study was to estimate the incidence and risk factors of 
myopathy in patients using a statin product with and without PIMs using Texas Medicaid 
 
384 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
385 Ibid. 
386 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
387 Gaist D, Garcia Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a 
population-based follow-up study. Epidemiology 2001;12:565-9. 
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database.  The study objectives were addressed in patients who were new users of statins, 
using five years of data.  The study included patients with a greater number of risk factors 
and a greater number of PIMs than previous studies.  The large sample size (N=8,222) 
provided sufficient statistical power to detect differences between the two cohorts.  
Incidences for statin users and statin interacters were calculated and logistic regression 
analyses were used to determine the risk of myopathy and risk factors associated with 
myopathy.  Next, study objectives will be discussed by comparing and contrasting the 
study results with findings of previous studies. 
 
STUDY OBJECTIVES: 
 Two goals corresponding to nine objectives and 23 hypotheses were addressed in 




Table 4.1: Study objectives and hypotheses  
Study Objectives Hypotheses
Evaluation of trends in prescribing patterns of potentially interacting medications with statins
1. To provide descriptive statistics on type and dose of statins. 
 
N/A 
2. To provide descriptive statistics on type of potentially interacting 
medications. 
N/A 
3. To describe demographic characteristics of study population based on 
whether or not they receive potentially interacting medications.
N/A 
4. To identify demographic, health-related, treatment, and physician-related 
factors that are associated with the receipt of PIMs. 
1-7 
Evaluation of incidence and risk factors for myopathy in patients receiving statins with and 
without potentially interacting medications
5. To estimate the overall incidence of myopathy among study population. 
 
N/A 
6. To describe demographic characteristics of study population based on 
presence or absence of myopathy. 
 
N/A 
7. To describe the “time to occurrence of myopathy” in patients receiving 
statins and potentially interacting medications, and patients receiving statins 
without potentially interacting medications. 
 
N/A 
8. To assess the relationship between the development of myopathy and use of 
potentially interacting medications with statins, while controlling for other risk 
factors for myopathy. 
 
8
9. To determine the risk factors (demographic factors, health risk factors, 




 The first objective of the study was to describe the type and dose of statin therapy 
used by Texas Medicaid population.  The most commonly prescribed statins were 
atorvastatin (55.5%), simvastatin (25.2%), pravastatin (13.1%), fluvastatin (5.3%), and 
lovastatin (0.9%).  These results were similar to results of another study that assessed the 
drug utilization patterns in Texas Medicaid.388 Both studies had a similar hierarchy of 
use of statin drugs.  These results were also consistent with national trends in statin use.  
In a recent study that used data from the National Ambulatory Medical Care Survey and 
National Hospital Medical Care survey, in 2002, the most frequently used statin was 
atorvastatin (approximately 50%), followed by simvastatin, pravastatin, fluvastatin and 
lovastatin.389 This national study included patients above the age of 65 years; 
nevertheless, the trends in statin use were similar to the current study. 
 In the present study, a majority of the patients (80.1%) were initiated on 
recommended doses of statins.  Based on package inserts, the recommended starting 
doses were as follows: atorvastatin 10 or 20 mg once daily;390 simvastatin 20 or 40 mg 
once daily;391 pravastatin 40 mg once daily;392 fluvastatin 40 mg once daily;393 and 
lovastatin 20 mg once daily.394 These results were also consistent with a previous study 
 
388 Dastani HB. Assessment of drug utilization patterns, medication compliance, and physician adherence 
to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid 
system. Austin, TX: The University of Texas at Austin; 2005. Dissertation. 
389 Ma J, Shegal NL, Ayanian JZ. National trends in statin use by coronary heart disease risk category. 
PLoS Med 2005;2:e123. 
390 Lipitor (atorvastatin) [package insert]. Morris Plains, NJ: Pfizer; 2005. 
391 Zocor. (simvastatin) [packcage insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2005. 
392 Pravachol (pravastatin) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2004. 
393 Lescol (fluvastatin) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003. 
394 Mevacor (lovastatin) [package insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2005. 
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that assessed statin utilization patterns in Texas Medicaid where most patients (78.7%) 
were initiated on recommended starting doses.395 
When type and dose of statins were broken down by the two cohorts, the statin 
user and statin interacter groups, both groups were similar.  However, there was a greater 
use of pravastatin in the statin interacter group (14.2%) than the statin user group 
(12.6%).  Among all patients who received statins and PIMs concurrently, patients using 
pravastatin received the highest percent of PIMs (36.0%) compared to patients using 
other statins.  This is not surprising given the fact that pravastatin is the only statin which 
is not metabolized by the CYP450 system; thus, there is less likelihood of drug 
interaction.396 Therefore, greater numbers of patients were using pravastatin and PIMs 
together.  These results were also consistent with another study where among all statin 
users who received potentially interacting medications, patients on pravastatin received 
the highest percentage of potentially interacting medications.397 However, Etemad et al. 
found patients on pravastatin had the lowest frequency of receiving potentially interacting 
medications as compared to other statin users.398 One explanation could be that the time 
period selected for that study was right around withdrawal of cerivastatin (01/01/00 – 
12/31/01).  Therefore, physicians may have been less aware and more liberal in 
prescribing PIMs with other statins.  The current study as well as the study by Cziarky 
 
395 Dastani HB. Assessment of drug utilization patterns, medication compliance, and physician adherence 
to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid 
system. Austin, TX: The University of Texas at Austin; 2005. Dissertation. 
396 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 
397 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
398 Etemad LR, Fairchild C, Waldeck R. Prevalence and cost implications of potential interactions with 
statin medications in a managed care population. ISPOR Ninth Annual International Meeting 2004. 
Washington, D.C. 
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and colleagues399 included time periods two to three years after withdrawal of 
cerivastatin.  Therefore, physicians may have been more aware that there is relatively less 
risk of prescribing PIMs with pravastatin compared to other statins, given the withdrawal 
of cerivastatin. 
 
CHARACTERISTICS OF POTENTIALLY INTERACTING MEDICATIONS 
The second objective was to provide descriptive statistics on the type of 
potentially interacting medications received in this study.  The ACC/AHA/NHLBI 
clinical advisory on use and safety of statins has provided a list of PIMs which potentially 
increase the risk of statin-associated myopathy.400 These medications are fibrates, niacin, 
cyclosporine, azole antifungals, macrolide antibiotics, HIV protease inhibitors, 
nefazodone, calcium channel blockers, and amiodarone.  All of these medications were 
included in the current study except cyclosporine and HIV protease inhibitors. 
The most frequently used PIMs with statins were macrolide antibiotics (40.8%), 
calcium channel blockers (29.2%), and fibrates (12.6%) comprising 82.6% of all PIM 
prescriptions.  These results were consistent with another study conducted in the Veterans 
Affairs Health Care System where fibrates and calcium channel blockers were the top 
two PIMs prescribed with simvastatin.401 This study did not include short-term 
 
399 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
400 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
401 Petropoulos JB, Bello-Quintero CE. Frequency of simvastatin prescriptions with potentially interacting 
medications in a Veterans Affairs health care system. J Manag Care Pharm 2004;10:239-43. 
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medications such as antibiotics.  However, in a Canadian study macrolide antibiotics 
were the most frequently used PIMs with statins.402 
When type of PIM used was classified based on level of significance of drug 
interaction,403 more than half the patients (56.4%) received PIMs with a Level 1 
significance of drug interaction, which is defined as a potentially severe or life 
threatening interaction.  This is because fibrates and antibiotics were included in Level 1 
and more than half the patients received these drugs.  The increased prescribing of these 
drugs with statins may be because health care professionals may judge that the benefits 
outweigh the risks and thus prescribe the drugs together. 
 
DEMOGRAPHIC CHARACTERISTICS 
 Objectives three and six were related to demographic characteristics of the patient 
population.  Objective three aimed to describe the patient population based on whether 
the patient utilized statin therapy with or without PIM.  Objective six described 
demographics based on the presence or absence of myopathy.  First, the overall 
demographics of patients in Texas Medicaid are discussed. 
 A majority of patients in this study were females (58.9%).  These results were 
consistent with the current statistics of Texas Medicaid which is comprised mainly of 
 
402 Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug 
interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a 
Canadian population-based study. Clin Ther 2002;24:2126-36. 
403 Drug Interaction Facts. Wolters Kluwer Health, Inc, 2003-2005. Available at: 
http://www.efactsonline.com/Fac/servlet/MainPage. Accessed on: January 2005 
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women (56%) and non-disabled children (59%).404 This study included patients between 
the ages of 21-64 years of age.  Patients aged 65 years and older were not included in the 
study as their medical claims may be incomplete due to dual eligibility in Medicare and 
Medicaid.  The mean age of the patient population was 51.2 years.  This result was 
similar with a previous study conducted on statin users enrolled in Texas Medicaid; the 
average age of statin users in that study was 49.7 years.405 However, in other studies 
conducted in primary care settings the mean age of patients was 58.5 years.406,407 This 
difference may be due to exclusion of patients aged 65 and above in the current study. 
 Whites comprised 38.4% of the total patient population followed by Hispanics 
(31.3%), and Blacks (22.1%).  A greater percentage of Whites were receiving statins than 
other ethnic groups.  These results were not surprising given the statistics from the state 
of Texas which reveal a higher prevalence of hyperlipidemia in Whites than in other 
ethnic groups.408 These results were also consistent with a previous study conducted on 
statin users in Texas Medicaid where 42.7% were Whites, 32.7% patients were 
Hispanics, and 22.5% patients were Blacks.409 A national sample of patients showed 
 
404 Texas Health and Human Services. Clients and Benefits. Texas Medicaid in Perspective 2004;4-1 -  4-
28. 
405 Dastani HB. Assessment of drug utilization patterns, medication compliance, and physician adherence 
to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid 
system. Austin, TX: The University of Texas at Austin; 2005. Dissertation. 
406 White J, Chang E, Leslie S. Patient adherence with HMG reductase inhibitor therapy mong users of two 
types of prescription services. JMCP 2002;8:186-191. 
407 Harley CR, Setareh WA, McDonough KL. Cholesterol management in a population of managed care 
enrollees. J Clin Outcomes Manage 2003;10:147-154. 
408 Cardiovascular Disease (CVD) in Texas: A surveillance report and program strategy. Bureau of 
Chronic Disease and Tobacco Prevention, Texas Department of Health, 2003. Available at: 
http://www.tdh.state.tx.us/wellness/cvd/cvdsurv2003.pdf. Accessed on: May 04, 2006 
409 Dastani HB. Assessment of drug utilization patterns, medication compliance, and physician adherence 
to lipid and safety monitoring guidelines among patients on lipid-lowering drugs in the Texas Medicaid 
system. Austin, TX: The University of Texas at Austin; 2005. Dissertation. 
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similar trends; based on ATP II guidelines, a greater percentage of Whites (29.5%) 
qualified for dietary and drug therapy than Hispanics (24.7%), and Blacks (18.2%).410 
Objective 3: To describe demographic characteristics of the study population based 
on whether or not they receive potentially interacting medications. 
Both cohorts had a greater number of females than males.  This was not surprising 
considering that a greater percent of females are enrolled in Texas Medicaid than 
males.411 However, the statin interacter group had a higher percent of females (65.3%) 
than the statin user group (55.6%).  This means that more females received statins and 
PIMs concurrently.  This may be because some of the PIMs prescribed such as macrolide 
antibiotics and azole antifungals, which comprised approximately 51% of all PIMs 
prescribed, were prescribed primarily for conditions experienced by females such as 
vaginal infections.  These results are similar to a Canadian study which found more 
females (55.5%) received PIMs with statins than males (44.5%).412 
The average age was similar for both the statin interacter (51.4 years) and statin 
user groups (51.1 years).  This may be surprising as increasing age is associated with 
increased comorbidities and thus, increased use of PIMs.  However, this study did not 
include patients above the age of 65 years and therefore, the average age may be similar 
between two groups.  Table 3.5 depicts each cohort broken by age group and gender.  
 
410 Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein 
cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5. 
411 Texas Health and Human Services. Clients and Benefits. Texas Medicaid in Perspective 2004;4-1 -  4-
28. 
412 Einarson TR, Metge CJ, Iskedjian M, et al. An examination of the effect of cytochrome P450 drug 
interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a 
Canadian population-based study. Clin Ther 2002;24:2126-36. 
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The statin user group had more males under the age of 50 and more females above the 
age of 50.  A chi-square analysis revealed that this difference was statistically significant 
(χ2 = 88.29; d.f. = 4; p <0.0001).  This means that males under the age of 50 are more 
likely to receive statins than females.  Previous research has shown that more males 
receive lipid tests than females, and thus, have a greater probability of being diagnosed 
with hyperlipidemia and receiving statins.413,414 In this population, this may be especially 
true for patients under the age of 50 and needs further investigation. 
 A higher percent of Whites (41.2) received PIMs than other ethnic groups.  Also, 
there were fewer Hispanics in the statin interacter group (27.2%) than the statin user 
group (33.6%).  There is no reason to believe that there should be differences among 
ethnic groups when receiving statins and PIMs concurrently.   
 
Objective 6: To describe demographic characteristics of study population based on 
presence or absence of myopathy. 
More females than males had myopathy in both cohorts.  This is consistent with 
the ACC/AHA/NHBLI clinical advisory on the use and safety of statins which has listed 
being female as one of the risk factors of myopathy.415 In the current study, whether 
being female is associated with the risk of myopathy will be discussed later on. 
 
413 Nau DP, Mallya U. Sex disparity in the management of dyslipidemia among patients with type 2 
diabetes mellitus in a managed care organization. Am J Manag Care 2005;11:69-73. 
414 Roe CM, McNamara AM, Motheral BR. Gender- and age-related prescription drug use patterns. Ann 
Pharmacother 2002;36:30-9. 
415 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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In the statin user group, the mean age was similar for patients experiencing 
myopathy (50.3 years) and those without myopathy (51.1 years).  However, in the statin 
interacter group, patients having myopathy were older (54.0 years) than those without 
myopathy (51.3 years).  Increasing age is one of the risk factors of myopathy416 and 
receiving PIMs may further increase the risk of myopathy.  The association of age and 
risk of myopathy is discussed later in objective nine. 
 In both cohorts, more whites experienced myopathy than the other ethnic groups.  
In the statin user group, fewer Hispanics (28.6%) experienced myopathy than those 
without myopathy (33.5%).  However, for the statin interacter group, more Hispanics 
(29.7%) had myopathy than those without myopathy (27.2%).  This means being 
Hispanic and receiving PIMs with statins may further increase the probability of 
experiencing myopathy.  More research needs to be done to understand the role of 
ethnicity in developing myopathy. 
 
FACTORS ASSOCIATED WITH RECEIPT OF POTENTIALLY INTERACTING 
MEDICATIONS WITH STATINS 
 Objective four addressed identification of factors associated with receipt of PIMs 
with statins.  A total of 3,005 patients received PIMs.  This group was compared with the 
5,817 patients who never received PIMs.  Logistic regression analysis was used to 
identify risk factors associated with receiving PIMs and statins together.  The risk factors 




comorbidities and type and dose of statin used.  Physician specialty was excluded from 
the analysis due to missing data. 
 
Demographic factors 
 Three patient-related factors included in the analysis were age, gender, and 
ethnicity.  Increasing age was associated with lower odds of receiving PIMs with statins 
(OR: 0.995; 95% CI: 0.990 – 0.999).  Even though the result was statistically significant, 
as seen from 95% CI values, the difference was only minimal. Therefore, clinically it 
may be safe to say that age had no effect on the odds of receiving PIMs. This result may 
be counterintuitive as increasing age is associated with increased morbidity and therefore 
,increased use of PIMs with statins.  However, this study did not include patients above 
the age of 65 years and therefore the effect may be minimal. 
 Females had 1.5 (95% CI: 1.399–1.686) higher odds of receiving PIMs than 
males.  As mentioned earlier, almost half the PIMs received in this study included 
antibiotics and antifungals, which were used primarily for conditions in females such as 
vaginal infections.  Therefore, females may have higher odds of receiving PIMs with 
statins than males. 
 There was no statistically significant difference in the odds of receiving PIMs 
among different ethnic groups, except Hispanics.  Hispanics had lower odds (OR: 0.755; 
95% CI: 0.676 – 0.842) of receiving PIMs than Whites.  It is unknown as to why this 




 The number of comorbidities was included as a health-related risk factor in the 
logistic regression analysis to determine if the number of comorbidities was associated 
with receipt of PIMs.  The list of comorbidities included was as listed in Table 2.6 in 
Chapter 2. 
 The odds of receiving PIMs with statins increased with an increasing number of 
comorbidities (OR: 1.427; 95% CI: 1.355-1.502).  This finding is not surprising as one or 
more drugs may be prescribed to manage comorbidities that are diagnosed; this increases 
the odds of receiving PIMs with statins.  Previous research has revealed that certain 
diagnoses are highly correlated with specific drug therapies that are known to interact 
with statins and given concurrently with statins.417 Given the fact that close to 41% of 
population had at least one comorbidity in this study, it can be expected that the odds of 
receipt of PIMs with statins significantly increases with increasing comorbidities.  The 
consequence of receiving PIMs with statins to manage other comorbidities may be a 
greater likelihood of experiencing an adverse event.  It has been suggested that the 
possibility of interactions increases sharply with polypharmacy.418,419 Physicians and 
pharmacists should be very cautious about managing patients with multiple comorbidities 
and should weigh the risks and benefits before prescribing/dispensing PIMs with statins. 
 
417 Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, et al. Prevalence of potentially severe drug-drug 
interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. 
Drug Saf 2005;28:263-75. 
418 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 




 The type and dose of statin used may be an important factor based on which a 
PIM may or may not be prescribed.  The pharmacokinetic properties of drugs such as 
dose of drugs and routes of elimination play a very important role in drug interactions.420 
The pharmacokinetic properties of statins are different.  The two important properties that 
differ are solubility and elimination of statins.421,422 It is important to understand these 
differences as they may have clinical consequences.  If physicians/pharmacists are aware 
of these subtle differences between statins, it may influence their decisions and 
consequently the receipt of PIMs with statins. 
 Patients receiving high doses of statins had lower odds of receiving of PIMs (OR: 
0.967; 95% CI: 0.867 – 1.078) when compared with patients receiving low doses of 
statins; however, this result was not statistically significant.  This result is not surprising 
as the ACC/AHA/NHBLI advisory on clinical use and safety of statins suggests that 
receiving PIMs with higher doses of statins increases the likelihood of myopathy.423 
Therefore, it can be expected that patients would receive PIMs more with lower doses of 
statins than with higher doses of statins.  This indicates that there may be awareness 
among physicians/pharmacists to avoid prescribing/dispensing PIMs with high doses of 
statins.  The consequence of statin dose on myopathy is discussed further in objective 
nine. 
 
420 Hansten PD. Understanding drug-drug interactions. Science & Medicine 1998;5:16-25. 
421 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol 2005;19:117-25. 
422 Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase 
inhibitors. Clin Pharmacokinet 2002;41:343-70. 
423 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
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All statins had lower odds of receiving PIMs when compared to pravastatin.  
However, this result was only statistically significant in patients using simvastatin.  
Pravastatin was used as the reference group as this is the only statin that is not 
metabolized by the CYP450 isoenzyme system.  Specifically, simvastatin had 0.83 times 
lower of odds of receiving PIMs (95% CI: 0.712-0.973) as compared to pravastatin.  This 
may be because simvastatin is metabolized by the CYP450 isoenzyme system and has 
higher likelihood of drug interaction than pravastatin which has carrier-mediated uptake 
in the liver making them less toxic.424 Therefore, simvastatin had lower odds of receiving 
PIMs as the risk of drug interaction is higher than pravastatin.  Similarly all other statins 
are also metabolized by CYP450 isoenzyme system425 and therefore, have a higher 
likelihood of drug interaction with PIMs and therefore, lower odds of receiving PIMs 
with these statins.  These results were consistent with one study in which pravastatin 
users received the highest percent of PIMs along with it compared to other statins.426 
However, these results contrast with those of another study where patients on simvastatin 
and atorvastatin had higher odds of receiving PIMs than pravastatin.427 One explanation 
for this difference could be the time periods selected for the three studies.  In the study by 
Etemad et al.,428 the study period was around the withdrawal of cerivastatin.  At that time, 
physicians may not have been very cautious about prescribing PIMs with statins.  
 
424 Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. 
Fundam Clin Pharmacol 2005;19:117-25. 
425 Ibid. 
426 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
427 Etemad LR, Fairchild C, Waldeck R. Prevalence and cost implications of potential interactions with 




However, the current study as well as the study by Cziarky and colleagues429 extended 
the study period two to three years before and after the withdrawal of cerivastatin.  As a 
result, the physicians/pharmacists may have been more aware of the risks of prescribing 
PIMs with statins, due to the withdrawal of cerivastatin.  Therefore, the odds of receiving 
PIMs were lower for all statins in this study when compared with pravastatin. 
 
INCIDENCE OF MYOPATHY 
 The 8,822 study subjects were followed for an average of 3.9 months (S.D. = 2.1 
months).  During the study period, 113 patients (1.2%) developed new cases of 
myopathy.  These results are consistent with those in clinical trials where the incidences 
of myopathy, mild or severe, have been reported between 0.1% and 5% depending on the 
dose and type of statin.430,431 However, this study included patients who used PIMs with 
statins; therefore the estimated overall risk may be higher than in clinical trials.   
 A total of 8,822 persons contributed 35,022 person-months or 2,878 person-years 
of monotherapy.  The total cases of myopathy in this study were 113 corresponding to an 
incidence rate of 0.32 per 100 person-months or 3.9 per 100 person-years.  The overall 
incidence rate for myopathy was much higher than reported in previous studies.  Gaist et 
al.432 reported an incidence rate 0.023 per 100 person-years for myopathy while a study 
 
429 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
430 Pasternak RC, Smith SC, Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use 
and safety of statins. J Am Coll Cardiol 2002;40:567-72. 
431 Bays H. Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006;97:S6-S26. 
432 Gaist D, Garcia Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a 
population-based follow-up study. Epidemiology 2001;12:565-9. 
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conducted in the US reported an incidence rate of 0.0044 per 100 person-years.433 
However, these incidences were only for patients who used statins by themselves.  This 
study included patients who used statins with and without PIMs.  Therefore, the overall 
incidence of myopathy may be higher than those reported in previous studies. 
 Incidence density was calculated for the statin user and statin interacter groups 
separately.  Statin interacters had a higher incidence density (0.54 per 100 person-months 
or 6.5 per 100 person-years) as compared to statin users (0.21 per 100 person-months or 
2.5 per 100 person-years).  These results were compared to three other studies which 
examined the incidence rates for patients using only statins.  The incidence rates were 
0.023 per 100 person-years,434 0.0044 per 100 person-years435 and 0.026 per 100 person-
years.436 These numbers are much lower than the incidence rate estimated for patients 
using statins in the current study (2.5 per 100 person-years).  This difference may be 
because the study conducted on the US population by Graham and colleagues437 and 
Cziarky and researchers438 included only hospitalized cases of myopathy; whereas the 
current study included cases of myopathy that were diagnosed in hospitals, physicians’ 
office as well as outpatient departments.  Myopathy cases may be diagnosed at 
physicians’ office and may not always require hospitalization.  The cases of myopathy 
 
433 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
434 Gaist D, Garcia Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a 
population-based follow-up study. Epidemiology 2001;12:565-9. 
435 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
436 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
437 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
438 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
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that do require hospitalization are probably the more severe forms of myopathy resulting 
in rhabdomyolysis. 
 The incidence density for statin interacters was 6.5 per 100 person-years.  Data is 
sparse on the incidence of myopathy when patients use statins with PIMs.  Graham and 
colleagues estimated the incidence of myopathy in patients using statins and fibrates at 
0.0598 per 100 person-years.439 The risk for myopathy was approximately 12 times 
higher in patients using statins and fibrates compared to those using statins by 
themselves.  In the current study, which also included other PIMs besides fibrates, the 
risk for myopathy for statin interacters was approximately twice that for statin users.  In 
another study, the risk of myopathy was six times higher in patients using statins and 
PIMs concurrently.440 Thus, even though there is limited information on absolute 
incidence estimates for myopathy in statin interacters, the trends were very similar in the 
three known studies i.e. there appears to be higher risk for myopathy in patients using 
statins and PIMs than in those who use statins by themselves.  The odds of myopathy 
associated with statins and PIMs will be discussed in detail later. 
 
TIME TO DEVELOPMENT OF MYOPATHY 
 Objective 7 aimed at describing the time to development of myopathy for statin 
user and statin interacter group.  The mean days of “survival” without myopathy was 115 
days (S.E.: 1.19) for the statin interacter group and 120 days (S.E.: 0.81) for the statin 
 
439 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
440 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
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user group (Standard Error was reported in the output instead of Standard Deviation).  
This means that patients in the statin interacter group experienced myopathy earlier than 
patients in the statin user group. Graham and colleagues estimated the mean time to onset 
of myopathy for statin-fibrate combination therapy (32 days) which was lower than for 
patients using statins by themselves (348 days).441 
There was a statistically significant difference in the probability of survival times 
between the two groups (χ2 = 10.77; df = 1; p < 0.05).  This difference was largest at the 
start of observation period.  The probability of survival at the end of one month was 0.99 
for the statin user group and 0.88 for the statin interacter group.  However, this difference 
decreased later in the follow-up period.  At the end of follow-up period, the difference in 
probability of survival times was only minimal between the statin interacter (0.42) and 
statin user groups (0.45).  This means patients using statins and PIMs concurrently 
developed myopathy faster than patients using statins by themselves; this is especially 
true at the start of therapy.  This result was not surprising as concurrent use of PIMs with 
statins increases the blood levels of statins due to inhibition of metabolism of statins by 
PIMs, increasing the risk of myopathy.442,443 However, it is not clear why the risk is 
greater at the start of therapy and decreased later on.  More research needs to be 
conducted to determine why some patients experience myopathy early whereas some 
patients experience myopathy later. 
 
441 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
442 Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:S27-31. 
443 Bottorf M. Safety and statins: Pharmacologic and clinical perspective. Am J Manag Care 2004;4:S30-
S37. 
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RISK OF MYOPATHY AND USE OF STATINS AND POTENTIALLY 
INTERACTING MEDICATIONS 
 The focus of objective eight was to assess the relationship between the 
development of myopathy and use of PIMs with statins.  Logistic regression analysis was 
used to determine the odds of myopathy in patients using statins and PIMs, while 
controlling for other risk factors.  The presence or absence of myopathy was the 
dependent variable and whether or not a patient received a PIM with statin was the 
independent variable.  Other independent variables that were controlled for were age, 
gender, ethnicity, presence of diabetes, number of co-morbidities, type and dose of statin 
and duration of statin use. 
 Logistic regression analysis results revealed that the model had an acceptable fit 
based on global chi-square test (χ2 = 61.2; df = 13; p < 0.0001) and the Hosmer and 
Lemeshow statistic (χ2 = 15.1; df = 8; p > 0.05).  The odds of developing myopathy were 
significantly higher for patients using statins and PIMs compared to patients using statins 
without PIMs.  Specifically, statin interacters had 2. 7 (95% CI: 1.83–4.03) times greater 
odds of developing myopathy than statin users.  These results were consistent with a 
previous study that reported a higher risk of myopathy in patients using statins and PIMs 
(RR: 6.01; 95% CI: 2.08–17.38) than those using statins alone.444 However, the risk was 
much higher in that study than in the current study.  One explanation may be that the 
previous study included drugs such as cyclosporine and HIV protease inhibitors which 
 
444 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
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were excluded from the current study.  No other known study has compared the risk of 
myopathy in patients taking statins and PIMs concurrently.   
 
Sub-group analysis to determine risk of myopathy for each category of potentially 
interacting medication used with statins 
 To determine the risk of myopathy with each type of PIM sub-group analyses 
were conducted.  First, a chi-square analysis was conducted to determine if there were 
differences between groups.  If there were significant differences and the sample size was 
large enough, then a logistic regression analysis was conducted to determine the odds of 
myopathy for each type of PIM used with statins.  Table 4.2 provides information on the 
results of the chi-square analysis. 
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Table 4.2: Results of chi-square analysis of difference in myopathy cases between 
statin user group and each type of PIM used with statin 
 




χ2 d.f. p-value 
Fibratesc 379 14 28.74h 1 <0.0001*
Calcium Channel Blockerd 879 18 11.20 1 0.0008* 
Antidepressantse 90 4 12.93h 1 0.0003* 
Macrolide Antibioticsf 1,225 22 9.21 1 0.002* 
Azole Antifungalsg 308 5 2.04h 1 0.15 
* p < 0.05 
a. PIM – Potentially Interacting Medication 
b. The comparator group was statin user group with a total of 5,817 patients and 49 cases of myopathy 
c. Fibrates include gemfibrozil and fenofibrate 
d. Calcium Channel Blockers include diltiazem and verpamil 
e. Antidepressant include nefazodone 
f. Macrolide antibiotics include erythromycin, clarithromycin, and azithromycin 
g. Azole Antifungals include fluconazole, ketoconazole and itraconazole 
h. 25% of the cells have expected counts less than 5. Chi-Square may not be a valid test 
 
As seen from Table 4.2, there was no statistically significant difference in the 
number of myopathy cases between the statin user group and patients using statins and 
azole antifungals concurrently.  A chi-square analysis could not be conducted on patients 
using nicotinic acid and amiodarone due to small cell sizes.  However, data from clinical 
trials have reported no cases of myopathy with the use of statins and niacin.445,446 
Similarly, data from clinical trials have not reported any cases of myopathy with the use 
of amiodarone and low doses of statins.447 The patient using amiodarone who 
experienced myopathy in this study was using 10 mg atorvastatin.  Very few patients 
 
445 Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination 
for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. 
446 Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk 
patients. Arch Intern Med 2003;163:553-64. 
447 Zocor. (simvastatin) [packcage insert]. Whitehouse Station, NJ: Merck & Co. Inc.; 2005. 
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were taking niacin or amiodarone in this study.  A larger study with more patients may be 
warranted to have conclusive results about the risk of myopathy and use of niacin or 
amiodarone with statins.  
Logistic regression analysis was done on other categories of PIMs to determine 
the odds of myopathy.  Table 4.3 provides data on the results of logistic regression results 
for each category of PIM used with statins.  The independent variables controlled for 
were age, gender, ethnicity, diabetes, number of comorbidities, type and dose of statin, 
and duration of statin use.  
 
Table 4.3: Logistic regression analyses results to determine the odds of 
myopathy in patients using various PIMs and statins, concurrently 
 










Fibratesc 1.561 0.325 23.111 1 <0.0001* 4.763 2.521 9.000 
Calcium Channel 
Blockerd
0.811 0.289 7.851 1 0.005* 2.251 1.276 3.967 
Antidepressantse 1.715 0.550 9.720 1 0.002* 5.558 1.891 16.336 
Macrolide Antibioticsf 0.951 0.289 10.821 1 0.001* 2.588 1.469 4.560 
Azole Antifungalsg 0.947 0.498 3.615 1 0.057 2.579 0.971 6.849 
* p < 0.05 
a. PIM – Potentially Interacting Medication 
b. Reference category is statin user group 
c. Fibrates include gemfibrozil and fenofibrate 
d. Calcium Channel Blockers include diltiazem and verpamil 
e. Antidepressant include nefazodone 
f. Macrolide antibiotics include erythromycin, clarithromycin, and azithromycin 
g. Azole Antifungals include fluconazole, ketoconazole and itraconazole 
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As seen from Table 4.3, using nefazodone and statins concurrently had the highest 
odds of developing myopathy, followed by patients using statins and fibrates together.  
Statistically, use of azole antifungals with statins had no difference in odds of developing 
myopathy as compared to statin users.  The next section discusses each of these results in 
light of the current literature. 
 
Risk of myopathy associated with use of statins and fibrates 
 The odds of developing myopathy was 4.7 times (95% CI: 2.521–9.000) higher in 
patients using statins and fibrates than those using statins by themselves.  Graham and 
colleagues estimated the risk of myopathy to be 12 times greater in statin-fibrate 
combination therapy than statin monotherapy.448 Another study estimated the risk of 
myopathy to be 0.84 for statin-gemfibrozil combination therapy and 1.84 for statin-
fenofibrate combination therapy when compared with statin monotherapy; however, these 
results were not statistically significant.449 These results were not surprising given the 
fact the both statins and fibrates are independently associated with the risk of 
myopathy.450,451 Therefore, both drugs together increase the risk of myopathy.  In 
addition to a pharmacodynamic reaction, there appears to be a pharmacokinetic reaction 
 
448 Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with 
lipid-lowering drugs. JAMA 2004;292:2585-90. 
449 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
450 Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein 
cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 
2005;45:185-97. 
451 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
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occurring between statins and fibrates.452 The results of this study are consistent with the 
physiologic process involved in statin-fibrate drug interaction as well as other known 
epidemiological studies. 
 
Risk of myopathy associated with the use of statins and calcium channel blockers 
 There was a statistically significant difference in the odds of developing 
myopathy in patients using statins and calcium channel blockers (CCBs) as compared to 
patients using statins by themselves.  Specifically, the odds of developing myopathy was 
2.25 (95% CI: 1.276 - 3.967) times higher in patients using statins and CCBs 
concurrently than those using statins by themselves.   
 The body of evidence regarding the effect of use of statins and CCBs on risk of 
myopathy is very limited.  In two clinical trials, the 4S and HPS trials, approximately 
4,000 patients were taking a calcium channel blocker with statins; however, there was 
only one case of myopathy after four years of therapy.453,454 This suggests that there is a 
low risk of myopathy with the use of statins and calcium channel blockers.  However, 
there have been at least six case reports of rhabdomyolysis reported with the use of 
statins and calcium channel blockers in real world.455,456,457 This is not surprising as 
 
452 Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006;97:S27-31. 
453 Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin 
during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156:2085-92. 
454 Gruer PJK, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and 
simvastatin. Am J Cardiol 1999;84:811-815. 
455 Lewin JJ, 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann 
Pharmacother 2002;36:1546-9. 
456 Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. Ann 
Intern Med 2004;140:W31. 
457 Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann 
Pharmacother 2002;36:288-95. 
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pharmacokinetic studies have shown that both verapamil and dilitazem increase the mean 
peak serum concentration of statins (approximately three times).458,459 CCBs inhibit the 
CYP 450 isoenzyme metabolism of statins increasing the blood of levels of statins.460 
This increases the risk of myopathy. The current study reinstates the fact that there is an 
increased risk of myopathy associated with the use of statins and CCBs.  Health care 
professionals need to be aware and cautious when using these two drugs together. 
 
Risk of myopathy associated with the use of statins and nefazodone 
 Antidepressant drugs such as fluxoetine, fluvoxamine, sertraline, and nefazodone 
inhibit CYP3A isoenzymes and should be used cautiously with statins.461 The clinical 
advisory on clinical use and safety of statins has listed nefazodone as the only drug that 
may increase the risk of myopathy.462 This is because case-reports of myopathy have 
only been reported with the use of statins and nefazodone.  For this reason, only 
nefazodone was included in this study. 
 The odds of developing myopathy was 5.5 (95% CI: 1.89 – 16.36) times higher in 
patients using statins and nefazodone than those using statins by themselves.  In fact, 
among all the statin and PIMs combinations, concurrent use of statin and nefazodone had 
the highest odds of developing myopathy.  No other known study has evaluated the risk 
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of myopathy in patients using statins and nefazodone.  However, pharmacokinetic studies 
have revealed an increase in concentration of atorvastatin and simvastatin by 3.4-fold and 
20-fold respectively.463 This study further emphasizes that the data seen in the 
pharmacokinetic study may be translated into increased risk of myopathy when statins 
and nefazodone are taken together.  More studies need to be conducted to further support 
the results found in the current study.  Nevertheless, physicians need to be aware when 
prescribing these drugs together. 
 
Risk of myopathy with statins and macrolide antibiotics 
 Macrolide antibiotics increase the blood levels of statins by inhibiting statin 
metabolism.464 This increases the risk of myopathy.  The current study results were 
consistent with the proposed mechanism of increased risk of myopathy when both drugs 
are taken together.  The odds of developing myopathy was 2.5 (95% CI: 1.46 – 4.56) 
times higher for patients using statins and macrolide antibiotics concurrently than those 
using statins alone.  No other known study has evaluated the risk of myopathy in patients 
using statins and macrolide antibiotics.  However, pharmacokinetic studies have revealed 
that macrolide antibiotics significantly increase the concentration of statins two- to eight- 
fold depending on type and dose of statin used.465,466 Similarly, in a review of the FDA 
database of adverse events, 42 cases of rhabdomyolysis were associated with the use of 
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statins and macrolide antibiotics.467 Given this information, it was not surprising to find 
an increased risk of myopathy associated with use of statins and macrolide antibiotics.  
Physicians/pharmacists need to be aware of this interaction, and may be stop statins for a 
short interval when patients are using macrolide antibiotics.468 
Risk of myopathy associated with the use of statins and azole antifungals 
 The odds of developing myopathy was higher (OR: 2.579; 95% CI: 0.971-6.849) 
in patients using statins and azole antifungals as compared to those using statins by 
themselves; however, this result was not statistically significant.  The mechanism of drug 
interaction is similar to other PIMs i.e. inhibition of CYP450 isoenzyme system 
increasing the blood levels of statins; thereby, increasing risk of myopathy.469 
Pharmacokinetic studies evaluating the effect of azole antifungals on statins have shown 
on an average two- to thirteen-fold increases in concentrations of statins, based on type of 
statin used.470,471,472 Case reports of rhabdomyolysis have been reported with the use of 
statins and azole antifungals; most of these patients were old with multiple 
comorbidities.473,474 Therefore, the results of this study are supported by current 
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literature.  However, more research needs to be conducted to support the results of this 
study.  Caution should be exercised when using these drugs together. 
 
In summary, the results of the current study show that there is an increased risk of 
myopathy when using statins and PIMs together.  This risk is varied for each class of 
PIM used with statins, with the highest risk of myopathy being for patients using 
nefazodone and fibrates with statins.  There is some information on risk of myopathy in 
patients using statins and PIMs, and the current study further supports other research 
findings.  More research needs to be conducted to study the effect of use of statins and 
PIMs on risk of myopathy.  This will help health care professionals better manage 
patients receiving PIMs. 
 
RISK FACTORS ASSOCIATED WITH MYOPATHY 
 The last and final objective of this study was to determine the risk factors 
associated with myopathy.  Some of the risk factors listed by the AHA/ACC/NHBLI 
clinical advisory on clinical use and safety of statins include increasing age, female, 
increased physical activity, small body size, presence of comorbid conditions and dose of 
statin used.475 Data were not available on all the risk factors.  However, the effects of the 
following risk factors on odds of developing myopathy were evaluated: age, gender, 
ethnicity, presence of diabetes, number of comorbidities, statins characteristics and PIM 
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characteristics.  Logistic regression analyses were utilized to address this objective.  Two 
models were run: one on the entire population and a second only on statin interacters to 
determine the PIM characteristics that are associated with myopathy.  The results for each 




 Increasing age had higher odds (OR: 1.009; 95% CI: 0.988-1.030) of developing 
myopathy; however, the results were not statistically significant.  Previous studies have 
reported increased risk of myopathy in patients aged 65 years and above, with the risk 
being 1.8 to 5.0 times higher in older patients than in younger patients.476,477 Increasing 
age is known to affect muscles and thus increasing risk of myopathy.478 However in this 
study age was not statistically significant. 
 
Gender 
 The ACC/AHA/NHBLI clinical advisory of safety of statins suggests that females 
have a higher risk for myopathy than males.479 The current study reported no statistically 
significant difference (OR: 1.317; 95% CI: 0.881-1.970) between males and females in 
odds of developing myopathy.  These results are consistent with two studies that assessed 
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the association between gender and risk of myopathy. These studies also reported no 
difference in risk of myopathy between males and females.480,481 Increasing evidence 




 There was no difference in the odds of myopathy based on ethnicity/race.  Whites 
had higher odds of myopathy as compared to all other ethnicities but the results were not 
statistically significant.  There is an assumption made that difference in genetic makeup 
of various ethnicities/races may affect the risk of myopathy.  However, no known 
epidemiological studies have evaluated the association between the risk of myopathy and 
ethnicity/race.  One pharmacokinetic study conducted on rosuvastatin revealed a greater 
risk of myopathy in Asians than other sub-populations.482 There were very few Asians in 
the current study.  More research needs to be conducted to understand the association of 
ethnicity and risk of myopathy. 
 
Diabetes 
 It has been postulated that patients having diabetes have reduced drug metabolism 
which increases the concentrations of statins in blood thereby increasing the risk of 
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myopathy.483 In the current study, the odds of myopathy were higher (OR: 1.151; 95% 
CI: 0.783-1.692) for patients having diabetes than those without diabetes; however, the 
results were not statistically significant.  Similar results were observed in another study 
where the risk of myopathy was 1.40 times higher in patients with diabetes, but the 
results were not statistically significant.484 Graham and colleagues also reported 
increased risk of myopathy (RR: 2.9; 95% CI: 0.7- 11.8) in patients with diabetes; 
however, the results were not statistically significant.485 According to ATP III 
guidelines, patients with diabetes have the same risk of developing cardiovascular disease 
as patients who have cardiovascular diseases.486 Therefore, it is important to manage 
hyperlipidemia in patients with diabetes.  Health care professionals should closely 
monitor patients with diabetes using statins and be aware of the risk of myopathy in these 
patients. 
 
Number of co-morbidities 
 Presence of comorbid conditions may increase the risk of myopathy.  It is known 
that renal insufficiency, hepatic dysfunction and hypothyroidism have risk of myopathy 
independent of statin use due to polypharmacy and altered drug metabolism.487,488 
483 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. 
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Adding statin therapy further increases this risk.  These patients were excluded from the 
current study.  However, the risk of myopathy in presence of other comorbid conditions 
is not known.  In addition, the presence of comorbid conditions may increase the receipt 
of PIMs to manage these conditions which further increase risk of myopathy.  This study 
results revealed that the odds of receiving PIMs increases with increasing number of 
comorbidities. Previous research has suggested the probability of interactions increases 
sharply with polypharmacy, which in turn, is related to number of comorbidities.489,490 
This increases the risk of adverse events like myopathy.  Therefore it is important to 
assess the association between number of comorbidities and risk of myopathy. 
 The odds of myopathy increased 1.3 times (95%CI: 1.159-1.637) with increasing 
number of comorbidities.  No other known study has evaluated the association between 
myopathy and comorbidities.  However, one study showed five times (95% CI: 2.42 – 
10.85) increased risk of myopathy in patients with hypertension.491 These results are not 
surprising as patients with comorbidities may be taking multiple medications to manage 
comorbidities.  Taking multiple medications with statins is listed as one of the risk factors 
of statin-associated myopathy.492 This may be because polypharmacy results in altered 
statin metabolism or inhibition of statin metabolism.493 This may increase blood levels of 
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statins increasing risk of myopathy.  Physicians/pharmacists need to be more aware of 
patients with multiple comorbidities and closely monitor these patients. 
 
Statin characteristics 
 Three factors related to statin use were included in this study.  These were type of 
statin used, dose of statin used and duration of statin use before end of observation 
period.  The discussion of each of the factors follows. 
 
Type of statin 
 The odds of myopathy were higher for atorvastatin (OR: 1.311; 95% CI: 0.725-
2.372) and simvastatin (OR: 1.071; 95% CI: 0.549-2.091) as compared to pravastatin 
whereas lower for other statins (OR: 0.388; 95% CI: 0.076-1.497); however, none of 
these results were statistically significant.  These results are consistent with the study 
conducted by Graham and colleagues where the researchers found statistically 
indistinguishable rates of incidences of rhabdomyolysis among statins, even though the 
incidence rates of rhabdomyolysis were higher among atorvastatin and simvastatin users 
as compared to pravastatin users.494 In another study, simvastatin and fluvastatin had a 
higher risk of myopathy when compared with pravastatin; however, atorvastatin and 
lovastatin had a lower risk of myopathy than pravastatin.495 Again, none of the results in 
that study were statistically significant.  Even though the results of studies are 
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inconsistent, all three studies revealed that the risk of myopathy is similar among all 
statins.  It is believed that the difference in the pharmacokinetic properties of statins may 
affect the risk of myopathy.496,497 Due to a different metabolism mechanism of 
pravastatin as compared to other statins, it has the least potential of myopathy.498 
However, the current study as well as previous studies reveals that there are no 
statistically significant differences in risk of myopathy among statins. 
 
Dose of statin 
 There was no statistically significant difference in the odds of myopathy (OR: 
0.853; 95% CI: 0.545-1.333) based on whether a patient received lower or higher doses 
of statins.  This is inconsistent with the current suggestions which states myopathy occurs 
more likely in patients with higher doses of statins and lower doses.  Clinical trials have 
also shown that myopathy most likely occurs in higher doses of statins than lower doses.  
This is because higher the dose, greater the concentration of statin in blood and greater 
the risk of myopathy.  It is not clear why these results were not obtained in the current 
study.  One explanation may be grouping of doses of statins into just two categories, 
which was done based on efficacy of statins.  For example, 10 mg of atorvastatin was 
grouped with 40 mg of pravastatin as at these doses both drugs had similar efficacy 
(Table 2.7).  This may have resulted in grouping of high doses of one drug with lower 
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doses of another.  Future studies should evaluate the association between dose of statins 
and myopathy for each statin separately to better understand the link between the two. 
 
Duration of statin use 
 The odds of developing myopathy decreased (OR: 0.997; 95% CI: 0.995-0.999) 
with increasing duration of statin use.  Even though the results are statistically significant, 
the confidence interval is so close to one that it is safe to say that clinically there may be 
no association between odds of myopathy and duration of statin use.  In a review of the 
FDA database, the mean duration of statin use before experiencing myopathy varied from 
10 days for fluvastatin to 309 days for atorvastatin.499 The association between duration 
of statin use and myopathy is not well understood. This study supports slightly lowers 
odds of developing myopathy with increasing duration.  This means that odds of 
developing myopathy is greater at the start of statin therapy and decreases as patient 
continues the therapy.  This result is also supported by results of th survival analysis 
where more patients experienced myopathy at the start of observation period.  More 
research needs to be conducted to understand why some patients experience myopathy at 
the start of statin therapy while others experience it later.  However, based on the results 
of this study, patients should be monitored closely when they first start therapy. 
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Characteristics of potentially interacting medications 
 The risk of developing myopathy may be affected by characteristics of PIMs 
used with statins.  It is known that PIMs increase the risk of myopathy; however, not 
much research has been done on characteristics of PIMs that are associated with 
myopathy.  Therefore, this study analyzed the association between myopathy and PIM 
characteristics such as level of significance of drug interaction, whether PIM was 
received before or after the start of statin therapy and duration of PIM use before 
experiencing myopathy.  Logistic regression analysis was conducted only on statin 
interacters to assess the link between myopathy and PIM characteristics.  The next part 
discusses each of these factors in detail. 
 
Level of significance of drug interaction 
 Based on type of PIM received with statins concurrently, the drug interaction was 
classified as follows: 1) Level 1- potentially life-threatening; 2) Level 2 - deterioration in 
patients’ clinical status; or 3) Level 3 - causing moderate to minor side-effects.500 The 
Level 1 drug interaction included fibrates, antidepressants and macrolide antibiotics, 
Level 2 drug interaction included calcium channel blockers and antifungals, and Level 3 
drug interactions included nicotinic acid and amiodarone.  
 The results of this study showed that the odds of developing myopathy was lower 
for Level 2 (OR: 0.757; 95% CI: 0.416-1.376) and Level 3 (OR: 0.280; 95% CI: 0.037-
2.145) significance of drug interaction as compared to Level 1; however, the results were 
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not statistically significant.  These results are surprising given the fact that drugs included 
in Level 1 such as fibrates are know to increase the risk of myopathy approximately 12 
times than those without these medications.501 It is not clear why differentiation based on 
Level of significance of drug interaction was not found; however, sub-group analysis 
based on type of PIM used revealed a difference in odds of myopathy based on type of 
PIM used. 
 
Time of receipt of potentially interacting medications 
 Risk of myopathy may be associated with whether a patient received a PIM 
before or after the start of statin therapy.  The assumption behind this association is if a 
patient is already on a PIM before start of statin therapy, the metabolism of the statin may 
be inhibited right from the start of therapy, increasing the risk of myopathy.  However, if 
a patient receives a PIM after starting statin therapy, the effect of PIM on statin 
metabolism may be slower, and therefore, risk of myopathy may be lower.  The current 
study revealed that there is no statistically significant difference in the odds of myopathy 
(OR: 1.272; 95% CI: 0.647-2.500) based on whether patient receives PIM before or after 
start of statin therapy.  However, as discussed earlier, receipt of PIMs with statins has 
higher risk of myopathy than patients using statins by themselves. 
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Duration of PIM use 
 Duration of PIM use had no statistically significant association (OR: 0.997; 95% 
CI: 0.992-1.002) with the odds of developing of myopathy.  No known previous studies 
have reported the association between two.  The average duration of PIM use was 58 
days.  However, approximately 50% of patients received macrolide antibiotics or azole 
antifungals, which are used for shorter duration.  In spite of this fact, patients using 
statins and PIMs seemed to have increased risk of myopathy.  Thus it seems that short 
duration of PIM use may be as harmful as longer duration of PIM use.  More research 
needs to be conducted on the association of duration of PIM use and risk of myopathy, 
especially PIMs used for a shorter duration of time. 
 
STUDY LIMITATIONS 
 Some limitations of the study need to be pointed out before discussing the 
implications of this study.  First of all, the results of current study are generalizable only 
to the Texas Medicaid population.  The enrollment of patients into Medicaid is based on 
certain eligibility criteria and poverty levels.  These criteria vary from state to state.  
Therefore, these results cannot be applicable to other state Medicaid programs as well as 
non-Medicaid programs. 
 The second limitation is related to the use of a claims database for an 
epidemiological study.  The details of limitations of claims database are discussed in 
Appendix A.  In brief, claims databases are subject to errors in coding, errors in data 
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entry and missing data as well as threats to construct validity when proxies are used for 
medical conditions. 
 The third limitation is lack of information on several variables that are associated 
with risk of myopathy.  Texas Medicaid does not have information on several important 
lifestyle risk factors such as physical activity, body size, and consumption of 
grapefruit/alcohol.  These factors increase the risk of myopathy; however, these factors 
could not be controlled for in this study.  Also, laboratory data were not available to 
monitor creatine kinase levels, which is an indicator of myopathy.  Therefore, the current 
study relied on ICD-9-CM codes for diagnosis of myopathy, which as discussed before, 
are subject to coding errors. 
 The fourth limitation is that the data in this study included only those 
prescriptions paid for by Texas Medicaid.  There is a three prescription per month drug 
limit for some enrolled patients.  It is possible that patients may have received 
medications from physicians’ office or paid for medications themselves due to this limit.  
These prescriptions have not been captured in the current study.  This may result in 
biased estimates in the current study.  A more complete study would include all drugs 
used by the patient and not just those paid by Texas Medicaid. 
 The fifth limitation involves threats to internal validity.  The most important of all 
is history.  During the study time period of this study, cerivastatin was withdrawn due to 
deaths caused by rhabdomyolysis.  Therefore, physicians may have been more careful 
with statins and monitored patients more closely for myopathy.  As result of this, 
myopathy may have been over diagnosed leading to over estimation of risk of myopathy.  
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Also, there may be selection bias due to lack of randomly assigned groups.  The statin 
interacter group may be more chronically ill than the statin user group increasing the 
likelihood of myopathy in that group. 
 Finally, due to multiple statistical tests, there could be the possibility of inflated 
type I errors.  Also, the current study was designed to evaluate the association of risk of 
myopathy and use of statins with PIMs; however, it would be inappropriate to draw 
causal inferences from the current study.  A controlled clinical trial or a prospective 
cohort study should be designed for causal inferences. 
 
STUDY IMPLICATIONS AND FUTURE RESEARCH 
 This study aimed to help fill the gap in the literature related to risk of myopathy 
and use of statins with PIMs.  The principal objective of this study was to assess the 
relationship between development of myopathy and use of statins with PIMs and identify 
the risk factors of myopathy.  The results of the current study revealed the following: 
1) The odds of myopathy increased two-fold in patients receiving statins and PIMs 
when compared with patients using statins by themselves.  This risk was highest 
in patients using nefazodone, fibrates, and macrolide antibiotics. 
2) Increasing age, being female, having diabetes, and using atorvastatin and 
simvastatin had higher odds of developing myopathy; however, the results were 
not statistically significant 
3) The odds of myopathy increased 1.3 times with increasing number of 
comorbidities. 
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4) The odds of myopathy were greater when statin therapy was first started and 
gradually decreased after prolonged use. 
5) There was no difference in the odds of myopathy based on ethnicity and dose of 
statins. 
 Previous research studies have shown similar results when conducting studies 
evaluating the association between statins and myopathy and risk factors.502,503 However, 
these studies included only hospitalized cases of myopathy and did not evaluate the risk 
of myopathy with the concurrent use of statins and PIMs.  The current study included all 
cases of myopathy including those being diagnosed in physicians’ offices and outpatient 
departments and those related to the concurrent use of statins and PIMs.  The 
ACC/AHA/NHBLI clinical advisory on clinical use and safety of statins has listed certain 
PIMs as increasing the risk for statin-associated myopathy.504 Their recommendations 
were based primarily on case-reports and reports of adverse events to the FDA database.  
This study adds scientific evidence to their recommendations that use of PIMs with 
statins increases the risk of myopathy.  Further sub-group analysis revealed that 
nefazodone and fibrates had the highest odds of developing myopathy.  Future studies 
should be designed to determine the risk of each category of PIM used with statins to 
further confirm the results of the current study. 
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In addition, the ACC/AHA/NHBLI clinical advisory on clinical use and safety of 
statins had identified a number of demographic, health-related and treatment-related 
factors that might increase the risk of myopathy.  The most important factor that 
increased the risk of myopathy was number of comorbidities.  This is not surprising 
considering patients with comorbidities may receive multiple medications and may have 
altered drug metabolism.  Future studies should identify the comorbidities that increase 
the risk of myopathy.   
 The odds of myopathy decreased with increasing duration of statin use.  These 
results are supported by survival analysis results where more patients experience 
myopathy at the start of therapy and this number slowly decreases.  In spite of the current 
study results, there is insufficient evidence to conclude that myopathy occurs earlier in 
statin therapy than later.  Future studies should identify factors that affect time to develop 
myopathy. 
 Increasing age was identified as one of the risk factors of myopathy.  In the 
current study, the odds of myopathy increased with age; however, this result was not 
statistically significant.  The present study did not include patients above the age of 65 
years, due to lack information.  More research is needed on patients aged 65 and older to 
determine what factors trigger myopathy in these patients. 
 Atorvastatin and simvastatin had higher odds of myopathy than pravastatin, even 
though the results were not statistically significant.  Pravastatin has a different 
mechanism of metabolism than other statins, which decreases the risk of myopathy in 
patients using pravastatin.  The current study did not study the effect of switching statins 
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on myopathy.  Future research should be conducted on patients switching medications to 
better understand the role of different statins on risk of myopathy. 
 Based on the current study findings and the literature available on statin-
associated myopathy, the following suggestions are made to the health care professionals: 
1) Patients using statins and PIMs should be monitored closely.  It is recommended 
that patients should stop statins for a short time when taking PIMs such as 
macrolide antibiotics or switch to pravastatin when using PIMs for long-term to 
decrease the risk of statin-associated myopathy.505 
2) Patients should be monitored more closely for myopathy when they first start 
statin therapy as well as when they start using PIMs with statin therapy. 
3) Patients having multiple comorbidities are more likely to experience myopathy.  
Physicians/pharmacist should be aware of these patients and appropriately 
manage all comorbidities to minimize the risk of adverse events.506 
4) Patients receiving statin therapy should be counseled about risk of myopathy and 
be advised to report such cases to health care professionals.507 
5) CK measurements are recommended in patients experiencing muscle symptoms 
or patients having risk factors such as renal insufficiency or hepatic dysfunction.  
However, pretreatment baseline CK measurements or those in asymptomatic 
patients are not required.508,509 
505 Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006;97:S52-60. 
506 Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J 
Cardiol 2006;97:S69-76. 
507 McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the 




 This study showed that there is an increased risk of myopathy in patients using 
statins and certain PIMs.  This is consistent with the finding of previous research which 
also showed an increased risk with concurrent use of statins and PIMs.510 In addition, 
increasing number of comorbidities further increased the risk of myopathy.  Recent 
guidelines recommend more aggressive treatment of elevated cholesterol levels.511 This 
means there will be a substantial number of people who will receive statin therapy, of 
which many will have comorbidities and receive PIMs.  Given this scenario, it will be the 
responsibility of health care professionals to appropriately monitor patients to prevent 
statin-associated myopathy.  The benefits of statin therapy in reducing cardiovascular risk 
is tremendous.  Vigilance and awareness on the part of health care professionals in 
understanding the risk factors and the role of PIMs related to myopathy can help patients 
obtain benefits of statin therapy without worrying about statin-associated myopathy. 
 
509 Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J 
Cardiol 2006;97:S69-76. 
510 Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative 
claims database. Am J Cardiol 2006;97:S61-8. 
511 Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National 
Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. 
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APPENDIX A 
ADVANTAGES AND DISADVANTAGES OF USING CLAIMS DATABASES 
 
The proposed study used Texas Medicaid prescription and medical claims to meet 
the study goals.   The use of databases for pharmacoepidemology studies has advantages 
and disadvantages.  This section contains a brief discussion of the advantages and 
disadvantages for the use of claims databases.  This discussion is based on reviews of use 
of databases for outcomes research and pharmacoepidemiology by Motheral and 
colleagues,512,513 and Strom and colleagues.514,515 
Advantages of using claims databases 
1) Claims databases allow the evaluation of treatments in “real-life” situations such 
as effectiveness and safety of treatments in clinical practice settings. 
2) Claims databases are large with information on a large number of patients.  This 
allows epidemiological research even when the drug exposure or the disease of 
interest is uncommon. 
3) Research using claims databases is less expensive and time consuming as 
compared to prospective studies or clinical trials. 
 
512 Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, 
and strategies. Clin Ther 1997;19:346-66. 
513 Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies--report of the 
ISPOR Task Force on Retrospective Databases. Value Health 2003;6:90-7. 
514 Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001;10:389-92. 
515 Carson J, Wayne R, Strom BL. Medicaid Databases. In: Strom BL, ed. Pharmacoepidemiology. 
London: John Wiley & Sons, Ltd., 2000:307-24. 
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4) In a claims database, the data on exposure are not subject to recall or interviewer 
bias. 
5) Claims database research allows linking of pharmacy claims with medical claims.  
This permits the examination of different aspects or providing health care 
including patient outcomes and health care cost and utilization. 
6) Theoretically, databases are population-based.  This allows calculation of 
incidence rates. 
7) An advantage of the Medicaid database is overrepresentation of special 
populations such as women, children, and different ethnic groups.  As these 
populations are underrepresented in clinical trials, information on different 
outcomes in these vulnerable populations is important. 
 
Disadvantages of using claims database 
1) The information available for a population in a certain claims database may not be 
generalizable to other populations.  This is especially true for Medicaid 
populations because of specific characteristics of populations served by Medicaid. 
2) Using claims databases for research poses a threat to construct validity.  Construct 
validity refers to the degree to which a variable measures what it is meant to 
measure.  For example, the use of a drug as a proxy for the presence of a medical 
condition can be misleading. 
3) Using claims databases for research poses a threat to internal validity. Some 
examples include the following: 
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a. Using ICD-9-CM codes in database research may not always be reliable or 
valid.  Under-coding or over-coding of diagnoses can occur that could 
result in study bias.   
b. Misclassification of exposure could lead to bias in the study results. 
c. Presence of confounding variables such as severity of illness can lead to 
biased results.  Information on many important confounding variables are 
missing from Medicaid databases and hence cannot be controlled for in 
the study. 
4) Eligibility changes to insurance programs such as Medicaid may cause patients to 
be terminated from the study.  This may result in misinterpretation that the 
outcome of interest did not occur, when in reality, the patient was no longer a part 
of the study. 
5) Medical claims for individuals above 65 years of age may be incomplete due to 
dual eligibility in Medicaid and Medicare programs. 
6) Missing data such as those for prescription claims could be problematic especially 
when assessing prescription refill patterns since the apparent failure to refill 





ICD-9-CM CODES AND DRUGS USED FOR PATIENT SELECTION CRITERIA 
 
Table B.1: Description of ICD-9-CM codes used to identify myopathy events 
 
ICD-9-CM codes Description 
791.3 Myoglobinuria 
359.4, 359.8, 359.9 Myopathy 
729.1 Myositis 
710.4 Polymyositis 
728.9 Muscle Weakness 
729.81, 729.82, 729.89 Musculoskeletal symptoms of the limbs 
E942.2 Adverse effect from antihyperlipidemic agents 
Table B.2: Description of ICD-9-CM codes used to identify renal insufficieny 
 
ICD-9-CM codes Description 
585.1-585.6, 585.9 Chronic Kidney Disease 
586 Renal failure, unspecified 
593.9 Unspecified disorder of Kidney 
Table B.3: Description of ICD-9-CM codes used to identify hepatic dysfunction 
 
ICD-9-CM codes Description 
570 Acute and subacute necrosis of liver 
571.xx Chronic liver disease and cirrhosis 
572.xx Liver abscess and sequelae of chronic liver disease 
Table B.4: Description of ICD-9-CM codes to identify hypothyroidism 
 
ICD-9-CM codes Description 
243 Congenital Hypothyroidism 
244.xx Acquired Hypothyrodism 
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Table B.5: List of hypothyroid drugs 
 











Table B.6: Description of ICD-9-CM codes to identify HIV 
 
ICD-9-CM codes Description 
042.x – 044.x HIV infection 
250
Table B.7 List of HIV drugs 
 
Therapeutic Class Brand Name Generic Name 
Combivir lamivudine and zidovudine 
Emtriva FTC, emtricitabine 
Epivir lamivudine, 3TC 
Epzicom abacavir/ lamivudine 
Hivid zalcitabine, ddC, dideoxycytidine 
Retrovir zidovudine, AZT, azidothymidine, ZDV 
Trizivir abacavir, zidovudine, and lamivudine 
Videx EC enteric coated didanosine 
Videx didanosine, ddI, dideoxyinosine 
Viread tenofovir disoproxil fumarate 






Rescriptor delavirdine, DLV 
Sustiva efavirenz 
Viramune nevirapine, BI-RG-587 
Protease Inhibitors Agenerase amprenavir 
Crixivan indinavir, IDV, MK-639 
Fortovase saquinavir 
Invirase saquinavir mesylate, SQV 
Kaletra lopinavir and ritonavir 
Norvir ritonavir, ABT-538 
Reyataz atazanavir sulfate 
Viracept nelfinavir mesylate, NFV 
Fusion Inhibitors  Fuzeon enfuvirtide, T-20 
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APPENDIX C 
PROPOSED METHODOLOGY FOR COHORT FORMATION AND 
STATISTICAL ANALYSES PLAN 
 
The current section describes the methodology initially proposed for conducting 
the current study.  However, this methodology was not followed.  After data cleaning and 
assembling cohorts based on the initial proposed methodology a small number of patients 
were identified who were initially statin users and then switched cohorts after receipt of 
PIMs.  A further analysis of these patients revealed that none of these patients had 
myopathy before receipt of PIMs.  In order to obtain clean cohorts, it was decided to 
include these patients only in the statin interacter group.  Therefore, only two clean 
groups were assembled without any overlapping of patients. 
 
Cohort 1, the statin user 
For the purpose of this study, a patient who receives a statin without any 
potentially interacting medication is defined as a statin user. A statin user can receive 
any other medications besides the list of potentially interacting medications listed in 
Table 2.1.   
The index date for statin user will be defined as the date of first pharmacy claim 
for any statin starting from March 1, 1999.  To include only new users of statins, the 
patient should not receive any statin medication six months prior to the first pharmacy 
claim.  The patients will be followed until they experience myopathy, discontinue therapy 
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(a gap of 45 days or greater), receive a potentially interacting medication or end of the 
follow-up period.  If a patient receives a potentially interacting medication he will then be 
switched to cohort 2 (i.e.the statin interacter cohort). 
Thus, cohort 1 (statin users) is divided into two separate groups of patients.  The 
first group consists of statin users who never received any potentially interacting 
medication throughout the study period.  The second group consists of statins users who 
initially did not receive any potentially interacting medication but later on a potentially 
interacting medication was added to their therapy (at which point they changed cohorts). 
Thus, some of the patients in the second group will be in cohort 1 and cohort 2, which is 
described in detail in the next section. These two groups of patients will be kept separated 
and will be analyzed separately. This will be done for the ease of statistical analyses 
(discussed later in the statistical analyses section). 
 
Cohort 2, the statin interacter 
 In this study, a patient who receives a statin drug and potentially interacting 
medication (as listed in Table 2.1) is defined as a statin interacter.  The index date for a 
statin interacter will be the date statin therapy and potentially interacting medication were 
first received together.  A PIM can be received at different time periods.  Based on when 
a PIM was received, patients can be included in one or both cohorts.  Figure 2.2 
demonstrates different scenarios when a potentially interacting medication can be 
received and a description of the different scenarios. 
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Figure C.1: Description of proposed grouping of patients based on the time a PIM was received
New statin user +
PIM (index date)
Patient is on PIM when he starts statin







Patient receives PIM 3 months after
start of statin therapy. This patient will






Patient receives PIM 6 months after start of statin
therapy. This patient will be in cohort 1 and also in
cohort 2 provided there is no myopathy 3 months









Patient receives PIM 9 months after start of statin
therapy. This patient will be in cohort 1 and also in
cohort 2 provided there is no myopathy 3 months









As seen from Figure C.1, some patients are in cohort 1 and cohort 2 based on 
when a potentially interacting medication was received.  As mentioned earlier, there 
should be no myopathy event three months before the index date, which for cohort two is 
the date the statin and potentially interacting medication was first received together.  This 
is to be sure that the myopathy event is attributed to the concurrent use of statins and 
potentially interacting medications, and is not a carry-over effect from previous statin 
use.  Statin interacters will be followed from the index date until the patients experience 
myopathy or discontinuation of statin therapy (a gap of 45 days or more) or PIM use or 
end of the follow-up period.  A separate sub-group analysis will be conducted on the 
statin interacter groups to determine whether the risk of myopathy differs based on 
whether both statin and  potentially interacting medication were received at the start of 
statin therapy or at a later date.  
 In summary, three multivariate analyses (discussed later) will be conducted 
evaluating the risk factors of myopathy.  In Model 1, statin users who never received any 
potentially interacting medications throughout the study period will be compared with 
statin interacters.  In Model 2, patients who initially were statin users receive potentially 
interacting medication and switch cohort to statin interacter group.  Thus in Model 2, the 
same patient is being compared before and after they receive potentially interacting 
medication.  In Model 3, only the statin interacter group will be included to evaluate the 




 Logistic regression was used to assess the risk and risk factors of myopathy.  
Three separate multivariate models will be tested as mentioned earlier.  In Model 1, statin 
users who never received any potentially interacting medications throughout the 
observation period will be compared with statin interacters.  In Model 2, only the statin 
interacter group will be included to evaluate the effect of time/duration of potentially 
interacting medication on the risk of myopathy.  For both of these models, logistic 
regression will be used.   
In Model 2, patients who were initially statins users receive potentially interacting 
medication and switch to the statin interacter cohort.  Thus, the same patients are being 
compared before and after they receive potentially interacting medications.  Thus, there is 
correlation among observations due to the observations being made on the same patient.  
Logistic regression cannot be used for this model due to violation of the assumption of 
independence of observations.  A new technique known as generalized estimating 
equations (GEE), which accounts for the correlation among observations, will be used for 
Model 2.  A description of GEE is given in the next section. 
 
Generalized Estimating Equations 
Liang and Zeger516 introduced generalized estimating equations to account for the 
correlation between observations in generalized linear regression models.  GEE models 
treat the correlation structure of within-patient responses as nuisance parameters, and 
 
516 Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 
1986;42:121-30. 
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calculate coefficients (and corresponding SEs) using “robust” estimators.  GEE models 
have the following characteristics: 1) can be used with continuous, binary or discrete 
outcomes; 2) number of observations can vary per patient; and 3) covariates can vary 
over time and can be continuous or categorical.517 
GEE are marginal models, i.e., the analyst is interested in modeling the marginal 
expectation (average response for observations sharing the same covariates) as a function 
of explanatory variables.518 The marginal regression model for binary data is: 
Log (E[Yij]/(1-E[Yij]) = x`ijβ
Where Log (E[Yij]/(1-E[Yij]) = logit link which is a link function 
 x`ij = vector of study variables 
 β = regression parameters. 
Therefore,  
E (Yij) = µij = exp(x`ijβ)____ and 
 1 + exp(x`ijβ)
Var (Yij) = Vij = exp(x`ijβ)______
[1 + exp(x`ijβ)]2
In addition to this marginal mean model, we need to define a working correlation 
matrix to account for the correlated observations on a given subject.  Many types of 
 
517 Delea T, Weycker D. Advanced retrospective database analyses. ISPOR 7th Annual International 
Meeting 2002. Washington, DC. 
518 Horton NJ, Lipsitz SR. Review of software to fit generalized estimating equation regression models. 
The American Statistician 1999;53:160-169. 
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correlation structures can be used for GEE.519 In the simplest form, when all the 
observations are independent, the independence correlation structure is used where if ρjk 
is the correlation between observations j and k, ρjk = 1 and ρjk [j ≠ k] = 0. In the case where 
the observations are correlated, an exchangeable correlation matrix can be used.  An 
exchangeable correlation matrix indicates that every observation within an individual is 
equally correlated with every other observation in that individual.  Thus, ρjj = 1 and ρjk [j ≠
k] = ρ where ρ is the intraclass correlation coefficient.520 
GEE models are solved using maximum likelihood estimation.  There are three 
assumptions of the GEE method: 1) observations for different patients are independent; 
2) number of patients is large (> 200); and 3) data must be missing completely at 
random.521 
519 Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated 
responses: an introduction to generalized estimating equations and multi-level mixed modelling. Stat Med 
1998;17:1261-91. 
520 Ibid. 
521 Delea T, Weycker D. Advanced retrospective database analyses. ISPOR 7th Annual International 
Meeting 2002. Washington, DC. 
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APPENDIX D 
SENSITIVITY ANALYSIS RESULTS 
 
A sensitivity analysis was conducted on variable duration of statin use.  Duration 
of statin use was defined as the time a patient is exposed to statin therapy before the end 
of observation period.  The end of observation period was defined when any one of the 
following three occurs: 1) diagnosis of myopathy; 2) discontinuation of statin therapy (a 
gap greater than 45 days between refills) or PIM use and; 3) end of six month follow-up 
period.  In sensitivity analysis one of the criterion for end of observation period was 
changed.  Discontinuation of statin therapy was defined as a gap of greater than 60 days 
between refills.  Therefore duration of statin use was changed. 
 As a result of change in duration of statin use, the number of patients receiving 
PIMs during that duration also changed.  A total of 8,911 patients were included in the 
analyses of which 5,817 patients were statin users and 3,094 were statin interacters.  
Objectives four, five, eight and nine were re-analyzed with this new definition of 
discontinuation of statin therapy and new number of total patients.  The results were 
similar to the original results and are presented in the following section. 
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Objective 4: To identify demographic, health-related, treatment, and physician-
related factors that are associated with the receipt of potentially interacting 
medications with statins. 
 
Table D.1: Sensitivity analysis results using logistic regression to identify risk 
factors associated with odds of receiving a potentially interacting medication using a 












Age -0.005 0.002 5.046 1 0.025* 0.995 0.990 0.999 
Gender (Female)a 0.422 0.047 79.963 1 <0.0001* 1.525 1.390 1.673 
Ethnicity (Black)b -0.095 0.060 2.462 1 0.117 0.910 0.808 1.024 
Ethnicity 
(Hispanic)b
-0.281 0.055 25.845 1 <0.0001* 0.755 0.678 0.841 
Ethnicity (Asian)b 0.059 0.155 0.146 1 0.702 1.061 0.783 1.439 
Ethnicity (Other)b -0.028 0.099 0.078 1 0.780 0.973 0.801 1.181 
Comorbidities 0.359 0.026 192.790 1 <0.0001* 1.432 1.362 1.507 
Fluvastatinc -0.223 0.118 3.569 1 0.058 0.800 0.634 1.008 
Atorvastatinc -0.109 0.070 2.442 1 0.118 0.896 0.781 1.028 
Lovastatinc -0.522 0.259 4.065 1 0.044* 0.593 0.357 0.986 
Simvastatinc -0.189 0.077 5.725 1 0.017* 0.828 0.709 0.966 
Dose of statind -0.033 0.055 0.363 1 0.547 0.967 0.869 1.077 
* p<0.05 
a. Reference category is male 
b. Reference category is Whites 
c. Reference category is pravastatin 
d. Reference category is low dose of statin 
 
In sensitivity analysis, the odds of receiving PIM were lower in patients receiving 
lovastatin than pravastatin.  This was not observed in the original results. 
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Objective 5: To estimate the overall incidence of myopathy among study population. 
 
Table D.2: Person-months, frequency and incidence of myopathy by statin users 
and statin interacters in sensitivity analysis using 60-day gap between refills 
 
Statin Users Statin Interacters 
n 5,817 3,094
Follow-up in person-months 24,263 14,746 
Myopathy (%) 49 (0.8) 67 (2.1) 
Incidencea 0.20 0.45 
a. New myopathy cases per 100 person-months 
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Objective 8: To assess the relationship between the development of myopathy and 
use of potentially interacting medications with statins, while controlling for other 
risk factors for myopathy. 
 
Table D.3: Sensitivity analysis results using logistic regression to assess the 
relationship between odds of developing myopathy and use of potentially interacting 












Receipt of PIMa 1.042 0.198 27.618 1 <0.0001* 2.835 1.922 4.181 
Age 0.012 0.010 1.302 1 0.254 1.012 0.992 1.033 
Gender (Female)b 0.307 0.204 2.267 1 0.132 1.359 0.912 2.026 
Ethnicity (Black)c -0.379 0.258 2.162 1 0.141 0.684 0.413 1.135 
Ethnicity 
(Hispanic)c
-0.289 0.227 1.626 1 0.202 0.748 0.480 1.168 
Ethnicity (Other)c -0.570 0.407 1.961 1 0.161 0.566 0.255 1.256 
Diabetesd 0.157 0.192 0.667 1 0.414 1.170 0.802 1.708 
Comorbidities 0.189 0.058 10.664 1 0.001* 1.209 1.079 1.354 
Atorvastatine 0.288 0.301 0.916 1 0.338 1.334 0.739 2.407 
Simvastatine 0.122 0.339 0.129 1 0.719 1.130 0.582 2.194 
Other statinse -1.111 0.759 2.143 1 0.143 0.329 0.074 1.457 
Duration of statin 
use 
-0.002 0.000 8.922 1 0.003* 0.998 0.996 0.999 
Dose of statinf -0.190 0.226 0.709 1 0.399 0.827 0.531 1.288 
* p<0.05 
a. PIM – Potentially interacting medication 
b. Reference category is male 
c. Reference category is Whites 
d. Reference category is absence of diabetes 
e. Reference category is pravastatin 
f. Reference category is low doses of statin 
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Objective 9: To determine the risk factors (demographic factors, health risk factors, 
and treatment factors) for myopathy. 
 
Table D.4: Sensitivity analysis results using logistic regression to determine the 












Receipt of PIMa 1.042 0.198 27.618 1 <0.0001* 2.835 1.922 4.181 
Age 0.012 0.010 1.302 1 0.254 1.012 0.992 1.033 
Gender (Female)b 0.307 0.204 2.267 1 0.132 1.359 0.912 2.026 
Ethnicity (Black)c -0.379 0.258 2.162 1 0.141 0.684 0.413 1.135 
Ethnicity 
(Hispanic)c
-0.289 0.227 1.626 1 0.202 0.748 0.480 1.168 
Ethnicity (Other)c -0.570 0.407 1.961 1 0.161 0.566 0.255 1.256 
Diabetesd 0.157 0.192 0.667 1 0.414 1.170 0.802 1.708 
Comorbidities 0.189 0.058 10.664 1 0.001* 1.209 1.079 1.354 
Atorvastatine 0.288 0.301 0.916 1 0.338 1.334 0.739 2.407 
Simvastatine 0.122 0.339 0.129 1 0.719 1.130 0.582 2.194 
Other statinse -1.111 0.759 2.143 1 0.143 0.329 0.074 1.457 
Duration of statin 
use 
-0.002 0.000 8.922 1 0.003* 0.998 0.996 0.999 
Dose of statinf -0.190 0.226 0.709 1 0.399 0.827 0.531 1.288 
* p<0.05 
a. PIM – Potentially interacting medication 
b. Reference category is male 
c. Reference category is Whites 
d. Reference category is absence of diabetes 
e. Reference category is pravastatin 
f. Reference category is low doses of statin 
 
263
Table D.5: Sensitivity analysis results using logistic regression to determine PIM 
characteristics that are risk factors for myopathy for statin interacters suing 60-day 












Age 0.037 0.015 6.124 1 0.013* 1.038 1.008 1.069 
Gender (Female)a 0.077 0.273 0.081 1 0.776 1.081 0.632 1.848 
Ethnicity (Black)b -0.253 0.342 0.546 1 0.459 0.777 0.397 1.518 
Ethnicity 
(Hispanic)b
-0.106 0.305 0.122 1 0.727 0.899 0.495 1.634 
Ethnicity (Other)b -0.395 0.492 0.643 1 0.422 0.673 0.256 1.770 
Diabetesc 0.080 0.254 0.101 1 0.751 1.084 0.658 1.787 
Comorbidities 0.138 0.066 4.305 1 0.038* 1.148 1.008 1.308 
Atorvastatind 0.315 0.399 0.622 1 0.430 1.371 0.626 3.002 
Simvastatind 0.458 0.435 1.106 1 0.293 1.581 0.674 3.711 
Other statinsd -1.145 1.066 1.153 1 0.282 0.318 0.039 2.572 
Duration of statin 
use  
-0.001 0.000 3.074 1 0.079 0.999 0.997 1.000 



























Time of receipt of 
PIMg, h 
0.303 0.342 0.7844 1 0.376 1.354 0.692 2.648 
Duration of PIMh
use 
-0.003 0.002 1.805 1 0.179 0.330 0.044 2.506 
* p<0.05 
a. Reference category is male 
b. Reference category is Whites 
c. Reference category is absence of diabetes 
d. Reference category is pravastatin 
e. Reference category is low doses of statin 
f. Reference category is Level 1  
g. Reference category is PIM received after start of statin therapy 
h. PIM – Potentially interacting medication 
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APPENDIX E 
RESULTS OF NORMALITY TESTING 
 
Normality plots and tests were conducted for continuous variables age, duration 
of statin use, and duration of PIM use.  Table E.1 provide information on skewness and 
kurtosis.  Figures E.1 to E.3 show the normality plots for the three variables 
 
Table E.1: Skewness and kurtosis for age, duration of statin use and duration of 
PIM use 
 
Variables Skewness (S.E.) Kurtosis (S.E.)
Age -0.822 (0.026) -0.017 (0.52)
Duration of statin use 3.668 (0.026) 21.685 (0.052)
Duration of PIM use 0.944 (0.045) -0.674 (0.089)
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RESULTS OF TESTING ASSUMPTIONS OF LOGISTIC REGRESSION 
ANALYSES 
 
LINEARITY AMONG PREDICTORS 
 
Table F.1: Results of Box-Tidwell approach to test linearity among predictors for 
logistic regression model that identifies risk factors associated with odds of receiving 
a potentially interacting medication 
 
Variable Parameter Estimate Standard Error Wald χ2 df p-value 
Age 0.156 0.088 3.128 1 0.077 
Gender (Female)a 0.429 0.047 81.234 1 <0.0001 
Ethnicity (Black)b -0.083 0.060 1.894 1 0.168 
Ethnicity (Hispanic)b -0.278 0.055 24.832 1 <0.001 
Ethnicity (Asian)b 0.109 0.155 0.496 1 0.481 
Ethnicity (Other)b 0.013 0.099 0.019 1 0.889 
Comorbidities 0.355 0.026 183.155 1 <0.0001 
Fluvastatinc -0.222 0.119 3.488 1 0.061 
Atorvastatinc -0.1135 0.079 2.565 1 0.109 
Lovastatinc -0.496 0.258 3.683 1 0.055 
Simvastatinc -0.186 0.079 5.505 1 0.019 
Dose of statind -0.034 0.055 0.385 1 0.534 
Age*Log(Age) -0.033 0.018 3.349 1 0.067 
a. Reference category is male 
b. Reference category is Whites 
c. Reference category is pravastatin 
d. Reference category is low dose of statin 
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Table F.2: Results of Box-Tidwell approach to test linearity among predictors for 







Wald χ2 df p-value 
Receipt of PIMa 1.023 0.201 25.761 1 <0.0001 
Age -0.255 0.371 0.472 1 0.491 
Gender (Female)b 0.263 0.205 1.645 1 0.199 
Ethnicity (Black)c -0.403 0.264 2.330 1 0.126 
Ethnicity (Hispanic)c -0.252 0.231 1.191        1 0.275 
Ethnicity (Other)c -0.526      0.409        1.658        1 0.197 
Diabetesd 0.168 0.197 0.733 1 0.391 
Comorbidities 0.322      0.089 13.026 1 0.000 
Atorvastatine 0.276 0.302 0.835 1 0.360 
Simvastatine 0.073 0.341 0.045 1 0.830 
Other statinse -1.139 0.760 2.244 1 0.134 
Duration of statin use -0.024 0.006 13.969 1 0.000 
Dose of statinf -0.154 0.228 0.455 1 0.499 
age*log (age) 0.054 0.076 0.509        1 0.475 
Duration of statin use* 
log (Duration of statin) 
-0.221 0.119 3.450 1 0.063 
a. PIM – Potentially interacting medication 
b. Reference category is male 
c. Reference category is Whites 
d. Reference category is absence of diabetes 
e. Reference category is pravastatin 
f. Reference category is low doses of statin 
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Table F.3: Results of Box-Tidwell approach to test linearity among predictors for 







Wald χ2 df p-value 
Age -0.768 0.520 2.175 1 0.140 
Gender (Female)a 0.100 0.278 0.130 1 0.717 
Ethnicity (Black)b -0.164 0.358 0.209 1 0.647 
Ethnicity (Hispanic)b 0.023 0.312 0.005 1 0.940 
Ethnicity (Other)b -0.310 0.498 0.388 1 0.533 
Diabetesc 0.053 0.265 0.041 1 0.839 
Comorbidities 0.310 0.113 7.462 1 0.006 
Atorvastatind 0.296 0.404 0.535 1 0.464 
Simvastatind 0.4217      0.4426        0.9077        1 0.340 
Other statinsd -1.094 1.069 1.049 1 0.305 
Duration of statin use 0.0009 0.010 0.008 1 0.928 
Dose of statine -0.468 0.325 2.063 1 0.150 
Significance of drug 
interaction 
 Level 2f, g 











Time of receipt of PIMi,  j 0.093 0.333 0.078        1 0.779 
Duration of PIMj use 0.098 0.033 8.507 1 0.003 
age*log (age) 0.164 0.107 2.355 1 0.124 
duration of statin use*log 
(duration of statin use) 
-0.0003 0.001 0.040 1 0.841 
Duration of PIM use*log 
(duration of PIM use) 
0.073 0.341 0.045 1 0.830 
a. Reference category is male 
b. Reference category is Whites 
c. Reference category is absence of diabetes 
d. Reference category is pravastatin 
e. Reference category is low doses of statin 
f. Reference category is Level 1 which is defined as severe or potentially life-threatening. 
g. Level 2 is defined as interaction that causes detoriation in patients’ clinical status. 
h. Level 3 is defined as moderate to minor side effects.   
i. Reference category is PIM received after start of statin therapy 




Table F.4: Tolerance and variance inflation factor to test multicollinearity for 
logistic regression model that identifies risk factors associated with odds of receiving 
a potentially interacting medication 
 
Variable df Tolerance Variance Inflation Factor 
Age 1 0.946 1.056 
Gender (Female) 1 0.980 1.020 
Ethnicity (Black) 1 0.804 1.242 
Ethnicity (Hispanic) 1 0.795 1.257 
Ethnicity (Asian) 1 0.957 1.044 
Ethnicity (Other) 1 0.909 1.099 
Comorbidities 1 0.953 1.049 
Fluvastatin 1 0.749 1.334 
Atorvastatin 1 0.409 2.439 
Lovastatin 1 0.939 1.064 
Simvastatin 1 0.431 2.318 
Dose of statin 1 0.916 1.090 
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Table F.5: Tolerance and variance inflation factor to test multicollinearity for 
logistic regression model that evaluates risk factors associated with odds of 
developing myopathy 
 
Variable df Tolerance Variance Inflation Factor 
Receipt of PIM 1 0.851 1.174 
Age 1 0.927 1.078 
Gender (Female) 1 0.965 1.035 
Ethnicity (Black) 1 0.798 1.251 
Ethnicity (Hispanic) 1 0.772 1.294 
Ethnicity (Other) 1 0.882 1.132 
Diabetes 1 0.948 1.054 
Comorbidities 1 0.930 1.075 
Atorvastatin 1 0.409 2.443 
Simvastatin 1 0.430 2.321 
Other statins 1 0.719 1.390 
Duration of statin use 1 0.859 1.163 
Dose of statin 1 0.915 1.092 
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Table F.6: Tolerance and variance inflation factor to test multicollinearity for 
logistic regression model that evaluates PIM characteristics associated with odds of 
developing myopathy 
 
Variable df Tolerance Variance Inflation Factor 
Age 1 0.90308 1.10732 
Gender (Female) 1 0.93351 1.07122 
Ethnicity (Black) 1 0.80737 1.23858 
Ethnicity (Hispanic) 1 0.78998 1.26586 
Ethnicity (Other) 1 0.88512 1.12979 
Diabetes 1 0.94643 1.05660 
Comorbidities 1 0.93399 1.07067 
Atorvastatin 1 0.43195 2.31509 
Simvastatin 1 0.45557 2.19504 
Other statins 1 0.75491 1.32465 
Duration of statin use 1 0.87476 1.14317 
Dose of statin 1 0.90597 1.10379 
Significance of drug interaction 
 Level 2 









Time of receipt of PIM 1 0.67782 1.47532 
Duration of PIM use 1 0.59675 1.67574 
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